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Abstract
ABSTRACT OF THE DISSERTATION
The role of Bhlhe40 in autoimmune neuroinflammation and Mycobacterial infection
by
Chih-Chung Lin
Doctor of Philosophy in Biology and Biomedical Sciences
Immunology
Washington University in St. Louis, 2017
Professor Brian T. Edelson, Chair

The mammalian immune system is composed of innate and adaptive compartments, which
cooperate with each other to maintain homeostasis and protect the host from the invasion by a
variety of pathogens. The tight control of immune responses is extremely important for all
individuals. Here, we discovered that the transcription factor basic helix-loop-helix family,
member e40 (Bhlhe40) is a critical protein that regulates the autoimmune ("against self") and
anti-microbial ("against non-self") responses of myeloid cells and T lymphocytes. Multiple
sclerosis (MS) is a human neuroinflammatory disease in the central nervous system with an
autoimmune etiology. We have reported that Bhlhe40 positively regulates the production of the
pro-inflammatory cytokine, GM-CSF, but negatively regulates the production of the anti-

xi

inflammatory cytokine, IL-10, by CD4+ T cells. The absence of Bhlhe40 abrogates T cell
pathogenicity and thus Bhlhe40-/- mice were resistant to the animal model of MS. Tuberculosis,
caused by Mycobacterium tuberculosis (Mtb), is one of the most serious infectious diseases in
the world. We have demonstrated that Bhlhe40 suppresses IL-10 expression by myeloid cells
and T cells to ensure protective immunity to Mtb. Bhlhe40-deficient immune cells produce high
levels of IL-10 which dampens the immune responses to Mtb infection and therefore renders
Bhlhe40-/- mice highly susceptible to this pathogen. Our findings have uncovered the critical
roles of Bhlhe40 in regulating inflammation during an autoimmune disorder and an infectious
disease. Bhlhe40, or pathways that regulate its expression or function, might represent
therapeutic targets for researchers to manipulate immune responses in human autoimmunity and
infection.

xii

Chapter 1: Introduction

1

In 1989, Charles Janeway, Jr. proposed that the immune system has evolved to discriminate
“infectious nonself from noninfectious self”1, 2. He later described a "two-signal" system,
whereby innate immune cells recognize microbial products and subsequently activate adaptive
lymphocytes, as a reflection of the evolution of host defense2. However, the immune system is
not always perfect: autoimmune disorders still occur, and not all pathogens can be successfully
controlled.
Adjuvants, nicknamed the "immunologist's dirty little secret" by Janeway, are potent reagents
containing immunogenic materials which can activate the innate immune compartment and help
generate antigen-specific adaptive immune responses3. Complete Freund's adjuvant (CFA),
consisting of heat-killed Mtb in non-metabolizable oils, is a powerful adjuvant which induces
fast and strong immune responses4. In experimental autoimmune encephalomyelitis (EAE), the
animal model of multiple sclerosis (MS), heat-killed Mtb within CFA activates innate immune
cells to present the co-injected myelin antigen to self-reactive T cells which have escaped from
thymic negative selection. As a result, these activated autoreactive T cells infiltrate the central
nervous system (CNS) and cause autoimmune neuroinflammation5.
Despite having a variety of pathogen-associated molecular patterns (PAMPs), virulent Mtb has
co-evolved with humans for more than 70,000 years and has developed immune evasion
strategies to avoid being eliminated by the host6, 7, 8. It is estimated that one-third of the world's
population is infected by Mtb, with the majority having asymptomatic latent infection. In these
individuals, innate and adaptive immune defenses keep Mtb contained within the lung at a low
level. In a small fraction of individuals, active tuberculosis (TB) develops, with the pathogen
growing progressively in the lungs and in some cases disseminating to other organs, without
control by the host immune system. In the mouse model of infection, virulent Mtb also can
2

evade innate immunity, delay the initiation of adaptive host defenses, and persist as a chronic
infection8. Wild-type (WT) C57BL/6 mice do not show symptoms for the first several months
after Mtb infection, but eventually die of the disease between 8 and 12 months .
Accepting that the immune system is still in the slow process of evolution and is not yet perfect
to maintain health at all times, biomedical scientists have come up with the idea of immunedirected therapies to treat autoimmune and infectious diseases. Immunotherapies include the
administration of antibodies to target certain immune cell types or molecules. As an example,
blockade of immune cell trafficking with a monoclonal antibodies recognizing alpha 4 integrin
has been shown to be an effective treatment for relapsing-remitting MS (RRMS)9. Several hostdirected therapies that aim to enhance antimicrobial mechanisms and reduce inflammation are
currently being considered as adjunctive treatments for human TB10. To advance the
development of novel immune-directed therapies, it is fundamentally important to explore the
immune reactions underlying MS and TB. A clearer understanding of the players and pathways
used by the immune response during autoimmunity and infection may provide novel therapeutic
targets.
In this dissertation, I will describe the cellular and molecular mechanisms whereby the
transcription factor basic helix-loop-helix family, member e40 (Bhlhe40) and several cytokines
regulate autoimmune and anti-microbial responses. The Edelson Lab has found that Bhlhe40,
plays a critical role in controlling the balance of immune response against noninfectious self and
infectious non-self. Bhlhe40 is essential for CD4+ T cell pathogenicity and the induction of the
murine autoimmune model, EAE. We found that myeloid cell-derived IL-1β induces Bhlhe40
expression by CD4+ T cells, and this factor promote neuroinflammation by enhancing the proinflammatory cytokine GM-CSF but suppressing the anti-inflammatory cytokine IL-10 (Chapter
3

2 and Chapter 3)11, 12. While rendering mice susceptible to autoimmunity, Bhlhe40 is
indispensable for both innate and adaptive compartments to engender protective host defense
against Mtb. Bhlhe40 in myeloid cells as well as T cells directly represses Il10 transcription to
secure the protective host defense after Mtb infection (Chapter 4; manuscript in preparation).
We hope our findings in the mouse offer new insights for immune-directed therapies and can be
translated to human medicine (Chapter 5).
In this chapter, I will first introduce the biology and function of the transcription factor, Bhlhe40.
Second, I will describe the human neuroinflammatory disease, MS and its mouse model, EAE. I
will also elaborate on the impact of IL-1β in MS and EAE. In the last section of this chapter, I
will discuss human tuberculosis (TB) and its mouse model, followed by a discussion on the role
of IL-10 in both human and mouse TB.

1.1 The Transcription Factor Bhlhe40
Between 1997 and 2002, the gene Bhlhe40 in mouse, rat, and human was discovered by several
independent laboratories and given different names: Bhlhb2, Stra13, Sharp2, Eip1, Dec1, CR-8,
and Clast5 13, 14, 15, 16, 17, 18. The gene is located on chromosome 6 in mouse, chromosome 4 in
rat, and chromosome 3 in human. Bhlhe40 is an evolutionarily-conserved gene which can be
found not only in mammals but in fish, amphibians, reptiles, and birds. Murine Bhlhe40
encompasses five exons, encoding a transcription factor called the basic helix-loop-helix family,
member e40. The protein is composed of 411-412 amino acids, with a molecular weight of 46
kD. Bhlhe40 belongs to the family of basic helix–loop–helix transcriptional regulators sharing
structural features including a basic DNA-binding domain, a helix–loop–helix domain mediating
4

dimerization, and a 41 residue-long protein-protein interaction “orange domain” 19, 20. In 2002,
researchers identified the class B E-box element (CACGTG) as the preferred binding site for
Bhlhe4021.
Bhlhe40 is expressed in both the hematopoietic and non-hematopoietic compartments22. It has
been shown to play roles in circadian rhythms, neuronal excitability, muscle repair, and
responses to environmental stimuli such as light pulses, growth factors, and hypoxia23, 24, 25, 26 27,
28, 29

. Within immune cell populations, this factor can be found in many cell types, including

granulocytes, macrophages, dendritic cells (DCs), natural killer cells (NK cells), and activated T
cells12. However, the functions of Bhlhe40 in immune cells are not well appreciated. In 2001,
Reshma Taneja’s group generated Bhlhe40-/- mice and reported that they suffered from a nonfully penetrant, late-onset lymphoproliferative disease. The authors suggested that the
autoimmune disorder might result from a failure of elimination of activated T and B cells30.
Bhlhe40 and its related transcription factor Bhlhe41, have been shown to regulate the
maintenance and phenotype of peritoneal and splenic B-1a cells31. In T cells, Bhlhe40 is
expressed upon T-cell receptor (TCR) stimulation and CD28 co-stimulation 32, 33. Miyazaki et al.
suggested that Bhlhe40 is critical for the homeostasis of regulatory T cells (Tregs) both in vitro
and in vivo 32. Kanda et al. showed that Bhlhe40 served as a cofactor of T-bet and is required for
full IFN-γ production by iNKT cells34. The importance of immune cell-expressed Bhlhe40 in
disease models is just beginning to be appreciated. In this dissertation, I will describe the roles
of this transcription factor in murine models of MS and TB.

5

1.2 Multiple Sclerosis and Its Mouse Model
1.2.1 Multiple sclerosis (MS)
MS is a chronic inflammatory disease of the brain, spinal cord, and optic nerves that presents
clinically with different temporal and pathologic patterns and results in a variety of neurologic
signs and symptoms. The symptoms of MS include fatigue, vision loss, numbness, muscle
spasms, mobility problems, cognitive dysfunction, depression and anxiety, bladder problems,
and autonomic dysfunction35. It is estimated that 2.5 million people in the world suffer from
MS, with two-third being women. Most patients are diagnosed with MS between 20 and 45
years of age. The disease can last for decades, having a minimal impact on lifespan. The
symptoms of MS hinder young adults from working and raising children, and as much MS poses
a large socioeconomic burden. Although 13 MS-modifying medications have been approved by
U.S. Food and Drug Administration (FDA), there is still no cure for MS. Current MS therapies
mainly target the functions of lymphocytes, but are not universally-effective.
Although the autoantigens have not been identified, MS is thought to be an autoimmune disease.
Studies in MS patients reveal that CNS-invading immune cells induce demyelination and axon
loss, and communicate with resident astrocytes, glia, and neurons36. Pathogenic CD4+ TH cells
play an important role in driving MS pathology, although γδ T cells, CD8+ T cells, and B cells
also appear to contribute to disease37, 38, 39, 40, 41. How autoreactive TH cells acquire pathogenicity
and how they mediate CNS damage remain important outstanding questions.

6

1.2.2 Experimental autoimmune encephalomyelitis (EAE)
Experimental autoimmune encephalomyelitis (EAE) serves as an animal model of MS and can
be elicited in several species through active immunization with myelin antigen or via adoptive
transfer of T lymphocytes (“passive EAE”)42, 43. In recent years, the C57BL/6 mouse model of
EAE has become the most popular, as it has allowed the use of knockout and transgenic mouse
strains on this genetic background. In the C57BL/6 EAE model, mice are immunized with a
CFA-based emulsion containing a peptide from murine myelin oligodendrocyte glycoprotein
(MOG35-55)5. Although this immunization elicits peptide-specific TH cells, mice must also be
systemically injected with pertussis toxin (PTX) as a coadjuvant to induce a monophasic,
paralytic clinical disease44, 45.
Following EAE induction, priming and differentiation of MOG-specific TH cells take place
during the first week in secondary lymphoid organs. In the subsequent days, these TH cells and
blood-derived myeloid cells traffic through the meninges and across the blood-brain barrier
(BBB), with clinical signs of disease typically apparent by 10 days post-immunization. TH cells
are thought to re-encounter their cognate antigen (MOG35-55) in the context of MHC class IIexpressing antigen presenting cells both in the meninges and the CNS parenchyma, with these
interactions resulting in the production of pathogenic cytokines by the TH cells46, 47. In 2011, two
groups reported that CD4+ T cells produce granulocyte macrophage colony-stimulating factor
(GM-CSF) to initiate neuroinflammation in mice. Using several GM-CSF receptor conditional
knockout mice, the group of Burkhard Becher demonstrated that the CCR2+
monocyte/monocyte-derived dendritic cells/macrophages (moDCs/Macs) must respond to T cellderived GM-CSF to cause disease48. This same group recently showed that even transgenic
overexpression of GM-CSF by myelin antigen non-specific CD4+ T cells can induce myeloid
7

cell infiltration to the CNS and lead to neurological deficits49. These findings indicate that
dysregulation of T cell-derived cytokines can influence autoimmune inflammation.

1.2.3 The associations between IL-1 and autoimmune neuroinflammation
Note: the contents of this section are modified from the manuscript “New Insights into the Role
of IL-1β in EAE and MS” written by Chih-Chung Lin and Brian T. Edelson. This manuscript has
been accepted for publication at the Journal of Immunology at the time of this dissertation.
The IL-1 family of cytokines displays pleiotropic effects on a variety of hematopoietic and nonhematopoietic cells relevant to neuroinflammation. IL-1α is generated constitutively by
epithelial cells and induced upon stimulation of most immune cell types50. IL-1β is produced via
both inflammasome-dependent and -independent pathways upon activation of a variety of
leukocytes51, 52, 53, 54, 55. Both of these IL-1 family members bind to a single activating receptor
complex, composed of the IL-1R1 and IL-1RAcP (the IL-1R accessory protein, also called IL1R3) chains, each containing a cytosolic Toll/interleukin-1 receptor homology (TIR) domain56.
Cytokine binding by this receptor engages the MyD88 signaling cascade, including IRAK1/2/4,
TRAF6, and TAK1, to ultimately result in AP-1 and NF-κB activation and pro-inflammatory
gene transcription. Separately, another IL-1 family member, IL-1Ra (also called IL-1RN),
functions as a soluble receptor antagonist, capable of binding to IL-1R1.
Several members of the IL-1 family of cytokines have been studied in the context of EAE and
MS, with initial work in EAE beginning in the late 1980s. In 1987, Symons et al. found
increased levels of IL-1 activity, measured at the time by a mouse thymocyte proliferation assay,
in the plasma and cerebrospinal fluid (CSF) of guinea pigs immunized with spinal cord
homogenates to induce a chronic relapsing form of EAE57. In the same year, using a rat model
8

of passive EAE, Mannie et al. showed lymph node cells from EAE-induced rats treated with
human IL-1β were more encephalitogenic, and suggested that this effect was via the action of IL1β on T lymphocytes 58. Two studies later found evidence for IL-1α within the spinal cord of
mice with EAE59, 60, and one report showed that IL-1β protein could be detected in rats with EAE
within meningeal macrophages, parenchymal infiltrating macrophages, and activated
microglia61. Subsequent studies in rats showed that recombinant human IL-1α treatment after
EAE induction exacerbated clinical disease and that treatment with soluble recombinant murine
IL-1 receptor or IL-1Ra could ameliorate disease62, 63, 64, 65. Schiffenbauer et al. first reported
that IL-1R-deficient mice (on a mixed genetic background) were resistant to active EAE
induction 66. Their results have been confirmed by several other groups using IL-1R-deficient
mice on the C57BL/6 background12, 48, 67, 68, 69, 70, although the degree to which these mice were
protected from clinical disease was somewhat variable. Despite one report to the contrary71, IL1β appears to be the critical mediator of EAE, rather than IL-1α, as IL-1β-deficient mice were
seen to resist EAE by two groups69, 72, while IL-1α-deficient mice remained susceptible69, 71.
Consistent with a critical requirement for IL-1β for EAE susceptibility, mice deficient in the
inflammasome components NLRP373, 74, 75, 76, 77, ASC72, 78), caspase 179, and caspase 1180 were
also at least partially resistant to EAE, as were mice treated with inhibitors of NLRP381, 82 or
caspase 183. It is worth noting that in some reports75, 76, 78, mice immunized with larger amounts
of heat-killed Mtb (usually greater than 300 micrograms per mouse) as part of the MOG35-55/CFA
emulsion developed an NLPR3- and ASC-independent form of aggressive EAE. However, this
form of EAE still appears to be IL-1β- and IL-1R-dependent, given that the experiments in IL1β- and IL-1R-deficient mice which demonstrated EAE resistance were typically performed with
large amounts of heat-killed Mtb12, 48, 67, 68, 69, 70, 72.
9

Beginning in 1990, reports emerged showing that IL-1β protein or IL1B transcript could be
detected in the CSF84, 85 or within CNS lesions of MS patients86, 87, 88, 89, 90, 91. More recently,
these findings were extended by Seppi et al. who showed that CSF levels of IL-1β correlate with
the number and volume of brain cortical demyelinating lesions92, and by Rossi et al. who showed
that relapsing-remitting MS (RRMS) patients with detectable IL-1β in the CSF at the time of
clinical remission had a more severe course of disease93. In addition, transcript levels of IL1B
and two inflammasome components (CASP1 and NLRP3) were more highly expressed by
peripheral blood mononuclear cells from MS patients compared to healthy controls94, 95, 96.
Collectively, while these results indicate that IL-1β expression in the CNS and blood is
associated with disease activity in MS, they do not establish a causal role for the cytokine in
disease pathogenesis.
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1.3 Immune responses to Mycobacterial infection
1.3.1 Human tuberculosis
Tuberculosis (TB) is one of the top 10 causes of death in the world. In 2015, it was estimated
that 1.8 million people died from the disease, with more than one-fifth of these patients being coinfected with HIV (WHO Fact Sheet 2017 http://www.who.int/mediacentre/factsheets/fs104/en/).
Sub-Saharan Africa, South Asia, and East Asia have the highest TB burden; about 60% of the
TB cases were reported in India, Indonesia, China, Nigeria, Pakistan and South Africa (WHO
Fact Sheet 2017 http://www.who.int/mediacentre/factsheets/fs104/en/ )97. TB remains one of the
most important infectious diseases worldwide.
Human tuberculosis is caused by Mtb. While latent infection is the most common form, 5-10%
of infected individuals develop active TB with clinical symptoms (such as chronic cough, fever,
and weight loss). These patients become the contagious sources of Mtb. Mtb can be spread
through the air after an active TB patient coughs, sneezes or spits. After entering a new host, the
bacteria deposit in the lung and replicate in macrophages and epithelial cells. Recruited myeloid
cells and lymphocytes later surround infected cells and form granulomas, a hallmark feature of
human TB. This compact aggregate of immune cells prevents the further spread of Mtb but also
allows the bacteria to persist in the lungs98. Mtb primarily infects the lung but it can disseminate
other tissues (such as lymph nodes, bones, and the central nervous system) and cause
extrapulmonary disease99, 100.
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1.3.2 Mouse models of tuberculosis
The German microbiologist, Robert Koch, identified Mtb as the causative agents for TB in 1882,
and he was also the first to use the mouse as an experimental model. Subsequently, scientists
have utilized a variety of animals for TB research: guinea pigs, rats, rabbits, and non-human
primates101. Each model has its advantages for studying TB but mice are the most widely used
animal model mainly because of the relatively low cost and a broad availability of inbred and
genetically-modified strains as well as research reagents102. In addition, mouse models of human
mycobacterial diseases have been suggested to be genetically relevant to human TB. The
intensity of immune responses and disease prognosis is determined by several experimental
conditions: (1) the species and strain of the infectious pathogen, (2) the route of infection, and (3)
the genetic background of the host.
Mtb is the cause of human TB. Virulent strains include H37Rv, Erdman, NYH-27, and the
Beijing strain. In contrast, H37Ra is an attenuated strain derived from H37Rv encompassing 76
strain-specific single nucleotide variations that affect 32 genes103, 104. Another member of the
Mycobacterium genus, M. bovis, is the causative agents of bovine TB. The Ravenel and the
Branch strains of M. bovis are virulent while M. bovis Bacille Calmette-Guerin (BCG) is not103,
105

. M. bovis BCG is the only licensed vaccine used against human TB (the other vaccine

modified vaccinia Ankara 85A, MVA85A, is in clinical trials.) M. avium is another pathogen
used in TB animal models. This mycobacterial species infects cows, dogs, cats, and birds, and is
a threat to immunocompromised individuals.
Both intravenous and aerosol routes are used to infect mice with mycobacteria. To infect mice
intravenously, a large number of mycobacteria (eg. 1-10 x105) are delivered. Within one or two
12

weeks, the pathogen can infect splenic and lung cells and result in systemic infection102.
Infecting animals with mycobacteria using small aerosol droplets mimics the natural infection
route of human TB. Unlike intravenous infection, a low number of bacteria (50-200 CFU per
lung) are sufficient to infect a mouse, with the bacteria undergoing a three-week phase of
logarithmic growth in the lungs. Compared to mice infected through the intravenous route, it can
take three weeks to observe an immune response in mice infected via the aerosol route102.
It is known that mice of different genetic backgrounds show different degree of resistance to
mycobacterial challenge106, 107, 108. For instance, C57BL/6 and BALB/c mice showed higher M.
bovis BCG loads than DBA/2 or C3H/He mice did in the spleens at 28 days post-intravenous
infection106. Nevertheless, C57BL/6 and BALB/c mice are more resistant to intravenous
inoculation of Mtb when compared to DBA/2, C3H, or CBA mice, which all succumb to this
route of infection and die around 100 days post infection (p.i.)108. A variety of genes have been
knocked out in mice and tested for their functions during mycobacterial infection. Mice that are
unable to produce certain pro-inflammatory mediators (eg. Il1α-/-, Il1β-/-, Nos2-/-) or have no or
impaired T cell responses (eg. Rag1-/-, Tbx21-/-, Stat1-/-, Ifng-/- mice) are susceptible to TB109, 110,
111, 112, 113, 114

.

1.3.3 IL-10 in M. tuberculosis infection
IL-10 was discovered almost three decades ago and has been recognized as an anti-inflammatory
cytokine in autoimmune and infectious diseases 115, 116, 117. IL-10 can be secreted by a variety of
leukocytes including monocytes, macrophages, DCs, and T cells. Multiple cytokines such as IL4, IL-12, and IL-27 signal through STATs to induce IL-10 production by T cells118. Myeloid
cells secrete this cytokine after sensing certain microbial products through pathogen recognition
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receptors119. TLR2 agonists are potent inducers of IL-10 expression by macrophages and DCs120,
121, 122

. Mtb possesses a large repertoire of TLR2 ligands including lipomannan and

lipoproteins123, 124, 125, and thus can stimulate IL-10 production from myeloid cells126, 127, 128, 129.
IL-10 can act on nearly all immune cell subsets via binding to its receptor. IL-10 receptor is
composed of two chains, IL-10R1 and IL-10R2, which are associated with Jak1 and Tyk2,
respectively130. Upon ligand binding, the Jak kinases phosphorylate and activate STAT3 as well
as STAT1 and STAT5 to initiate suppressive functions117, 130.
A meta-analysis including 31 studies revealed that polymorphisms in the Il10 gene associate
with TB susceptibility in Asians, Europeans, and Americans131. Several reports showed that IL10 could be detected in the serum, PBMCs, sputum, and bronchoalvelar lavage (BAL) fluid of
active TB patients, and the blood levels of IL-10 are decreased after TB treatment132, 133, 134, 135,
136, 137

. In TB patients, IL-10 is secreted by monocytes, macrophages, DCs, and T cells, and this

cytokine can potentially dampen both myeloid cell and T cell responses to Mtb infection137, 138,
139, 140, 141, 142, 143

. In vitro studies using human mononuclear phagocytes showed that IL-10

inhibited phagosome maturation in Mtb-infected macrophages, down-regulated MHC and
costimulatory molecules of Mtb-infected monocytes, drove an "M2-like" phenotype of Mtbactivated monocytes/macrophages, inhibited monocyte-DC differentiation after Mtb stimulation,
and prevented the fusion of monocytes to become multi-nuclear giant cells144 139, 145, 146 147. IL10 also negative controls IL-12 production from human macrophages and DCs infected with Mtb
and thus possibly impairs TH1 cell priming141. IL-10 has been reported to suppress IFN-γ, IL-4,
and IL-17 production from PBMCs and inhibit Mtb-reactive CD4+ T cell proliferation in TB
patients132, 139, 143, 148, 149. Although numerous in vitro and ex vivo studies suggest an adverse
effect of IL-10 on immunity to Mtb, the definite role of IL-10 in TB patients remains unresolved.
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Despite the fact that two studies demonstrated comparable susceptibility to Mtb between WT and
Il10-/- mice150, 151, more recent reports have proposed that endogenous IL-10 restrains immune
responses to Mtb infection. Anti-IL-10R-treated or IL-10-deficient CBA/J, BALB/c, and
C57BL/6 mice showed stronger TH1 responses, decreased bacterial burdens in the lungs, and
even prolonged survival after infection152, 153, 154, 155. IL-10 deficiency is also able to completely
rescue Mtb-infected WT mice from a type I-driven exacerbation of tuberculosis induced by
polyinosinic-polycytidylic acid (Poly-IC) treatment156, 157.
In 1991, the group of Anne O'Garra reported that IL-10 inhibited pro-inflammatory cytokine
production from antigen-presenting cells (APCs) and IFN-γ expression from TH1 cells158, 159. In
the context of mycobacterial infection, Hickman et al. found that Mtb-infected bone marrowderived macrophages secreted IL-10 to suppress TH1 cell polarization160. Demangel et al.
showed that the autocrine IL-10 represses IL-12 expression by BCG-infected DCs and inhibits
the generation of IFN-γ-producing T cells161. McNab et al. reported that IFNβ-induced IL-10
suppressed IL-12 expression and microbial killing of Mtb-infected macrophages162. Recently,
Jeyanathan et al. found that DAP12 knockout mice were more resistant to Mtb infection because
this immunoadaptor promoted IL-10 production by APCs and delayed protective TH1 immune
response to Mtb infection163. Collectively, these studies concluded that IL-10 could impair
protective immune responses to mycobacteria through inhibiting intracellular bacterial killing,
IL-12 production, and TH1 cell priming.
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Chapter 2: Bhlhe40 controls cytokine
production by T cells and is essential for
pathogenicity in autoimmune
neuroinflammation

The contents of this chapter have been modified from the following published article:

Bhlhe40 controls cytokine production by T cells and is essential for pathogenicity in
autoimmune neuroinflammation.

Chih-Chung Lin, Tara R. Bradstreet, Elizabeth A. Schwarzkopf, Julia Sim, Javier A. Carrero,
Chun Chou, Lindsey E. Cook, Takeshi Egawa, Reshma Taneja, Theresa L. Murphy, John H.
Russell & Brian T. Edelson. Nat Commun. 2014 Apr 3;5:3551.
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2.1 Abstract
TH1 and TH17 cells mediate neuroinﬂammation in experimental autoimmune encephalomyelitis
(EAE), a mouse model of multiple sclerosis. Pathogenic TH cells in EAE must produce the proinﬂammatory cytokine granulocyte-macrophage colony stimulating factor (GM-CSF). TH cell
pathogenicity in EAE is also regulated by cell-intrinsic production of the immunosuppressive
cytokine interleukin 10 (IL-10). Here we demonstrate that mice deﬁcient for the basic helixloop-helix (bHLH) transcription factor Bhlhe40 (Bhlhe40-/-) are resistant to the induction of
EAE. Bhlhe40 is required in vivo in a T cell-intrinsic manner, where it positively regulates the
production of GM-CSF and negatively regulates the production of IL-10. In vitro, GM-CSF
secretion is selectively abrogated in polarized Bhlhe40-/- TH1 and TH17 cells, and these cells
show increased production of IL-10. Blockade of IL-10 receptor in Bhlhe40-/- mice renders them
susceptible to EAE. These ﬁndings identify Bhlhe40 as a critical regulator of autoreactive T-cell
pathogenicity.
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2.2 Introduction
Experimental autoimmune encephalomyelitis (EAE) serves as an animal model for the human
neuroinﬂammatory disease multiple sclerosis. Encephalomyelitis in C57BL/6 mice in response
to immunization with a peptide from myelin oligodendrocyte glycoprotein (MOG) is driven by
cytokine-producing autoreactive T helper (TH) cells164. Historically, interferon-g (IFN-γ)producing TH1 cells were thought to be responsible for EAE, but recent evidence has revealed a
more important role for interleukin 17 (IL-17)-producing TH17 cells165, 166. Nevertheless, neither
TH1 (IFN-γ) nor TH17 (IL-17A, IL-17F, IL-21 and IL-22) signature cytokines are required for
the development of EAE167, 168, 169, 170, 171. Instead, the cytokine granulocyte-macrophage colony
stimulating factor (GM-CSF) has proven to be a critical factor in the encephalitogenicity of both
TH1 and TH17 cells172, 173, 174, 175, 176. IL-1 receptor and IL-23 receptor signaling are required for
TH cell production of GM-CSF during EAE68, 174, 175. GM-CSF production by T cells is regulated
cell-intrinsically through the action of transcription factors. Factors that regulate its transcription
include AP-1 family members, NFAT, NF-kB family members, including c-Rel and NF-kB1,
and RUNX1177, 178, 179, 180, 181, 182. Recently, Codarri et al. reported a requirement for RORγt for
maximal production of GM-CSF by TH17 cells, although a second report observed no reduction
in GM-CSF secretion by Rorc-/- TH cells in vitro174, 175. TH1 cells also produce GM-CSF during
EAE, yet speciﬁc transcription factors regulating their production of GM-CSF have not been
identiﬁed176.
Immunoregulatory cytokines, including IL-10, modulate the development of EAE183. IL-10 is
produced by several cell types during EAE, including autoreactive non-pathogenic TH cells184, 185,
186, 187, 188, 189, 190

. IL-10 suppresses effector T cell responses and limits inﬂammation. IL-1018

deﬁcient mice develop more severe EAE than wild-type (WT) mice191, 192, 193. Expression of IL10 in TH cells can be regulated by several transcription factors, depending on the TH cell subset
and the cytokine environment119, 194, 195, 196, 197. Relevant to EAE is the production of IL-10 by
TH1, TH17, Tr1 cells and T regulatory cells (Tregs).
Bhlhe40 (also known as Dec1, Stra13, Sharp2 or Bhlhb2) belongs to a family of basic helix–
loop–helix transcriptional regulators sharing structural features including a basic DNA binding
domain, a helix–loop–helix domain mediating dimerization and a protein–protein interaction
‘Orange domain’19, 20. Members of this family are known to respond to environmental stimuli
and regulate several physiological processes in diverse cell types, including the cell cycle,
apoptosis and differentiation via their actions as both transcriptional activators and repressors.
Bhlhe40 is expressed in T cells upon T-cell receptor (TCR) stimulation38. Bhlhe40-/- mice
develop a non-fully penetrant late-onset (age greater than ~8 months) lymphoproliferative
disease associated with autoantibodies30, 32, which may be due to a requirement for Bhlhe40 for
Treg maintenance during ageing. Penetrance of this age-related disease appears to be inﬂuenced
by genetic background. How Bhlhe40 regulates effector T-cell responses is incompletely
characterized.
In this study, we show that Bhlhe40-/- mice are resistant to EAE induction due, at least in part, to
a TH cell-intrinsic defect. TH cells from these mice display nearly normal IFN-γ and IL-17A
production in TH1 and TH17 cultures, respectively, and produce these cytokines after
immunization, but fail to mediate EAE. Instead, transcriptional and phenotypic analyses of
Bhlhe40-/- TH cells reveal that they fail to produce GM-CSF. We also demonstrate a role for
Bhlhe40 in GM-CSF production by γδ T cells. Bhlhe40-/- TH1 and TH17 cells produce increased
amounts of IL-10, consistent with their nonencepahlitogenic phenotype. Moreover, blockade of
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IL-10 signaling renders Bhlhe40-/- mice susceptible to EAE. Chromatin immunoprecipitation
sequencing (ChIP-Seq) reveals binding of Bhlhe40 to the Il3/Csf2 and Il10 loci at several sites
bound by other transcriptional regulators. Overall, our results identify Bhlhe40 as a novel factor
regulating GM-CSF and IL-10 production by T cells, and one that is required for autoimmune
neuroinﬂammation.
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2.3 Results
2.3.1 Bhlhe40-deﬁcient mice are protected from EAE
To examine the role of Bhlhe40 in autoimmunity, we immunized Bhlhe40-/- mice with MOG
peptide (amino acids 35–55 (MOG35–55). Bhlhe40-/- mice were markedly resistant to EAE
(Figure. 2-1A), showing no leukocyte inﬁltration on histological examination of spinal cord
sections (Figure. 2-1B). Bhlhe40 was required by the hematopoietic compartment for EAE
susceptibility, since reconstitution of irradiated Bhlhe40-/- mice with WT bone marrow (BM)
caused susceptibility to EAE, whereas reconstitution of WT mice with Bhlhe40-/- BM engendered
EAE resistance (Figure. 2-1C). Bhlhe40 is expressed in activated TH cell subsets (Figure. 21D), as previously reported32, 198. Transfer of WT and Bhlhe40-/- TH cells each reconstituted the
T-cell compartment of recipient Rag1-/- mice equally (Figure. 2-1E), but only WT cells, and not
Bhlhe40-/- cells, allowed development of EAE after immunization (Figure. 2-1F). The central
nervous system (CNS) from MOG35–55-immunized Bhlhe40-/- mice had reduced inﬁltrating
myeloid cells (CD45hiCD11b+) relative to WT mice. In Bhlhe40-/- mice, these cells lacked MHC
class II expression, as did resident microglia (CD45intCD11b+) (Figure. 2-2, A and B).
Immunized Bhlhe40-/- mice also harbored fewer CNS-inﬁltrating CD4+ T cells (Fig. 2-2C). CNSinﬁltrating CD4+ T cells in WT mice produced IFN-γ and IL-17A, while the few CNS-inﬁltrating
CD4+ T cells in Bhlhe40-/- mice had reduced IFN-γ and IL-17A production (Figure. 2-2, D and
E). Notably, WT CD4+ T cells produced GM-CSF, but this was reduced by ~90% in Bhlhe40-/mice (Figure. 2-2, D, E, and F). WT and Bhlhe40-/- mice showed a similar low frequency of IL10-producing CD4+ T cells in the CNS at the peak of disease (Figure. 2-2G). Bhlhe40-/- mice
showed a slight reduction in the frequency of CNS-inﬁltrating Foxp3+ CD4+ T cells (analyzed at
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day 29 after immunization, Figure. 2-2H). γδ T cells are known to inﬁltrate the CNS during
EAE, and promote neuroinﬂammation via their production of IL-17 and GM-CSF68, 199. The role
of IFN-γ production by these cells in this setting is unclear. Immunized Bhlhe40-/- mice harbored
~30-fold fewer CNS-inﬁltrating γδ T cells compared with WT mice. Bhlhe40-/- γδ T cells
produced similar levels of IFN-γ and partially reduced levels of IL-17A, but more markedly
reduced levels of GM-CSF (Figure. 2-2, I and J). Together with our observations on
signiﬁcantly reduced GM-CSF production by Bhlhe40-/- CD4+ T cells, these results suggest that
Bhlhe40 is required for GM-CSF production by pathogenic T cells during neuroinﬂammation.
We also tested an adoptive transfer EAE system in which a WT TH1-polarized MOG35–55-speciﬁc
T cell line was transferred to WT or Bhlhe40-/- recipients200. These T cells produced IFN-γ and
GM-CSF, but not IL-17A, upon stimulation (Figure. 2-3A). When 5 million T cells were
transferred, Bhlhe40-/- mice were protected from EAE, although when 10 million T cells were
transferred, Bhlhe40-/- and WT mice both showed a similar incidence and severity of EAE
(Figure. 2-3, B and C). We speculate that these results are the result of a requirement for
Bhlhe40 in host T cells during the induction of neuroinﬂammation by low numbers of adoptively
transferred MOG-speciﬁc T cells. Overall, our results indicate a role for Bhlhe40 in both
immunization-induced and passive EAE.

2.3.2 Bhlhe40 regulates T-cell cytokine production after immunization
Draining lymph nodes (DLNs) from immunized Bhlhe40-/- mice had reduced cellularity relative
to WT mice (Figure. 2-4A). Flow cytometry of these DLNs indicated normal frequencies of
lymphoid and myeloid cell populations, indicating that the decreased cellularity was not due to
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the reduction in a particular cell type (Figure. 2-4B). Similar frequencies of interleukin 2 (IL-2)and IFN-γ-producing T cells and a modest reduction in the frequency of IL-17A-producing T
cells were observed in DLNs from Bhlhe40-/- mice relative to WT mice in response to stimulation
with MOG35–55 or concanavalin A (ConA) as measured by ELISPOT assays (Figure. 2-4C).
Consistent with their decreased IL-17A production, the frequency of RORγt+ CD4+ T cells was
moderately decreased in DLNs of Bhlhe40-/- mice (Figure. 2-4, D and E). DLNs from Bhlhe40-/mice showed a markedly reduced frequency of MOG35–55-speciﬁc GM-CSF-producing T cells
relative to WT mice, and an increased frequency of MOG35–55-speciﬁc IL-10-producing T cells
(Figure. 2-5A). Intracellular cytokine staining (ICS) of DLN cells also showed diminished GMCSF (Figure. 2-5, B & C) and increased IL-10 production (Figure. 2-5, D and E) from Bhlhe40/-

CD4+ T cells. The defect in GM-CSF production by Bhlhe40-/- CD4+ T cells could not be fully

restored in vitro by culture with IL-1β or IL-23, cytokines that are reported to promote GM-CSF
secretion68, 174, 175, 176(Figure. 2-5, F and G). The increased IL-10 production by Bhlhe40-/- CD4+
T cells was signiﬁcantly augmented by in vitro culture with IL-12 (Figure. 2-5, H and I). We
analyzed cytokine production by Bhlhe40-/- T cells in three additional settings. First, instead of
using the self-peptide MOG35–55, we immunized mice with the foreign, MHC class II-restricted
peptide of chicken ovalbumin (OVA323–339). Again, Bhlhe40-/- CD4+ T cells failed to produce
GM-CSF following this immunization, with intact IL-2 and IFN-γ production, and partially
decreased IL-17A production (Figure. 2-6A). Second, we analyzed CD4+ T-cell cytokine
responses in immunized mixed BM chimeric mice. Bhlhe40-/- T cells showed a T cell-intrinsic
defect in GM-CSF secretion in this setting, with normal IL-17A secretion (Figure. 2-6, B and
C). Third, we analyzed cytokine responses in immunized Rag1-/- mice that had received transfers
of puriﬁed WT or Bhlhe40-/- CD4+ T cells (Figure. 2-6D). Bhlhe40-/- CD4+ T cells showed
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reduced GM-CSF and increased IL-10 production in this setting, with normal IFN-γ production.
For unclear reasons, IL-17A secretion by Bhlhe40-/- CD4+ T cells appeared decreased in the
spleen, but increased in the DLN in this setting. γδ T cells in the DLNs of immunized Bhlhe40-/mice also showed a selective loss of GM-CSF production that could not be restored by in vitro
culture with IL-1β and/or IL-23 (Figure. 2-7, A and B). Naive splenic γδ T cells from nonimmunized Bhlhe40-/- mice were capable of responding to IL-1β, IL-23 and IL-12199, 201, as
demonstrated by their increased size and granularity, but failed to produce normal levels of GMCSF in these cultures (Figure. 2-7, C and D). Overall, these results assessing T-cell responses in
the periphery in combination with our ﬁndings in the CNS indicate that both CD4+ and γδ T cells
require Bhlhe40 to produce GM-CSF.

2.3.3 Bhlhe40 regulates cytokine production by in vitro polarized TH cells
We tested whether Bhlhe40-/- CD4+ T cells responded normally to in vitro activation. Stimulation
with plate-bound anti-CD3 alone or anti-CD3 and anti-CD28 led to normal IL-2 secretion,
reduced GM-CSF secretion and increased IL-10 secretion by Bhlhe40-/- CD4+ T cells (Figure. 28A). We next examined cytokine production by in vitro polarized TH cells from WT and
Bhlhe40-/- mice. In general, polarized TH cells from Bhlhe40-/- mice showed normal production of
their signature cytokines, although Bhlhe40-/- TH1 cells showed a ~40% decrease in IFN-γ
production, consistent with a previous report30(Figure. 2-8, B and C). It is possible that Bhlhe40
served as a cofactor for T-bet to enhance IFN-γ production in TH1 cells, like its role in iNKT
cells34. Consistent with these cytokine results, we found decreased expression of the transcription
factor T-bet in Bhlhe40-/- TH1 cells, with nearly normal expression of Gata-3 and RORγt in
Bhlhe40-/- TH2 and TH17 cells, respectively (Figure. 2-8D). GM-CSF production varied between
WT TH1, TH2 and TH17 cells, with the least production of GM-CSF found in TH1 cultures
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(Figure. 2-8, B, C and E), consistent with an earlier report174. Bhlhe40-/- T cells showed
markedly reduced production of GM-CSF under all conditions of differentiation (Figure. 2-8, B,
C and E). This lack of GM-CSF production by Bhlhe40-/- T cells was also seen in TH17 cultures
that utilized TGF-β3 in place of TGF-β1(data not shown)189. Bhlhe40-/- TH1 and TH17 cells
showed increased IL-10 production relative to WT cells, while WT and Bhlhe40-/- TH2 cells
showed similar, high-level IL-10 production (Figure. 2-8, B and C). The increased IL-10
production in Bhlhe40-/- TH1 cells came largely from IFN-γ+ cells, while in TH17 cultures it came
from both IL-17A+ and IL-17A- populations (Figure. 2-8F). We further tested whether the
increased IL-10 production by Bhlhe40-/- TH cells could contribute to their diminished GM-CSF
production. Co-culture of congenically marked WT and Bhlhe40-/- TH cells under non-polarizing
conditions showed that increased IL-10 secretion and decreased GM-CSF secretion were both
cell intrinsic properties of Bhlhe40-/- TH cells (Figure. 2-8G). We tested whether abnormal GMCSF and IL-10 production by Bhlhe40-/- CD4+ T cells could be restored by the reintroduction of
Bhlhe40. Retrovirally transduced Bhlhe40-/- TH1 and TH17 cells overexpressing Bhlhe40
produced increased levels of GM-CSF and decreased levels of IL-10 compared with nontransduced Bhlhe40-/- T cells or Bhlhe40-/- T cells transduced by an empty retrovirus (Figure. 29). Overexpressing Bhlhe40 modestly increased GM-CSF and decreased IL-10 production by
WT TH17 cells, but had little effect on WT TH1 cells.

2.3.4 Molecular analysis of Bhlhe40-regulated target genes
We performed expression microarray analysis on WT and Bhlhe40-/- CD4+ T cells cultured in
TH1, TH2 and TH17 conditions and validated these results by quantitative RT-PCR for selected
transcripts (Figure. 2-10). This analysis conﬁrmed that Bhlhe40-/- T cells were able to acquire
characteristics largely reﬂective of normal TH1, TH2 or TH17 differentiation, including their
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expression of signature cytokines and transcription factors (Figure. 2-10, A and C). However, a
common set of genes was affected by the loss of Bhlhe40 across two or more TH lineages
(Figure. 2-10, B, D and E), including reduced expression of Csf2, Il3, Il1a, Ccl1, Iﬁtm3 and
Ptgs2. Notably, expression levels of Il10, Ikzf3 (Aiolos) and Xcl1 were increased in Bhlhe40-/- T
cells. We conﬁrmed reduced secretion of IL-3 by Bhlhe40-/- CD4+ T cells following stimulation
with anti-CD3 alone or anti-CD3 and anti-CD28 (Figure. 2-10F). To examine whether the
Il3/Csf2 and Il10 loci were directly bound by Bhlhe40, we performed an analysis of Bhlhe40
ChIP-Seq data generated from CH12 cells by the Mouse Encyclopedia of DNA Elements
(ENCODE) Consortium202. RNA sequencing (RNA-Seq) performed on this B-cell lymphoma
line by the same Consortium showed these cells to express Bhlhe40, Il3, Csf2 and Il10. Within
the Il3/Csf2 locus, Bhlhe40 seemed to bind multiple sites, including a previously identiﬁed distal
enhancer located ~30kb downstream of Csf2 that regulates the expression of both cytokine genes
in this locus (Figure. 2-11A)203. Within the Il10 locus, Bhlhe40 also seemed to bind multiple
sites, including two known regulatory elements (Figure. 2-11B)204, 205. In both loci, many
regions bound by Bhlhe40 were also bound by the general transcriptional regulators p300206, 207
and BRG1203 and the TH cell subset-speciﬁc transcription factors T-bet208 and RORγt207. Bhlhe40
is likely one of many transcriptional regulators present at these regions working in concert to
control gene expression.

2.3.5 IL-10R blockade renders Bhlhe40-/- mice susceptible to EAE
As our expression microarray experiments demonstrate that Bhlhe40 deﬁciency leads to the
dysregulation of hundreds of genes in polarized TH cells, we expect that the summation of these
changes in gene expression underlies the T cell-intrinsic requirement for Bhlhe40 in T-cell
encephalitogenicity. Nevertheless, we sought to test whether the administration of exogenous
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GM-CSF could render Bhlhe40-/- mice susceptible to EAE. In two individual experiments,
Bhlhe40-/- mice treated daily with either 10 or 100 ng per day recombinant murine GM-CSF
intraperitoneally beginning on the day of immunization did not develop clinical EAE (n = 3–5
mice per experiment). In both of these experiments, control WT mice experienced a typical
course of EAE, indicating successful immunization. Systemic GM-CSF treatment at a dose of 10
ng per day was reported to replace endogenous GM-CSF in Csf2-/- mice, such that these mice
developed EAE when GM-CSF was administered after immunization209. Therefore, we take our
results to indicate that Bhlhe40-/- mice resist EAE for reasons beyond just their defective
production of GM-CSF by T cells. We also tested whether blockade of IL-10 signaling could
affect the development of EAE in Bhlhe40-/- mice. Groups of WT or Bhlhe40-/- mice were treated
biweekly with control rat IgG or anti-IL-10R blocking antibody (clone 1B1.3A), beginning 1 day
prior to immunization and continuing throughout the course of the experiment. Anti-IL-10R
antibody treatment of immunized WT mice led to the high incidence of early morbidity and a
shock-like syndrome, characterized by rufﬂed fur, weight loss and a hunched posture, with rapid
death prior to the onset of clinical EAE (Figure. 2-12A). This unexpected mortality, which we
attribute to acute IL-10R blockade in the setting of a strong immune stimulus, was not apparent
in immunized WT mice treated with control antibody, which experienced a typical course of
EAE (Figure. 2-12B and Table 1). Immunized Bhlhe40-/- mice treated with anti-IL-10R
antibody experienced only infrequent early morbidity. Those WT mice treated with anti-IL-10R
antibody that did not succumb to an early death developed very severe EAE. Immunized
Bhlhe40-/- mice treated with control antibody resisted EAE, while nearly half of all Bhlhe40-/mice treated with anti-IL10R antibody developed severe clinical EAE, like that of control
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antibody-treated WT mice. Overall, these results reveal that the pathogenicity of Bhlhe40-/autoreactive T cells is at least partially, regulated by IL-10.
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2.4 Discussion
Here we have shown that Bhlhe40-/- mice are protected from immunization-induced autoimmune
neuroinﬂammation. TH cells have a cell-intrinsic requirement for Bhlhe40 during
encephalomyelitis, and in these cells Bhlhe40 transcriptionally regulates the production of GMCSF and IL-10. In vivo blockade of IL-10R allows immunized Bhlhe40-/- mice to develop EAE,
indicating the important role of this cytokine in regulating autoreactive T-cell pathogenicity.
Bhlhe40-/- mice were also protected from adoptively transferred EAE using an encephalitogenic
TH1 cell line, but only when a low number of pathogenic T cells were transferred (Figure. 2-3, B
and C). In this system, cytokine-producing host TH cells inﬁltrate the CNS and participate in
regulating neuroinﬂammation200. Large numbers of adoptively transferred, autoreactive WT TH1
cells can overcome a requirement for Bhlhe40 in host cells (Figure. 2-3C). Overall, these results
are reminiscent of experiments in which low numbers of an encephalitogenic TH1 cell line were
unable to induce disease in IL-17A-deﬁcient mice, but in which higher cell numbers could
initiate neuroinﬂammation200. We favor a model in which the explanation for our adoptive
transfer results stems from a requirement for Bhlhe40 in host TH and γδ T cells, although it
remains a possibility that Bhlhe40 also functions in non-T cells during adoptively transferred
EAE.
The characteristics that deﬁne pathogenic TH cells in EAE have been a subject of recent
debate187, 188, 189. Neither IFN-γ nor IL-17, the signature cytokines of TH1 and TH17 cells,
respectively, are required for the development of EAE167, 169, yet in vitro derived TH1 and TH17
cells speciﬁc for myelin antigens both can induce encephalomyelitis172, 210. These seemingly
conﬂicting observations have been reconciled by the ﬁnding that GM-CSF, produced by both
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TH1 and TH17 cells, serves a non-redundant pro-inﬂammatory role in EAE development172, 173,
174, 175, 176

. Control of Csf2 expression involves AP-1, NFAT, Runx1, NF-kB, histone acetylation

and BRG1 recruitment177, 178, 179, 180, 181, 182, 203. c-Rel- and NF-kB1deﬁcient T cells produce less
GM-CSF, but these factors may be non-selective in their impact on cytokine production180, 181.
Malt1, a protease regulating the NF-kB pathway, was reported to be required for GM-CSF
production by TH17 cells, but not TH1 cells211, implying that the pathways that control GM-CSF
production may not be the same in all TH cell lineages. In fact, we ﬁnd that Bhlhe40 appears to
play a less important role in regulating GM-CSF production in TH2 cells compared with its role
in TH1 or TH17 cells, as GM-CSF secretion is only partly abrogated in Bhlhe40-/- TH2 cells.
Similarly, our observation that Bhlhe40-/- mice can infrequently develop clinical EAE with some
T-cell production of GM-CSF (Figure. 2-2F) in the CNS indicates that Bhlhe40 is not absolutely
required for Csf2 expression in T cells. Bhlhe41 (also known as Dec2, Sharp1 or Bhlhb3), the
closest homologue to Bhlhe40, is expressed most highly in TH2 cells among activated TH-cell
subsets198, 212, and perhaps this factor can substitute for Bhlhe40 in some settings in the
regulation of Csf2 transcription.
The role of RORγt in GM-CSF production by CD4+ T cells is controversial174, 175, 176. One study
found that Rorc-/- CD4+ T cells activated in the presence of anti-IFN-γ- and anti-IL-12
neutralizing antibodies produced less GM-CSF than WT CD4+ T cells, but Rorc-/- TH1 and TH17
cells produced normal or even greater GM-CSF than WT T cells174. These investigators found
that retroviral RORγt overexpression increased GM-CSF production, so despite these
incongruous results, they suggested that RORγt drives GM-CSF production. A second study also
showed that Rorc-/- TH17 cells produced an increased amount of GM-CSF relative to WT TH17
cells175, leading this group to suggest that RORγt is not required for GM-CSF production. We
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observed normal Rorc expression in Bhlhe40-/- TH17 cells in our microarrays (Figure. 2-10A),
and speculate that Bhlhe40 directly regulates Csf2 expression.
The recently described molecular signatures of pathogenic versus non-pathogenic TH17 cells189
195

includes four genes that we ﬁnd to be selectively regulated by Bhlhe40 (Csf2 and Il3 for

pathogenic TH17 cells; Il10 and Ikzf3 for non-pathogenic TH17 cells) (Figure. 2-10). Given these
data, we believe that Bhlhe40 serves as a transcription factor that shapes the encephalitogenicity
of TH17 cells. Considering IL-10 production in particular, we ﬁnd the largest difference between
WT and Bhlhe40-/- TH cells to be in TH1 cultures or in cells from immunized mice cultured with
IL-12. This type of IL-10 production by TH1 cells has been reported to involve signals through
ERK, STAT4 and c-Maf195. Our data point to a cell-intrinsic role for Bhlhe40 in regulating IL-10
production in T cells, and we speculate that Bhlhe40 serves as a direct negative regulator of Il10.
Bhlhe40 could be acting in TH cells in some cases as a transcriptional activator and in others as a
transcriptional repressor on different direct target genes, perhaps based on its interactions with
other transcription factors. Examples exist for both activating and repressive functions of
Bhlhe40213, 214. It also remains possible that some genes whose expression is abnormal in
Bhlhe40-/- TH cells are indirect targets of Bhlhe40.
Supporting the importance of IL-10 in EAE pathogenesis, we found that nearly half of all
Bhlhe40-/- mice treated with an anti-IL-10R blocking antibody developed EAE. Although IL-10deﬁcient mice are known to develop more severe EAE than WT191, 192, 193, they have not been
reported to exhibit early mortality prior to the onset of encephalomyelitis. We speculate that the
sudden inhibition of IL-10 signaling by anti-IL-10R antibody in our experiments is
fundamentally different than the lifelong absence of this signaling, such that antibody-mediated
blockade resulted in a pro-inﬂammatory cytokine-driven shock-like syndrome. Antibody-treated
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Bhlhe40-/- mice were largely protected from this syndrome, implying that pro-inﬂammatory
cytokines in these mice, perhaps including GM-CSF, were produced at lower levels.
Interestingly, some Bhlhe40-/- mice were fully protected from EAE even in the setting of IL-10R
blockade, and we speculate that this was also due to their decreased levels of pro-inﬂammatory
cytokines. Nevertheless, our results support the notion that Bhlhe40-/- TH cells can be
encephalitogenic in the setting of IL-10R blockade. Further experiments will be performed to
determine whether Bhlhe40-/- TH cells are themselves the critical source of IL-10 preventing
autoimmunity in these mice.
While we were preparing this manuscript, a separate study also identiﬁed Bhlhe40 as a
transcription factor required for autoreactive CD4+ T-cell responses using the EAE system33.
Martínez-Llordella et al. identiﬁed Bhlhe40 as a gene whose expression was induced in activated
CD4+ T cells in a CD28-dependent manner. These authors found Bhlhe40-deﬁcient mice (a
separately generated line than was used in our study26 to be resistant to the induction of EAE,
and found decreased CD4+ T cell production of several cytokines, including GM-CSF. Both our
study and theirs found decreased IL-17A responses in immunized Bhlhe40-/- mice, with both
identifying this defect as cell-extrinsic based on immunization experiments in mixed bone
marrow chimeras. Our in vitro experiments showing normal Il17a transcript and IL-17A
production by Bhlhe40-/- TH17 cells also suggest no direct role for Bhlhe40 in controlling this
cytokine.
There are some key differences between our study and the work of Martínez-Llordella et al.
They observed MOG35–55-speciﬁc CD4+ T-cell responses in Bhlhe40-/- mice to be only slightly
reduced in frequency at day 7 after immunization as determined by tetramer staining, but to be
completely absent when assessed with a proliferation assay or by ELISAs for IL-17A, IFN-γ and
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GM-CSF. In our assessment of CD4+ T-cell priming by ELISPOT assays using DLN cells at day
7 after immunization, we found essentially intact IL-2 and IFN-γ responses, partially decreased
IL-17A responses and absent GM-CSF responses (Figure. 2-4C and Figure. 2-5A). We
speculate that technical differences in the assay formats, cell culture densities or assay times
could explain these discrepancies. An additional difference between our study and that of
Martínez-Llordella et al. is that we found normal IL-2 production after in vitro stimulation of
Bhlhe40-/- CD4+ T cells (Figure. 2-8A), while they saw a ~50% reduction in IL-2 secretion. Our
results are consistent with those of Miyazaki et al.32 who reported normal IL-2 secretion by
Bhlhe40-/- CD4+ T cells, and we again speculate that differences in cell culture conditions may
explain these discrepancies. Finally, our expression microarrays and phenotypic analysis of
polarized Bhlhe40-/- TH cells identiﬁed increased transcription and secretion of IL-10 by these
cells compared with WT TH cells. Il10 was not identiﬁed as being differentially expressed in the
transcriptional analysis performed by Martínez-Llordella et al., although we speculate that this
may be related to their analysis of naive T cells activated under non-polarizing conditions at
early time points (4 and 24h).
In conclusion, we have demonstrated that Bhlhe40 is required for the encephalitogenicity of
CD4+ T cells, likely through its regulation of GM-CSF and IL-10 production. Bhlhe40 is also
required for γδ T-cell production of GM-CSF. Bhlhe40 controls these cytokines transcriptionally,
but further investigation will be required to understand the molecular details of this regulation.
Moreover, the question of whether regulation of these cytokines by Bhlhe40 in T cells inﬂuences
pathogenesis in other autoimmune or infectious diseases is intriguing. The role of GM-CSF in
autoimmune disease has prompted clinical interest in therapeutics to target this cytokine in
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rheumatoid arthritis and multiple sclerosis215. Bhlhe40, or pathways that regulate its expression
or function, could also represent therapeutic targets in human autoimmunity.
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2.5 Methods
Mice. C57BL/6 (Taconic), B6.SJL (Taconic), B6.PL-Thy1a/CyJ (Jackson), Rag1-/- (on a
C57BL/6 background, Jackson) and Bhlhe40-/- mice30 (backcrossed 10 generations to the
C57BL/6 background) were maintained in our SPF facility. Experiments were performed with
mice of either sex (groups were sex matched within individual experiments) at 8–24 weeks of
age. No Bhlhe40-/- mice on the C57BL/6 background displayed lymphoproliferative disease in
our colony throughout this age range, in keeping with a previous report of C57BL/6 Bhlhe40-/mice32. Flow cytometry of splenocytes and bone marrow from Bhlhe40-/- mice in our colony at
the ages used in these experiments showed normal leukocyte populations (Figure. 2-13). All
animal experiments were approved by the Animal Studies Committee of Washington University.
Bone marrow transplantation and TH cell transfers. Bone marrow cells were collected from
femurs and tibias of donor mice, and 10–20 million cells were injected intravenously into
recipient mice following irradiation (1,200 rads). Mixed chimeras were prepared by mixing
donor bone marrow cells at a 1:1 ratio before injection. Mice were used in experiments 13–16
weeks following transplantation. For cell transfers, total CD4+ T cells were magnetically puriﬁed
from donor splenocytes (Invitrogen Dynabeads FlowComp Mouse CD4 kit, typical purity ~90–
95%). CD4+ T cells (7 to 10 million) were injected intravenously into Rag1-/- mice 1 day prior to
the induction of EAE or immunization for the assessment of T-cell responses.

Induction of EAE and immunizations. For active EAE induction, mice were immunized
subcutaneously with 100mg MOG(35–55) (C S Bio Co.) emulsiﬁed in CFA (made with 5 mg/ml
heat-killed Mycobacterium tuberculosis H37Ra (BD Difco) in incomplete Freund’s adjuvant
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(BD Difco)). Pertussis toxin (List Biological Laboratories) was injected intraperitoneally (300ng)
on days 0 and 2. Mice were observed for signs of EAE and graded on a standard 0–5 scale as
described175. In some experiments, mice were treated daily with recombinant murine GM-CSF
(Peprotech) at a dose of 10 ng per day or 100 ng per day intraperitoneally, beginning on the day
of immunization and continuing throughout the course of the experiment. In some experiments,
mice were treated with control rat IgG (Sigma) or anti-IL-10R monoclonal antibody (clone
1B1.3A, BioXcell)216. Mice were given 250 mg of antibody intraperitoneally two times per
week, beginning 1 day prior to immunization. For histology experiments, spinal cords were
dissected, ﬁxed in formalin, embedded in parafﬁn, sectioned and stained with hematoxylin and
eosin (H&E).
For adoptively transferred EAE, MOG35–55-speciﬁc TH1 cell lines were generated by culturing
CD4+ T cells from MOG35–55-immunized CD90.1 congenic B6.PL-Thy1a/CyJ mice with
MOG35–55, irradiated C57BL/6 splenocytes, IL-2 and IL-12 for two or four rounds of
stimulation200. Four days after the last stimulation, 5–10 million live T cells were intravenously
transferred to recipient mice.
For analysis of T-cell responses in DLNs, mice were immunized in hind footpads with 10
nanomoles MOG35–55 or OVA323–339 emulsiﬁed in CFA. Popliteal lymph nodes were collected on
day 7.

Cell preparation. DLNs from immunized mice were digested with 250 mg/ml collagenase B
(Roche) and 30 U/ml Dnase I (EMD) for 40–60 min at 37°C with stirring in Iscove’s modiﬁed
Dulbecco’s media containing 10% FCS, L-glutamine, sodium pyruvate, non-essential amino
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acids, penicillin/streptomycin and 2-mercaptoethanol (cIMDM). EDTA (5 mM ﬁnal) was added
and cells were incubated on ice for 5 min. Cells were passed through a 70-mm strainer before
cell counting with trypan blue. Spleens were mashed between frosted glass slides and made into
a single-cell suspension. Red blood cells were lysed with ACK lysis buffer. Cells were passed
through a 70-mm strainer before cell counting with acetic acid.
Brains and spinal cords were removed following perfusion with 30 ml PBS via cardiac puncture
of the left ventricle. Organs were minced and digested with 500 mg/ml Type I collagenase
(Sigma) and 10 mg/ml DNAse I (Sigma) in the presence of 0.1 mg/ml TLCK trypsin inhibitor
(Sigma) and 10 mM Hepes (pH 7.4) in HBSS at room temperature for 1h. Following
centrifugation, cells were resuspended in 70% Percoll (Sigma) in HBSS and additional 37% and
30% layers were added above the cells. Gradients were centrifuged for 30 min at 1,200g. The
30% Percoll layer containing debris was discarded, and the cells from the 37% layer were
collected and washed in HBSS before stimulation or ﬂow cytometry.

Cell culture. DLN cells from MOG35–55-immunized mice were cultured in cIMDM and
stimulated with 10mM MOG35–55 for 4 days before supernatants were collected for ELISAs or
before ICS. In some cases, IL-1b (10 ng/ml, BioLegend), IL-23 (20 ng/ml, BioLegend) or IL-12
(2 ng/ml, BioLegend) was added to the culture at set-up.
Splenocytes or magnetically puriﬁed total splenic CD4+ T cells (Invitrogen Dynabeads
FlowComp Mouse CD4 kit) from untreated mice cultured in cIMDM were stimulated with platebound anti-CD3 antibody (10 mg/ml, clone 1452C11, BioLegend) with or without plate-bound
anti-CD28 antibody for 48–72h (5 mg/ml, clone 37.51, BioLegend). Supernatants were collected
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for ELISAs or ICS was performed on cells. In some experiments, splenocytes were cultured for 3
days with IL-1β and/or IL-23 without TCR stimulation. ICS was subsequently performed on
these cells, gating on γδ T cells.
For TH cell polarization, magnetically puriﬁed total CD4+ T cells (Invitrogen Dynabeads
FlowComp Mouse CD4 kit) or naive CD4+ T cells (Stemcell Technologies Easysep Mouse
Naive CD4+ T Cell Isolation kit, typical purity ~90–96%) were cultured in cIMDM with platebound anti-CD3 and anti-CD28 antibodies in the presence of cytokines (BioLegend except TGFβ3) and neutralizing antibodies (BioLegend except anti-IL-12) as follows. TH1 conditions: IFN-γ
(200 ng/ml), IL-12 (2 ng/ml), anti-IL-4 (5 mg/ml, clone 11B11). TH2 conditions: IL-4 (10
ng/ml), anti-IFN-γ (5 mg/ml, clone XMG1.2 or clone H22), anti-IL-12 (10 mg/ml, clone Tosh, a
gift from Emil R. Unanue, Washington University). TH17 conditions: TGF-β1 (2 ng/ml) or TGFβ3 (2 ng/ml) (Miltenyi), IL-6 (25 ng/ml), IL-1β (10 ng/ml), IL-23 (10 ng/ml), anti-IL-4 and antiIFN-γ. Cells were split at day 3, and on days 4–5 cells were either used for ICS or stimulated for
24h with plate-bound anti-CD3 and anti-CD28 for assessment of cytokine secretion by ELISA.

ELISPOT and ELISA assays. ELISPOT assays were performed on Mutiscreen Filter Plates
(Millipore). DLN cells from immunized mice were plated at 5x105–1x106 cells per well in
cIMDM and stimulated with 10 mM peptide or 1 mg/ml ConA overnight at 37°C. IL-2, IFN-γ
and IL-10 ELISPOT antibody pairs were from BD Bioscience. IL-17 and GM-CSF ELISPOT
antibody pairs and streptavidin-alkaline phosphatase were from BioLegend. Plates were
developed with NBT/BCIP substrate (Roche) and spots were counted on an Immunospot counter
(Cellular Technology Ltd.). ELISA assays were performed on Nunc Maxisorp plates using the
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same antibody pairs as above but were developed with streptavidin-HRP (BioLegend) and TMB
substrate (BioLegend). Standard curves for these ELISAs were generated with puriﬁed
cytokines. The Mouse IL-3 ELISA MAX kit was used to measure IL-3 (BioLegend).

Flow cytometry. All antibodies were used at a dilution of 1/200 except where noted.
Streptavidin conjugates were used at a dilution of 1/400. The following anti-mouse antibodies
were from BioLegend: FITC, APC or biotin anti-CD3e (1452C11), PB anti-CD4 (RM4-5), APCCy7 or PerCP-Cy5.5 anti-CD8a (53-6.7), APC or biotin anti-TCR γδ (GL3), FITC anti-CD25
(PC61), PB anti-CD44 (IM7), FITC anti-B220 (RA3-6B2), FITC anti-CD45.1 (A20), APC or
biotin anti-CD45.2 (104), PerCP-Cy5.5 anti-Siglec H (551), FITC anti-Ly6C (HK1.4), PE antiLy6G (1A8), PE-Cy7 anti-CD11b (M1/70), APC-Cy7 anti-CD11c (N418), PB anti-I-A/I-E (M5/
114.15.2, used at 1/500), PE-Cy7 anti-IFN-γ (XMG1.2), PerCP-Cy5.5 anti-IL-17A (TC1118H10.1), PE anti-GM-CSF (MP1-22E9), PE anti-KLH (RTK2758, isotype rat IgG2a, k), APC
or biotin anti-IL-10 (JES5-16E3) and streptavidin-APC. The following anti-mouse antibodies
were from BD Biosciences: V450 anti-CD4 (RM45) and V500 anti-B220 (RA3-6B2). APC antiCD62L (MEL-14), PE anti-CD25 (PC61.5), APC-e780 anti-CD45 (30-F11, used at 1/600), PE
anti-Foxp3 (FJK-16s), eFluor660 anti-T-bet (eBio4B10), PerCP-eFluor710 anti-Gata-3 (TWAJ),
APC anti-RORγt (AFKJS-9) and streptavidin-APC-e780 were from eBioscience.
For ICS, cells were stimulated with PMA (50 ng/ml, Enzo Life Sciences) and ionomycin (1 µM,
Enzo Life Sciences) in the presence of brefeldin A (1 mg/ml, Enzo Life Sciences) for 4–5 hours.
Surface staining was performed in FACS buffer (0.5% BSA, 2 mM EDTA, 0.02% sodium azide
in PBS) in the presence of Fc receptor blocking antibody (clone 93, BioLegend) for 20 min at
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4°C followed by streptavidin staining if necessary. Cells were ﬁxed in 4% paraformaldehyde
(Electron Microscopy Sciences) for 20 min at room temperature followed by permeabilization
(0.1% BSA, 0.5% saponin in PBS) or with the BD Cytoﬁx/Cytoperm Fixation and
Permeabilization Kit. Cytokine staining was performed in permeabilization buffer for 20 min at
4°C. Staining for intracellular Foxp3, T-bet, Gata-3 and RORγt was performed in the
Foxp3/Transcription Factor Staining Buffer Set (eBioscience). Flow cytometry was performed
on a FACSCanto II (BD Bioscience) and data was analyzed with FlowJo (Tree Star Inc.).
For microarray experiments, naive CD4+ T cells (CD4+B220-CD25-CD44loCD62Lhi) were
puriﬁed (98% purity) by cell sorting on a FACSAria II (BD Biosciences) after B-cell depletion
using anti-B220 magnetic beads (Invitrogen).

Expression microarrays. Naive CD4+ T cells were cultured in TH0, TH1, TH2 or TH17
conditions for 4 days and stimulated for 4h with PMA and ionomycin before total RNA was
isolated (EZNA MicroElute Total RNA Kit, Omega Bio-Tek). RNA was ampliﬁed (Ovation
PicoSL WTA System V2, Nugen), labelled (Encore Biotin Module, Nugen), fragmented and
hybridized to Affymetrix Gene 1.0ST arrays. Array data were imported into Arraystar 5 software
(DNAstar) and then normalized using the robust multi-array analysis method with quantile
normalization. Probesets were curated according to a validated gene annotation, and only these
probesets were utilized in subsequent analyses. Correlation analysis was performed using
Arraystar 5. Heat maps were generated using GENE-E software (Broad Institute,
http://www.broadinstitute.org/cancer/software/GENE-E/). For analysis of GSE14308217, which
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was performed on Affymetrix Mouse Genome 430 2.0 arrays, we also used the robust multiarray analysis method with quantile normalization using Arraystar 5 software.

Quantitative RT-PCR. Magnetically puriﬁed total splenic CD4+ T cells (Invitrogen Dynabeads
FlowComp Mouse CD4 kit) were cultured in TH1, TH2 or TH17 conditions for 4 days and
stimulated for 4h with plate-bound anti-CD3 and anti-CD28 before total RNA was isolated
(EZNA MicroElute Total RNA Kit, Omega Bio-Tek). cDNA was synthesized (High Capacity
RNA-to-cDNA Kit, Invitrogen) and quantitative real-time PCR was performed according to the
manufacturer’s instructions with Power SYBR Green PCR Master Mix (Applied Biosystems) on
a StepOnePlus Real-Time PCR system (Applied Biosystems). Expression of genes was
determined relative to Hprt by the DCT method.
The following primers were used for quantitative RT-PCR. Ccl1, forward 5’GGCTGCCGTGTGGATACAG-3’, reverse 5’-AGGTGATTTTGAACCCACGTTT-3’; Csf2,
forward 5’-GCCATCAAAGAAGCCCTGAA-3’, reverse 5’-GCGGGTCTGCACACATGTTA3’; Hprt, forward 5’-TCAGTCAACGGGGGACATAAA-3’, reverse 5’GGGGCTGTACTGCTTAACCAG-3’; Iﬁtm3, forward 5’-CCCCCAAACTACGAAAGAATCA3’, reverse 5’- ACCATCTTCCGATCCCTAGAC-3’; Ifng, forward 5’GGATGCATTCATGAGTATTGC-3’, reverse 5’-CCTTTTCCGCTTCCTGAGG-3’; Ikzf3,
forward 5’-CTGAATGACTACAGCTTGCCC-3’, reverse 5’GCTCCGGCTTCATAATGTTCT-3’; Il1a, forward 5’- CGAAGACTACAGTTCTGCCATT-3’,
reverse 5’-GACGTTTCAGAGGTTCTCAGAG-3’; Il3, forward 5’GGGATACCCACCGTTTAACCA-3’, reverse 5’-AGGTTTACTCTCCGAAAGCTCTT-3’; Il4,
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forward 5’-ATCATCGGCATTTTGAACGAGG-3’, reverse 5’TGCAGCTCCATGAGAACACTA-3’; Il10, forward 5’-AGCCTTATCGGAAATGATCCAGT3’, reverse 5’-GGCCTTGTAGACACCTTGGT-3’; Il17a, forward 5’TTTAACTCCCTTGGCGCAAAA-3’, reverse 5’-CTTTCCCTCCGCATTGACAC-3’; Ptgs2,
forward 5’-TGCACTATGGTTACAAAAGCTGG-3’, reverse 5’TCAGGAAGCTCCTTATTTCCCTT-3’; Xcl1, forward 5’TAGCTGTGTGAACTTACAAACCC-3’, reverse 5’-ACAGTCTTGATCGCTGCTTTC-3’.

ChIP-Seq data analysis. Bhlhe40 ChIP-Seq data and RNA-Seq data performed by
ENCODE/Stanford/Yale using CH12 cells were directly viewed in the University of California
Santa Cruz (UCSC) Genome Browser on the NCBI37/mm9 mouse genome assembly.
Discriminative DNA Motif Discovery (DREME) software218 was used as part of the online
version of MEME-ChIP (http://meme.nbcr. net/meme/cgi-bin/meme-chip.cgi)219 to validate that
Bhlhe40 ChIP-Seq data identiﬁed the expected consensus motif for Bhlhe40 (CACGTG)21 with a
signiﬁcant E-value (4.8x10-1,391).
Raw data for the following ChIP-Seq data sets were downloaded from the Gene Expression
Omnibus of the NCBI: GSE40463 (p300 in TH1 and TH2 cells)206, GSE33802 (T-bet in TH1
cells)208, GSE20898 (Gata-3 in TH2 cells) 220, GSE40918 (RORγt and p300 in TH17 cells)207, and
GSE23719 (BRG1 in stimulated TH1, TH2, and TH17 cells)221. Each of these data sets was put
through the following pipeline of analysis within Galaxy (http://usegalaxy.org/)222, 223, 224:
FASTQ ﬁles were groomed, mapped to the NCBI37/mm9 mouse genome assembly using

42

Bowtie, converted from SAM to BAM ﬁles and peak called using MACS software. Tracks were
then viewed in the UCSC Genome Browser.

Cloning of Bhlhe40 and retroviral transduction. The murine Bhlhe40 full-length cDNA
(coding for amino acids 2–411) was cloned with the addition of 50 and 30 BglII sites, and a
Kozak sequence upstream of an N-terminal Myc tag from cDNA derived from GM-CSF-derived
bone marrow dendritic cells. The following primers were used: forward, 5’AATAAGATCTCCACCATGGCAGAACAGAAGCTCATTTCTGAAGAAGACTTGAACGA
ACGGATCCCCAGCGC-3’, reverse, 5’ATAAAGATCTCCCTCCAGAGTTTAGTCTTTGGTTTCT-3’. The resulting fragment was
digested with BglII and cloned into the BglII site of the GFP-RV vector which contains an
internal ribosome entry sequence upstream of GFP70. Retroviral vectors were transfected into
Phoenix E cells by calcium phosphate coprecipitation225, and viral supernatants were collected
after 2 days of culture. Magnetically puriﬁed total CD4+ T cells (Invitrogen Dynabeads
FlowComp Mouse CD4 kit) were stimulated in TH1 or TH17 conditions, and viral supernatants
were used to infect T cells by spin infection at 2,000 r.p.m. in the presence of 2 mg/ml polybrene
for 1h on day 1 after activation. Cells were used for intracellular ﬂow cytometry on day 4 of
culture.

Statistical analysis. Differences between groups were analyzed by an unpaired, two-tailed
Student’s t-test (Prism; GraphPad Software, Inc.), with P ≤ 0.05 considered signiﬁcant.
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Figure 2-1. Bhlhe40-deficient mice are protected from EAE.
(A) Mean clinical scores of EAE in immunized WT (n=18) or Bhlhe40-/- mice (n=18). Data are
combined from four independent experiments. Incidence of disease: WT mice 17/18, Bhlhe40-/mice 2/18. (B) H&E staining of spinal cord sections from WT and Bhlhe40-/- mice at day 13
after EAE induction. Scale bars: 200 mm in left images, 50 mm in insets. (C) Mean clinical
scores of EAE in BM chimeric mice 13 weeks after bone marrow reconstitution (n=5 per group).
(D) Relative expression of Bhlhe40 determined by expression microarrays performed by Wei
et al. (GSE14308). (E) Spleens from Rag1-/- mice at day 38 after CD4+ T cell transfer (day 37
following EAE induction) were analyzed by flow cytometry. (F) Mean clinical scores of EAE in
Rag1-/- mice that received CD4+ T cells from either WT or Bhlhe40-/- mice 1 day before
immunization (n=4 per group). For all figures throughout, error bars show mean ± SEM.
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Figure 2-2. Diminished neuroinflammation in Bhlhe40-/- mice.
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Figure 2-2. Diminished neuroinflammation in Bhlhe40-/- mice.
(A) Flow cytometry of CNS myeloid cells from WT and Bhlhe40-/- mice (n=3 per group) on day
16 after immunization. (B) Percentage of MHC class II+ microglia and infiltrating myeloid cells.
(C-E) Flow cytometry of CD4+ T cells in the CNS of WT and Bhlhe40-/- mice (n=3 per group) on
day 16 after immunization. (C) CD4+ T cell number. (D) Representative ICS for the indicated
cytokines. (E) Frequency of CD4+ T cells secreting each of the indicated eight possible
combinations of GM-CSF, IL-17A and IFN-γ. (F) Infiltrating CNS cells were prepared from
WT and Bhlhe40-/- mice on day 16 after EAE induction and ICS was performed. Four mice are
shown. The first WT mouse achieved a peak EAE clinical score of 3 on day 11, and maintained
this score through day 16. The second WT mouse achieved a peak EAE clinical score of 3 on
days 12 and 13, but EAE had resolved to a clinical score of 1 on day 15 and 16. The first
Bhlhe40-/- mouse showed mild clinical EAE, with a peak clinical score of 1 on days 11 and 12
with resolution to a score of 0 on days 13 through 16. The second Bhlhe40-/- mouse showed no
evidence of disease through day 16 (clinical score of 0). (G) Flow cytometry of CD4+ T cells in
the CNS of WT and Bhlhe40-/- mice on day 14 after immunization. Representative ICS for IFN-γ
and IL-10. (H) Flow cytometry of CD4+ T cells in the CNS of WT and Bhlhe40-/- mice on day
29 after immunization. Representative staining for CD25 and Foxp3 to identify Tregs. (I, J)
Flow cytometry of γδ T cells in the CNS of WT and Bhlhe40-/- mice (n=3 per group) on day 14
after immunization. (I) Representative ICS for IFN-γ, IL-17A and GM- CSF. (J) Frequency of γδ
T cells secreting IFN-γ, IL-17A or GM-CSF.
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Figure 2-3. High but not low number of autoreactive TH1 cells induce passive EAE in
Bhlhe40-/- mice.
(A) ICS of our WT MOG35-55-specific TH1 cell line upon PMA/ionomycin stimulation tested on
the day of adoptive transfer. (B, C) Mean clinical scores of EAE in WT or Bhlhe40-/- mice after
receipt of (B) 5 million or (C) 10 million adoptively transferred MOG35-55-specific WT TH1 cells.
Incidence of disease: (B) WT mice 5/5, Bhlhe40-/- mice 0/5, (C) WT mice 5/5, Bhlhe40-/- mice
5/5.
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Figure 2-4. Decreased cellularity of DLNs and TH17 responses in immunized Bhlhe40-/mice.
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Figure 2-4. Decreased cellularity of DLNs and TH17 responses in immunized Bhlhe40-/mice.
(A) WT (n=33) and Bhlhe40-/- mice (n=32) mice were immunized with MOG35-55/CFA, and
DLNs were collected at day 7. Live cell numbers per DLN were determined. Data are compiled
from 10 independent experiments. (B) Frequencies of the indicated cell types in DLNs from
immunized mice at day 7 (n=3 mice per group). Cell types were identified by the following
surface markers using flow cytometry: B cells, B220+MHC II+ ; CD4+ T cells, B220CD3ε+CD4+CD8- ; CD8+ T cells, B220-CD3ε+CD4 -CD8+ ; γδ T cells, B220-CD3ε+CD4-CD8- γδ
TCR+ ; NK/NKT cells, B220-NK1.1+ ; Polymorphonuclear leukocytes (PMNs), B220-NK1.1Ly6Ghigh ,CD11b+ ; Ly6C+ monocytes, B220-NK1.1- Ly6Gneg/lowCD11b+Ly6Chigh; conventional
dendritic cells (cDCs), B220-NK1.1-Ly6Gneg/lowCD11chighMHC II+ ; plasmacytoid DCs (pDCs),
B220+CD3ε-Siglec H+. (C) ELISPOT assays for the quantitation of cells secreting IL-2, IFN-γ,
and IL-17A performed on DLN cells 7 days after immunization of WT and Bhlhe40-/- mice.
Data are combined from three independent experiments (n=9 mice per group). (D-E) WT and
Bhlhe40-/- mice were immunized with MOG35-55/CFA, and DLNs were collected at day 7. (D)
Representative plots showing intracellular staining for RORγt gated on CD4+ T cells. (E)
Frequencies of RORγt+CD4+ T cells (n=3 per group).

51

Figure 2-5. T cells require Bhlhe40 for normal cytokine production after immunization.
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Figure 2-5. T cells require Bhlhe40 for normal cytokine production after immunization.
A-E, WT and Bhlhe40-/- mice were immunized with MOG35-55/CFA, and DLNs were collected at
day 7. (A) ELISPOT assays for the quantitation of cells secreting GM-CSF and IL-10 performed
on DLN cells 7 days after immunization of WT and Bhlhe40-/- mice. Data for GM-CSF is
combined from three independent experiments (n=9 mice per group). Data for IL-10 is from one
representative experiment of two (n=4 mice per group). (B) Representative plots gated on CD4+
T cells, showing ICS data for the indicated cytokines. Data 5 from stains in which a PE-isotype
control antibody (anti-KLH) was included in place of PE anti-GM-CSF are also presented. (C)
Frequencies of IFN-γ+, IL-17A+, and GM-CSF+ CD4+ T cells (n=6 per group). (D)
Representative plots gated on CD4+ T cells, showing ICS data for IFN-γ and IL-10. (E)
Frequencies of IFN-γ+ IL-10+ and IFN-γ- IL-10+ CD4+ T cells (n=3-4 per group). (F,H) DLN
cells from immunized WT and Bhlhe40-/- mice (n=14 per group) were cultured with or without
MOG35-55 and with or without IL-1β, IL-23 and/or IL-12 as indicated. (F) GM-CSF or (H) IL-10
was measured in the supernatant at day 4. Data are combined from five independent
experiments. Cells from all mice were not used in all conditions in each of the four experiments.
(G) DLN cells from immunized WT and Bhlhe40-/- mice were cultured with MOG35-55 with or
without IL-1β for 4 days, followed by ICS. Representative plots are gated on CD4+ T cells. (I)
DLN cells from immunized WT and Bhlhe40-/- mice were cultured with MOG(35–55) with or
without IL-12 for 4 days, followed by ICS. Representative plots are gated on CD4+ T cells.
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Figure 2-6. Bhlhe40-/- CD4+ T cells display a cell-intrinsic defect in GM-CSF and IL-10
production.
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Figure 2-6. Bhlhe40-/- CD4+ T cells display a cell-intrinsic defect in GM-CSF and IL-10
production.
(A) ELISPOT assays for the quantitation of cells secreting GM-CSF, IL-2, IFN-γ, and IL-17
performed on DLN cells 7 days after immunization of WT and Bhlhe40-/- mice with OVA323- 339
(n=4 per group). (B-C) ICS on DLN cells from the indicated MOG35-55/CFA-immunized mixed
BM chimeric mice (n=3 per group). (B) Representative plots gated on CD4+CD45.1+ or
CD4+CD45.2+ T cells. (C) Frequencies of IL-17A+ and GM-CSF+ CD4+ T cells (either CD45.1+
or CD45.2+). (D) Rag1-/- mice were immunized with MOG35-55/CFA one day after receiving
transfers of 7 million purified WT or Bhlhe40-/- CD4+ T cells. At day 7, responses in the spleen
and DLN were analyzed by ICS for the indicated cytokines, gating on CD4+ T cells.
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Figure 2-7. γδ T cells require Bhlhe40 for GM-CSF production in response to cytokines.
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Figure 2-7. γδ T cells require Bhlhe40 for GM-CSF production in response to cytokines.
(A) Frequencies of GM-CSF+ and IL-17A+ γδ T cells in DLNs 7 days after immunization of WT
and Bhlhe40-/- mice (n=3 per group) as determined by ICS. (B) DLN cells from immunized WT
and Bhlhe40-/- mice were cultured with or without MOG35-55 and with or without IL-1β and/or
IL-23 as indicated for 4 days. Cells were stimulated with PMA/ionomycin in the presence of
brefeldin A for 4 h and then analyzed for IL-17A and GM-CSF by intracellular staining (that is,
our normal ICS protocol). (C) WT and Bhlhe40-/- splenocytes were cultured with the indicated
cytokines for 3 days in the absence of TCR stimulation. Cells were analyzed by flow cytometry
for forward scatter (FSC) and side scatter (SSC) after PMA/ionomycin stimulation. Plots are
gated on γδ T cells. (D) WT and Bhlhe40-/- splenocytes were cultured with the indicated
cytokines for 3 days in the absence of TCR stimulation. Cells were stimulated with
PMA/ionomycin in the presence of brefeldin A for 4 hours and analyzed for GM-CSF, IL-17A
(top), and IFN-γ (bottom) by intracellular staining. Representative plots are gated on γδ T cells.
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Figure 2-8. TH cells require Bhlhe40 for normal cytokine production in vitro.
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Figure 2-8. TH cells require Bhlhe40 for normal cytokine production in vitro.
(A) CD4+ T cells from WT and Bhlhe40-/- mice (n=4 per group) were stimulated for 48 hours
with plate-bound anti-CD3 and anti-CD28 antibodies as indicated. IL-2, GM-CSF, and IL-10
were measured in the supernatant by ELISA. (B-C) CD4+ T cells from WT and Bhlhe40-/- mice
(n=3 per group) were polarized in TH1, TH2 or TH17 culture conditions for 4 days. (B)
Representative ICS for the indicated cytokines. (C) Frequencies of IFN-γ+, IL-4+, IL-17A+, GMCSF+ and IL-10+ cells in TH1, TH2 and TH17 cultures. (D) CD4+ T cells from WT and Bhlhe40-/mice (n=2-4 per group) were polarized in TH1, TH2, or TH17 culture conditions for 4 days and
intracellularly stained for expression of T-bet, Gata-3, and RORγt. Representative histograms are
shown. (E) TH1, TH2 and TH17 cells were stimulated for 24 h with anti-CD3 and anti-CD28.
GM-CSF was measured in the supernatant by ELISA. (F) Representative ICS for the indicated
cytokines. (G) CD4+ T cells from the indicated congenic mice were mixed prior to culturing in
non-polarizing conditions for 4 days, followed by ICS. Cells were gated based on their
expression of CD45.1 or CD45.2. Representative ICS for IL-10 and GM-CSF is shown.
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Figure 2-9. Retroviral transduction of Bhlhe40 corrects the GM-CSF and IL- 10
production by Bhlhe40-/- TH cells.
ICS on CD4+ T cells from WT or Bhlhe40-/- mice following TH1 or TH17 polarization and
retroviral transduction with control empty retrovirus (RV) or Bhlhe40 RV. Plots are gated on
GFP+CD4+ T cells.
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Figure 2-10. Transcriptional analysis of Bhlhe40-deficient TH cells.
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Figure 2-10. Transcriptional analysis of Bhlhe40-deficient TH cells.
(A) Heat map of gene expression for selected TH1, TH2 and TH17 lineage-specific genes in
polarized WT and Bhlhe40-/- TH cells. (B) Pairwise comparison of WT and Bhlhe40-/- TH1, TH2
and TH17 cells. Probes that are overexpressed ≥2-fold in the indicated populations are shown in
red or blue. Numbers in corners indicate the total number of probes meeting these conditions.
Probes for selected relevant genes are shown in green. Coefficients of determination (R2) are
indicated for each comparison. (C) Quantitative RT-PCR analysis of Ifng, Il4 and Il17a
expression in WT and Bhlhe40-/- TH1, TH2 and TH17 cells (n=3 per group). (D) Quantitative RTPCR analysis of the expression of the indicated nine genes in WT and Bhlhe40-/- TH1, TH2 and
TH17 cells (n=3 per group). (E) Venn diagrams showing the overlap of probes differentially
expressed by WT and Bhlhe40-/- (KO) TH cell lineages. Numbers in regions indicate the number
of probes with greater than or equal to a twofold difference in expression (WT>KO or WT<KO).
(F) CD4+ T cells from WT and Bhlhe40-/- mice (n=4 per group) were stimulated for 48 hours
with plate-bound anti-CD3 and anti-CD28 antibodies as indicated. IL-3 was measured in the
supernatant by ELISA.
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Figure 2-11. Bhlhe40 binds multiple sites within the Il3/Csf2 and Il10 loci.
(A-B) ChIP-Seq binding tracks derived from TH cells for p300, BRG1, T-bet, Gata3, and RORγt,
and from CH12 cells for Bhlhe40 at the (A) Il3/Csf2 and (B) Il10 loci. Boxes indicate regions
previously identified as enhancers for Il3/Csf2 or Il10.
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Figure 2-12. IL-10R blockade renders Bhlhe40-/- mice susceptible to EAE.
(A) Survival of WT or Bhlhe40-/- mice after EAE induction and biweekly treatment with control
rat IgG or anti-IL-10R antibody. Data are combined from three independent experiments. (B)
Mean clinical scores of EAE in diseased WT or Bhlhe40-/- mice treated biweekly with either
control rat IgG or anti-IL-10R antibody. Data are combined from three independent
experiments. Error bars are not shown for clarity. All SEM values were ≤1.
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Figure 2-13. Flow cytometry of splenocytes and bone marrow cells from WT and Bhlhe40-/mice.
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Figure 2-13. Flow cytometry of splenocytes and bone marrow cells from WT and Bhlhe40-/mice.
(A) Representative flow cytometry on splenocytes from 15 week-old WT and Bhlhe40-/- mice
showing populations of B cells (B220+CD3ε- ), CD4+ T cells (B220- CD3ε+CD4+CD8-), CD8+ T
cells (B220-CD3ε+CD4-CD8+ ), and γδ T cells (B220- CD3ε+CD4-CD8- TCR γδ+). (B)
Percentages of splenic T cell populations in 12 (n=1 mouse per group), 15 (n=3 mice per group),
and 18 week-old (n=2 mice per group) WT and Bhlhe40-/- mice. (C) Representative flow
cytometry on splenocytes from 15 week-old WT and Bhlhe40-/- mice showing populations of
PMNs (B220-Siglec H-Ly6G+CD11b+), cDCs (B220-Siglec H-Ly6G-CD11chighMHC II+), and
Ly6C+ monocytes (B220-Siglec H-Ly6G-CD11b+ Ly6Chigh). (D) Representative flow cytometry
on bone marrow cells from 15 week-old WT and Bhlhe40-/- mice showing populations of B cells
(B220+Siglec H-), pDCs (B220+Siglec H+ ), PMNs (B220-Siglec H-CD11b+Ly6Cmid), and Ly6C+
monocytes (B220-Siglec H-CD11b+Ly6Chigh).
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Chapter 3: IL-1-Induced Bhlhe40 Identifies
Pathogenic TH Cells in a Model of
Autoimmune Neuroinflammation
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3.1 Abstract
The features that define autoreactive T helper (TH) cell pathogenicity remain obscure. We have
previously shown that TH cells require the transcription factor Bhlhe40 to mediate experimental
autoimmune encephalomyelitis (EAE), a mouse model of multiple sclerosis. Here, using
Bhlhe40 reporter mice and analyzing both polyclonal and TCR transgenic TH cells, we found that
Bhlhe40 expression was heterogeneous after EAE induction, with Bhlhe40-expressing cells
displaying marked production of IFN-γ, IL-17A, and granulocyte-macrophage colonystimulating factor. In adoptive transfer EAE models, Bhlhe40-deficient TH 1 and TH 17 cells
were both nonencephalitogenic. Pertussis toxin (PTX), a classical co-adjuvant for actively
induced EAE, promoted IL-1β production by myeloid cells in the draining lymph node and
served as a strong stimulus for Bhlhe40 expression in TH cells. Furthermore, PTX coadjuvanticity was Bhlhe40 dependent. IL-1β induced Bhlhe40 expression in polarized TH 17
cells, and Bhlhe40-expressing cells exhibited an encephalitogenic transcriptional signature. In
vivo, IL-1R signaling was required for full Bhlhe40 expression by TH cells after immunization.
Overall, we demonstrate that Bhlhe40 expression identifies encephalitogenic cells and defines a
PTX–IL-1–Bhlhe40 pathway active in EAE.
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3.2 Introduction
Autoreactive CD4+ T helper (TH) cells specific for components of myelin drive experimental
autoimmune encephalomyelitis (EAE), a widely-used animal model of the human
neuroinflammatory disease multiple sclerosis (MS). In the active EAE model in C57BL/6 mice,
naive TH cells are primed by subcutaneous immunization with a peptide derived from myelin
oligodendrocyte glycoprotein (MOG35-55) emulsified in CFA5. Along with MOG/CFA, mice are
treated systemically with the co-adjuvant pertussis toxin (PTX), an ADP-ribosylating exotoxin
derived from Bordetella pertussis that has been proven necessary for clinical disease in this
model44, 45. Although the target cell types and mechanisms of action of PTX are not fully
understood, PTX has been shown to increase blood–brain barrier permeability226, 227 and promote
the maturation and cytokine production of antigen-presenting cells228 229. Several studies have
shown PTX treatment or B. pertussis infection to induce IL-1β and IL-6 production by myeloid
cells230, 231 232 233, which, during EAE, could contribute to PTX-mediated effects on regulatory T
(Treg) cells 234, 235 and TH17 cells230 236.
We and others have previously demonstrated that the transcription factor basic helix–loop–helix
family member e40 (Bhlhe40; also known as Dec1, Stra13, Sharp2, and Bhlhb2) is required in a
TH cell–intrinsic fashion for susceptibility to EAE11, 33. Bhlhe40 is a member of the basic helix–
loop–helix–Orange subfamily of transcription factors with a recognized role in regulating
circadian rhythms, cellular differentiation, and immune cell function22. Bhlhe40-deficient
(Bhlhe40-/-) mice resist EAE, and although their TH cells are capable of mounting largely normal
antigen-specific responses to immunization, Bhlhe40-/- TH cells show markedly decreased
secretion of GM-CSF, an effector cytokine required for EAE174, 175, and increased secretion of
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IL-10, a cytokine with immunoregulatory properties11, 192. In vitro, Bhlhe40-/- TH cells
differentiate normally in appropriate polarizing conditions into TH1, TH2, and TH17 cells subsets,
although in each case Bhlhe40 deficiency results in the abnormal expression of ∼200–300 genes,
including Csf2 (encoding GM-CSF) and Il1011. Bhlhe40 is expressed in all subsets of polarized
TH cells in vitro, and is known to be regulated in part through a signal provided by CD28 in
combination with TCR signaling33. Nevertheless, the pathways that regulate Bhlhe40 expression
in TH cells in vivo during an immune response and the features of Bhlhe40-expressing TH cells
during EAE remain unknown.
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3.3 Results
3.3.1 Bhlhe40GFP Tg mice show Bhlhe40 expression in immune cells
We used bacterial artificial chromosome (BAC) transgenic (Tg) reporter mice generated by the
Gene Expression Nervous System Atlas (GENSAT) Project237 to identify and study Bhlhe40
expression in TH cells in vivo. Cells from these Bhlhe40GFP mice show Bhlhe40 expression
through enhanced GFP in the context of a BAC transgene spanning the 205-kb genomic DNA
segment containing Bhlhe40. To determine the steady-state expression of Bhlhe40, we
performed flow cytometry on tissues obtained from these reporter mice. Thymocytes of all
developmental stages did not express GFP (Figure. 3-1A). Splenic CD4+ and CD8+ T cells
expressed GFP in <0.5% of cells (Figure. 3-1B). These rare GFPpos cells stained as
CD44+CD62L−, indicating prior antigen experience. Other immune cells showed a range of GFP
expression (Figure. 3-1, C and D). An overall comparison of our flow cytometry results with the
expression of Bhlhe40 in immune cells based on expression microarray datasets from the
Immgen Consortium238 showed excellent agreement (Figure. 3-1, E and F). These data indicate
that Bhlhe40GFP mice faithfully reveal Bhlhe40 expression.

3.3.2 Bhlhe40-expressing TH cells are enriched in the CNS and are robust
cytokine producers during EAE
Based on the known cell-intrinsic requirement for Bhlhe40 expression in TH cells for EAE
susceptibility11, 33, we expected that Bhlhe40 would be expressed in effector T cells during EAE.
Flow cytometry of Bhlhe40GFP mice at day 13–14 after EAE induction showed that ∼1–10% of

splenic and ∼10–70% of CNS-infiltrating CD4+ T cells expressed GFP at this time (Figure. 3-2,
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A and B), notably more than in naive mice. In general, the frequency of GFPpos CD4+ T cells in
the CNS correlated with disease severity at the day of sacrifice. GFP expression was also notable
in CD8+ and γδ T cells during EAE, again at an increased frequency in the CNS relative to the
spleen, consistent with these cell types participating in disease pathogenesis199, 239. Some GFP
expression was also observed in CD11b+ infiltrating myeloid cells during EAE, but not in
microglia (unpublished data). Histological examination of spinal cord sections from diseased
mice confirmed GFP expression within CD4+ T cells (Figure. 3-2C) and CD11b+ myeloid cells
(unpublished data) present in inflammatory lesions. Strikingly, intracellular cytokine staining
(ICS) showed that Bhlhe40-expressing GFPpos CD4+ T cells produced almost all of the IFN-γ,
IL-17A, and GM-CSF in both the spleen and CNS (Figure. 3-2, D and E), suggesting that
Bhlhe40 expression could serve as an identifying feature of encephalitogenic TH cells.

3.3.3 PTX serves as an essential co-adjuvant by inducing Bhlhe40 expression
in TH cells
One week after immunization of Bhlhe40GFP mice with MOG/CFA, we observed only a very
small increase in the abundance of GFP-expressing CD4+ T cells in the DLNs relative to naive
mice (Figure. 3-3, A and B), with almost all GFPpos cells being CD44+. Because the same
immunization given with systemic administration of PTX had resulted in robust GFP expression
by CD4+ T cells during EAE, we reasoned that the co-adjuvant PTX might serve as a stimulus
for Bhlhe40 expression. Indeed, DLNs from mice immunized with MOG/CFA and treated with
PTX contained significantly increased numbers of GFPpos CD4+ T cells relative to naive mice,
PTX-only–treated mice, or non-PTX–treated MOG/CFA-immunized mice (Figure. 3-3, A and
B), with these GFPpos T cells again bearing CD44. To mediate this effect, the ADP-ribosylating
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activity of PTX was necessary, as treatment of MOG/CFA-immunized mice with mutant PTX
(mPTX) lacking this activity did not result in an increase in the frequency or number of GFPpos
CD4+ T cells relative to MOG/CFA-immunized mice given no PTX. In immunized mice
followed for the development of clinical EAE, only PTX, but not mPTX, was able to serve as a
co-adjuvant for disease induction (Figure. 3-3C). ICS showed PTX treatment to be a strong
inducer of IFN-γ, IL-17A, and GM-CSF secretion, particularly among GFPpos CD4+ T cells
(Figure. 3-3, D and E), again suggesting that Bhlhe40 expression serves to identify
encephalitogenic TH cells. In the setting of MOG/CFA immunization given with PTX treatment,
GFPpos CD4+ T cells showed higher expression of Ki-67, indicating that these cells were more
proliferative than their GFPneg counterparts (Figure. 3-3F). qRT-PCR analysis comparing GFPneg
and GFPpos CD4+ T cells from these mice showed that GFPpos cells expressed higher levels of
Egfp, Bhlhe40, and Csf2 transcripts (Figure. 3-3G).
We next tested the hypothesis that PTX co-adjuvanticity was Bhlhe40 dependent. We previously
showed by ELISPOT assays that antigen/CFA immunization in the absence of PTX primed
generally normal frequencies of antigen-specific IFN-γ and IL-17A responses in the DLNs of
Bhlhe40-/- mice 11. These mice, however, showed a markedly decreased frequency of antigenspecific GM-CSF–producing T cells, and an increased frequency of IL-10–producing cells
relative to WT mice. We repeated these ELISPOT assays in WT and Bhlhe40-/- mice, but
included additional groups of mice that were treated with PTX (Figure. 3-4). In WT mice, PTX
treatment significantly increased the frequency of MOG-specific cells producing all four
cytokines. Importantly, PTX treatment showed no ability to augment MOG-specific responses in
Bhlhe40-/- mice. These data indicate that PTX co-adjuvanticity is Bhlhe40 dependent, and
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explain, at least in part, why PTX is a required co-adjuvant for clinical EAE induction in
C57BL/6 mice.

3.3.4 Bhlhe40 expression identifies the cytokine-producing fraction of
autoreactive TH cells
We have shown that GFP expression in CD4+ T cells of Bhlhe40GFP mice identifies cytokineproducing TH cells, whereas GFPneg CD4+ T cells largely lack cytokine production. These results
could be explained by either of two non-mutually exclusive possibilities. In one scenario, GFPneg
cells may represent CD4+ T cells with TCR specificities unrelated to the ongoing myelin-specific
response. Bystander CD4+ T cells have been described in the CNS during EAE 240, so it is likely
that at least some GFPneg CD4+ T cells in this compartment are bystanders. Alternatively,
Bhlhe40 expression may be heterogeneous among autoreactive CD4+ T cells. In this scenario,
only those self-reactive T cells expressing Bhlhe40 would serve as encephalitogenic, cytokineproducing effectors.
We tested these possibilities by two approaches. First, we identified MOG-specific CD4+ T cells
using MOG38-49–I-Ab tetramers at day 15 after EAE induction in Bhlhe40GFP mice. Although we
failed to detect tetramerpos cells in the spleen, ∼7% of CNS-infiltrating CD4+ T cells were
stained by tetramer, and nearly half of them were GFPpos (Figure. 3-5, A and B). Among

tetramerpos cells, those expressing GFP showed the highest level of IFN-γ production (Figure. 35C). Interestingly, however, most CNS-infiltrating GFPpos cells did not stain with tetramer.
Although this may suggest bystander activation by non-MOG–specific T cells, we feel that this
is more consistent with the findings of Sabatino et al., where most MOG-specific cells after EAE
induction had a low affinity for MOG/I-Ab, such that they were negative for tetramer staining241.
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These low-affinity cells were reported to contribute significantly to the pool of IFN-γ –producing
T cells in the CNS. Consistent with this, we also found that among tetramerneg cells, a higher
frequency of GFPpos cells produced IFN-γ (Figure. 3-5C).
In our second approach, we crossed 2D2 TCR Tg mice, bearing T cells with a TCR specific for
MOG35-55 45 to Bhlhe40GFP mice and crossed in one allele of the congenic marker CD45.1
(resulting in hematopoietic cells with co-expression of CD45.1 and CD45.2). Purified CD4+ T
cells from these mice (henceforth termed 2D2 Bhlhe40GFP CD45.1/CD45.2) were transferred to
WT recipients (bearing only CD45.2), and one day later these mice were immunized with
MOG/CFA with or without PTX treatment (Figure. 3-5, D–G). To control for the possible
effects of microbial ligands in CFA or the effects of PTX that are independent of cognate antigen
stimulation, a separate group of mice that received 2D2 Bhlhe40GFP CD45.1/CD45.2 CD4+ T
cells was immunized with an irrelevant peptide antigen (OVA323-339)/CFA and treated with PTX.
Immunization with MOG resulted in an expansion of the population of transferred T cells in the
DLN one week later, with additional PTX treatment resulting in a markedly increased frequency
of GFPpos T cells (Figure. 3-5, D and E). In MOG/CFA-immunized mice treated with PTX, ICS
(Figure. 3-5, F and G) on DLN cells showed that host-derived polyclonal CD4+ T cells secreted
minimal amounts of IFN-γ, IL-17A, and GM-CSF. 2D2 Bhlhe40GFP CD45.1/CD45.2 CD4+ T
cells produced all of these cytokines, although cytokine production was significantly increased
among 2D2 GFPpos T cells compared with 2D2 GFPneg T cells, particularly for IFN-γ and GMCSF. Thus, there exists heterogeneity among clonal autoreactive T cells in their expression of
Bhlhe40, and expression of this transcription factor identifies those cells with encephalitogenic
features. In a variation of the aforementioned experiment, we transferred 2D2
Bhlhe40GFPCD45.1/CD45.2 CD4+ T cells to Bhlhe40GFP reporter mice (CD45.2) to allow for the
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simultaneous analysis of GFPneg and GFPpos host CD4+ T cells and GFPneg and GFPpos 2D2 CD4+
T cells after EAE induction (Figure. 3-5, H and I). In these mice, ICS staining showed
significantly increased cytokine production by both GFPpos host and GFPpos 2D2 CD4+ T cells,
relative to their GFPneg counterparts, supporting the notion that Bhlhe40 expression identified
both monoclonal and polyclonal encephalitogenic T cells.

3.3.5 Bhlhe40 is essential for the encephalitogenicity of TH cells in adoptive
transfer models of EAE
To further test the notion that Bhlhe40-expressing CD4+ T cells are encephalitogenic, we used an
adoptive transfer system of EAE that allows in vitro polarization of 2D2 cells without a
requirement for immunization to generate MOG-specific cells 210. Because in our immunizations
with MOG/CFA + PTX, we found GFPpos CD4+ T cells to produce both IFN-γ and IL-17A, we
separately tested both TH1 and TH17 adoptive transfer models, comparing the
encephalitogenicity of 2D2 WT (CD45.1) and 2D2 Bhlhe40-/- (CD45.2) cells after transfer to WT
recipients (CD45.1/CD45.2). Despite normal TH1 or TH17 polarization before transfer
(Figure. 3-6 A), 2D2 Bhlhe40-/- cells were completely nonencephalitogenic in vivo (Figure. 3-6,
B and C). Nevertheless, 2D2 Bhlhe40-/- cells could be identified in recipient mice at 28–34 days
after transfer. Stimulation of these cells recovered from spleens showed that they maintained
production of their hallmark cytokines at levels similar to 2D2 WT cells recovered from diseased
mice (Figure. 3-6, D–G). Notably, GM-CSF production by polarized 2D2 Bhlhe40-/- cells was
decreased relative to 2D2 WT cells both before transfer and upon recovery, consistent with our
previous experiments using polyclonal CD4+ T cells11. These findings confirm a cell-intrinsic
requirement for Bhlhe40 in both encephalitogenic TH1 and TH17 cells.
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3.3.6 Bhlhe40 expression negatively correlates with Foxp3 and IL-10
expression during EAE
Foxp3pos Treg cells and the suppressive cytokine IL-10 have been recognized to ameliorate
disease during EAE 242, 243, 244. Given our findings that Bhlhe40-expressing CD4+ T cells were
robust producers of inflammatory cytokines and that expression of Bhlhe40 was required in
adoptive transfer models of EAE, we hypothesized that Bhlhe40-expressing cells in the CNS
during EAE would be unlikely to express Foxp3 or IL-10. We performed intracellular staining
for Foxp3 on CNS-infiltrating immune cells after EAE induction in Bhlhe40GFP mice, but found
that this protocol significantly diminished our ability to discriminate GFPpos CD4+ T cells. To
circumvent this problem, we sorted three populations of CNS-infiltrating CD4+ T cells at day 16
after EAE induction in reporter mice based on their expression of CD44 and GFP, and performed
subsequent intracellular staining for Foxp3 (Figure. 3-7A). Many Foxp3pos CD4+ T cells were
present in the CD44−GFPneg (R1) and CD44+GFPneg (R2) gates, whereas within the population of
CD44+GFPpos (R3) cells, only a small fraction of T cells were Foxp3pos (Figure. 3-7, A and B).
We are unsure of the identity of these Bhlhe40 and Foxp3 double-positive cells, but they may be
akin to populations of Treg cells that express Foxp3 and a second transcription factor, as has
been reported for T-betposFoxp3pos Treg cells in EAE245, 246. We also analyzed IL-10 production
by CNS-infiltrating CD4+ T cells in reporter mice that received congenically-marked 2D2
Bhlhe40GFP cells to allow us to track both GFPneg and GFPpos host and TCR Tg T cells. Although
a high frequency of GFPpos host and GFPpos 2D2 cells produced IFN-γ, IL-10 production came
almost entirely from host GFPneg cells (Figure. 3-7, C and D). These IL-10–producing GFPneg
host cells likely represent a mixture of both Treg cells and IFN-γ+IL-10+ type 1 regulatory T cells
(Tr1) cells243, 247 197 248, whereas GFPpos host and 2D2 cells represent autoreactive effectors. At
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day 29, during the resolving phase of EAE, GFPneg CD4+ T cells in the CNS continued to express
higher levels of IL-10 than GFPpos T cells, with the latter continuing to robustly produce IFN-γ
(Figure. 3-7, E and F).

3.3.7 Bhlhe40-expressing TH17 cells exhibit a pathogenic molecular signature
Next, we polarized naive CD4+ T cells from Bhlhe40GFP mice in TH1 (IL-12) or TH17 (TGF-β1,
IL-6, IL-23, and IL-1β) conditions in vitro. On day 4, ∼5–10% of TH1 cells and ∼30–40% of

TH17 cells expressed GFP (Figure. 3-8A). Because of significant GFP expression by TH17 cells
and their relevance to the EAE model, we sorted GFPneg and GFPpos TH17 cells for
transcriptional analysis. Immunoblotting confirmed that GFPpos cells expressed ∼2.5 times more
Bhlhe40 than GFPneg cells (Figure. 3-8, B and C). Expression microarrays were performed on
these cells and differentially expressed transcripts were identified (Figure. 3-8D). Strikingly,
GFPpos TH17 cells exhibited a pathogenic signature, with higher expression of many genes
previously identified as being expressed by encephalitogenic TH17 cells, including Bhlhe40,
Csf2, Tgfb3, Il7r, Icos, and several chemokines 174, 175, 249 11, 33, 189. We confirmed differential
expression for four transcripts that encoded surface proteins by flow cytometry (Figure. 3-8E),
two with higher expression in GFPpos cells (CD93 and IL-7R) and two with higher expression in
GFPneg cells (Slamf6 and CD62L). Lastly, we compared our microarray data to a publicly
available Gene Expression Omnibus (GEO) dataset (GSE23505) in which microarrays were
performed on TH17 cells derived from cultures using a variety of cytokine conditions (Figure. 3-

8D)188. Using gene set analysis, we tested whether the 700 most differentially expressed genes
with higher expression in Bhlhe40-expressing (GFPpos) cells in our experiment (Figure. 3-8D,
yellow box) showed differential expression in TH17 cells across culture conditions. Interestingly,
as a group, these 700 genes showed an overall pattern to suggest that their expression was
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specifically increased by culture with IL-1β (Figure. 3-8D, red line), independent of whether
TH17 cells were derived by culture with TGF-β1 and/or IL-23. In these data, Bhlhe40 was also
expressed more highly in conditions that included IL-1β (Figure. 3-8D, green line). This finding
suggested a model in which IL-1β acted through Bhlhe40 to promote encephalitogenicity of
TH17 cells and led us to explore whether IL-1β directly regulated the expression of Bhlhe40.

3.3.8 IL-1β increases Bhlhe40 expression in TH17 and γδ T cells
We used our TH17 cell culture system with purified CD4+ T cells from Bhlhe40GFP mice to test
whether IL-1β induced the expression of Bhlhe40. Indeed, IL-1β, but not IL-23, induced strong
expression of GFP in this system (Figure. 3-9A). Expression of GFP was notable by day 2 in
these cultures, and increased steadily through day 7 (Figure. 3-9B). By performing TH17
cultures with irradiated splenocytes from Il1r1-/- mice, we confirmed that IL-1β acted directly on
CD4+ T cells to increase their GFP expression (Figure. 3-9C). Immunoblotting for Bhlhe40 also
confirmed induction of Bhlhe40 by IL-1β (Figure. 3-9D). IL-1β increased both IL-17A and GMCSF production by TH17 cells, with GFPpos cells displaying the highest production of these
cytokines (Figure. 3-9E). In contrast with our in vivo results (Figure. 3-7, C–F), in vitro, GFPpos
cells also produced slightly higher levels of IL-10 (Figure. 3-9E). IL-10 production derived
mainly from IL-17A+ cells (unpublished data). Consistent with the fact that IL-1R is expressed at
low levels on TH1 cells250, 251, IL-1β only minimally increased GFP expression when added to
TH1 cultures (Figure. 3-9, F–H). Nevertheless, a higher frequency of GFPpos TH1 cells expressed
IFN-γ, GM-CSF, and IL-10 (Figure. 3-9I), with GM-CSF and IL-10 production deriving mainly
from IFN-γ+ cells (not depicted). γδ T cells are known to produce GM-CSF in response to IL1β199, and we have previously shown that γδ T cells require Bhlhe40 to produce GM-CSF11.
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Similar to TH17 cells, TCR-activated γδ T cells from Bhlhe40GFP mice also increased their
expression of GFP in response to IL-1β (Figure. 3-9, J and K).

3.3.9 IL-1R signaling is required in vivo for full Bhlhe40 expression by TH
cells
To test whether IL-1 played a role in the induction of Bhlhe40 in CD4+ T cells in vivo, we
crossed Bhlhe40GFP reporter mice with Il1r1-/- mice. We immunized these mice with MOG/CFA,
along with PTX treatment, and compared their CD4+ T cell responses to control Bhlhe40GFP
mice. In the absence of IL-1R signaling, fewer CD4+ T cells in the DLN expressed GFP
(Figure. 3-10, A and B). Similarly, in vivo IL-1 blockade by antibodies in Bhlhe40GFP mice
resulted in fewer GFPpos CD4+ T cells after immunization and PTX treatment (Figure. 3-10, C
and D). Consistent with previous studies67, 71, 252 47, 48, 68, and the notion that Bhlhe40 expression
is partially dependent on IL-1R signaling, we observed a lower incidence of clinical EAE in
Il1r1-/- mice compared with WT mice, with a later onset and less severe disease (Figure. 3-10E).
Bhlhe40-/- mice showed complete EAE resistance, indicating that Bhlhe40 serves a more
essential role in the development of EAE than IL-1 does. To define a cell-intrinsic role for IL-1R
signaling in the induction of Bhlhe40, we co-transferred CD4+ T cells from Bhlhe40GFP
(CD45.1/CD45.2) or Il1r1-/- Bhlhe40GFP (CD45.2) mice that had previously been immunized
with MOG/CFA + PTX to WT (CD45.1) recipients. The next day, these mice were immunized
with MOG/CFA + PTX, and at day 7 DLNs were examined for GFP expression on the
transferred CD4+ T cells, which were found to uniformly express the activation marker CD44
(Figure. 3-10F). Within the population of GFPpos cells, IL-1R–sufficient Bhlhe40GFP cells were
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found at a ∼3:1 ratio over Il1r1-/- Bhlhe40GFP cells (Figure. 3-10, F and G), confirming a cellintrinsic role for IL-1R signaling in Bhlhe40 induction.

3.3.10 Systemic PTX treatment induces IL-1β production by lymph node cells
Because both PTX treatment and IL-1β regulated Bhlhe40 expression by CD4+ T cells after
immunization, we next asked whether PTX could regulate IL-1β production in vivo. DLN cells
from MOG/CFA + PTX-immunized mice at day 7 secreted IL-1β in culture (Figure. 3-10H).
Treatment with heat-killed Mycobacterium tuberculosis (Mtb), a component of CFA, could
further augment this secretion. mPTX, which failed to induce Bhlhe40 expression in CD4+ T
cells in vivo (Figure. 3-3, A and B), also was unable to drive IL-1β secretion by lymph node
cells when combined with MOG/CFA immunization. Pro–IL-1β was detectable in lymph node
cells only in mice that received PTX with immunization (Figure. 3-10, I and J), and DLNs from
these mice contained sizeable populations of Ly6G+ neutrophils and Ly6G−Ly6C+MHC class II+
monocytes/moDCs (Figure. 3-10K). Neutrophils and Ly6G−Ly6C+MHC class II+ cells, but not
migratory or resident DCs, were the major source of PTX-induced IL-1 (Figure. 3-10L).
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3.4 Discussion
We and others have previously demonstrated that the transcription factor Bhlhe40 is required for
autoimmune neuroinflammation through its action in TH cells11, 33. Here, we have used novel
Bhlhe40GFP reporter mice to study Bhlhe40-expressing cells during EAE. Bhlhe40-expressing TH
cells were abundant in the CNS, where they secreted IFN-γ, IL-17A, and GM-CSF. PTX, when
administered systemically with immunization, served as a strong stimulus for Bhlhe40
expression by TH cells. PTX treatment enhanced antigen-specific TH cell cytokine responses, and
this effect was abrogated in Bhlhe40-/- mice. IL-1β production by lymph node myeloid cells was
markedly augmented by systemic PTX treatment administered with MOG/CFA immunization.
IL-1β acted directly on TH17 cells to positively regulate the expression of Bhlhe40, with
Bhlhe40-expressing TH17 cells exhibiting an encephalitogenic transcriptional signature.
We find that Bhlhe40 expression is nonuniform in autoreactive CD4+ T cells during EAE.
Bhlhe40 is not expressed in naive CD4+ T cells, but is induced upon T cell activation 30, 32.
Polyclonal T cells with a spectrum of TCR affinities for MHC class II peptide could tune
Bhlhe40 expression levels, although in experiments with monoclonal TCR Tg CD4+ T cells, we
also found nonuniform Bhlhe40 expression. Recently, Helmstetter et al. described intraclonal
heterogeneity in the production of IFN-γ by TH1 cells, explained by intrapopulation differences
in the expression of the transcription factor T-bet253. These authors also studied monoclonal T
cells, and concluded that a diverse TCR repertoire was not essential to generate heterogeneity in
effector cell responses. Previous work has described a range of TCR signal strength, even in
stimulated monoclonal T cells, determined by the stochastic expression of proximal signaling
components downstream of the TCR254. Therefore, it remains possible that TCR signal strength
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could contribute to establishing a range of Bhlhe40 expression in activated T cells. Numerous
non-TCR signals also likely act in combination to establish a population of T cells with a wide
spectrum of transcription factor and effector molecule expression levels. CD28 signaling is
known to induce Bhlhe40 expression in CD4+ T cells33, and other positive or negative costimulatory signals may also participate. In naive PD-1–deficient mice, for example, CD8+ T
central memory phenotype cells express higher levels of Bhlhe40 than the same cells derived
from naive WT mice255. Diverse cytokine receptor signals also likely integrate to shape T cell
responses. We found IL-1R signaling to strongly impact on Bhlhe40 expression levels in TH17
cells. IL-1 has been shown to induce Bhlhe40 in primary human gingival epithelial cells through
a PI-3K–Akt pathway256, and in primary human amnion mesenchymal cells257. Recently, IL-1R
signals were shown to modulate TH17 cell responses through the repression of SOCS3 and the
subsequent strengthening of STAT3 activity258. It is interesting to consider whether these
pathways are involved in the induction of Bhlhe40 by IL-1 in TH17 cells.
The development of autoimmune diseases is thought to involve both genetic and environmental
factors. In the EAE model, roles for both pathogenic and commensal microbes have been
considered to regulate effector and regulatory TH cell responses259. Active EAE induction
protocols involve immunization with myelin antigens administered with CFA to prime dormant
autoreactive TH cells, although in C57BL/6 mice this strategy is insufficient to induce EAE. In
these mice, PTX is a required co-adjuvant44, 45, perhaps functioning as a surrogate for the
environmental factors that trigger MS in genetically susceptible hosts. Our work shows that PTX
co-adjuvanticity, as read out by an increase in antigen-specific CD4+ T cell cytokine responses,
requires Bhlhe40 expression in vivo. Immunization combined with PTX treatment induces
Bhlhe40 expression in CD4+ T cells, and this induction of Bhlhe40 is partially IL-1 dependent.
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PTX was unable to act directly on T cells in vitro to induce Bhlhe40 expression (unpublished
data), suggesting that PTX acts indirectly in vivo to promote CD4+ T cell responses.
We have found that immunization combined with PTX treatment induces IL-1β production by
neutrophils and monocytes/moDCs. Our data are consistent with two non-mutually exclusive
actions for PTX in this process. Evidence exists for the ability of PTX to directly stimulate
myeloid cell production of IL-1β. Zhang et al. showed that macrophages infected with PTXdeficient B. pertussis produced less IL-1β than those infected with WT bacteria231. More
recently, Dumas et al. showed that PTX administered by a protocol akin to its use in EAE rapidly
triggered IL-1β production by peritoneal macrophages and neutrophils in a pathway dependent
on the ADP-ribosylating activity of the toxin and on a pyrin-containing inflammasome233.
Alternatively, PTX may induce initial GM-CSF production (and perhaps Bhlhe40 expression) by
antigen-stimulated TH cells through an undefined mechanism. This GM-CSF may then act
directly on lymph node myeloid cells to induce their production of IL-1β, which could feed
forward to direct full Bhlhe40 expression and encephalitogenicity of TH cells. Consistent with
this proposed positive-feedback loop, a cell-intrinsic role for GM-CSF receptor signaling on
CCR2+ monocytes after EAE induction was recently described by Croxford et al.47, 48, who
concluded that T cell–derived GM-CSF served to regulate IL-1β production by Ly6C+MHC class
II+ cells, and that this signaling was required for the development of EAE. Khameneh et al. have
also reported that GM-CSF can synergize with a TLR ligand to enhance IL-1β secretion by bone
marrow–derived DCs/macrophages via increased NF-κB activation260. In MS, the detection of
IL-1 in the cerebrospinal fluid at disease onset has been linked with cortical pathology92, whereas
its detection during remission in relapsing-remitting MS has been shown to correlate with a more
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severe disease course93. The role of IL-1 in directly promoting TH cell pathogenicity in MS
remains unknown.
Our study demonstrates that among autoreactive TH cells, Bhlhe40 expression identifies those
with encephalitogenic features. No data exists on whether human BHLHE40 is expressed in T
cells in MS lesions. Some studies have focused on the role of IFN-γ/IL-17 double-producing
TH1/17 cells as being the bona fide pathogenic cells in EAE or MS261, 262, which in some cases
have also been reported to produce GM-CSF. A requirement for GM-CSF in EAE is well
established174, 175, and newer studies have suggested a role for this cytokine in MS263, 264, 265. IL1β in conjunction with IL-12 can direct human TH17 cells to differentiate into IFN-γ/IL-17/GMCSF triple-producing cells266. We have demonstrated that Bhlhe40 expression in murine TH cells
controls GM-CSF production11, identifies encephalitogenic TH17 cells, and is regulated by IL-1.
Our study provides impetus for exploring the role of BHLHE40 in autoreactive TH cells in
human autoimmune disease.
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3.5 Methods
Mice. C57BL/6 (Taconic), B6.SJL (CD45.1; Taconic), 2D2 TCR transgenic (The Jackson
Laboratory), Il1r1-/- (on a C57BL/6 background; The Jackson Laboratory), and Bhlhe40-/-30
(backcrossed 10 generations to the C57BL/6 background) mice were maintained in our SPF
facility. The Bhlhe40GFP BAC Tg mouse strain, STOCKTg(Bhlhe40-EGFP)PX84Gsat/Mmucd,
identification number 034730-UCD, was obtained from the Mutant Mouse Regional Resource
Center (MMRRC), a National Center for Research Resources-National Institutes of Health
(NCRR-NIH) funded strain repository, and was donated to the MMRRC by the National Institute
of Neurological Disorders and Stroke (NINDS) funded Gene Expression Nervous System Atlas
(GENSAT) BAC transgenic project. Frozen spermatozoa from hemizygotes were obtained and
mice were reanimated and backcrossed to the C57BL/6 background (hemizygous mice at
backcross 7–11 were used). A strain-specific PCR with primers suggested by the MMRRC was
used to type for the presence of the transgene (forward, 5’GGGCAGCCCTTTCTCAGACTCTAC-3’; reverse, 5’-GGTCGGGGTAGCGGCTGAA-3’).
2D2 TCR transgenic mice were crossed to B6.SJL mice to generate 2D2 CD45.1 mice that were
subsequently crossed to Bhlhe40GFP mice or Bhlhe40-/- mice for some experiments. Il1r1-/- mice
were crossed to Bhlhe40GFP mice for some experiments. Experiments were performed with mice
at 8–20 weeks of age. All animal experiments were approved by the Animal Studies Committee
of Washington University in St. Louis.

Induction of active EAE and immunizations. For EAE induction, mice were immunized
subcutaneously with 100 µg MOG35–55 (CS Bio Co.) emulsified in CFA (made with 5 mg/ml
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heat-killed Mtb H37Ra [BD] in incomplete Freund’s adjuvant [BD]). PTX (List Biological
Laboratories) or mutant PTX (mPTX; mutated at two positions in the S1 subunit [R9K and
E129A]; List Biological Laboratories) was injected i.p. (300 ng) on days 0 and 2. Mice were
monitored for signs of classical EAE for at least 28 days and graded on a standard 0–5 scale, as
previously described240. For analysis of T cell responses in DLNs, mice were immunized in hind
footpads with 10 nM MOG35–55 or OVA323-339 peptide emulsified in CFA. Some mice were
injected with PTX i.p. (300 ng) on days 0 and 2. To analyze MOG-specific T cell responses, 2 ×
106 magnetically purified 2D2 Bhlhe40GFP CD45.1/CD45.2 CD4+ T cells (Dynabeads
FlowComp Mouse CD4 kit; Invitrogen) were transferred i.p. to Bhlhe40GFP or WT recipient mice
(CD45.2) one day before MOG/CFA ± PTX immunization. In some experiments, 1.5 × 106
magnetically purified CD4+ T cells from the DLN of MOG/CFA + PTX-immunized (day 7)
Bhlhe40GFP (CD45.1/CD45.2) mice and 1.5 × 106 magnetically purified CD4+ T cells from the
DLN of MOG/CFA + PTX-immunized (day 7) Il1r1-/- Bhlhe40GFP (CD45.2) mice were cotransferred into WT (CD45.1) recipients one day before immunization with MOG/CFA + PTX.
At day 7 after this immunization, DLN cells were collected and analyzed for GFP expression.

In vivo IL-1 blockade. Anti–IL-1β antibody (200 µg/dose; clone B122; Bio X Cell or Leinco
Technologies, Inc.) and anti–IL-1R antibody (200 µg/dose; clone JAMA-147; Bio X Cell or
Leinco Technologies, Inc.) were combined (IL-1 blockade) in 200 µl of PBS and injected i.p.
into mice on days −1, 1, and 4. Controls received 400 µg/dose isotype control Armenian hamster
IgG (clone PIP; a gift from R.D. Schreiber, Washington University, St. Louis, MO) on the same
days. Mice were left unimmunized or were immunized with MOG/CFA or MOG/CFA + PTX on
day 0 and sacrificed on day 7.
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Cell preparation. Cells from bone marrow, peritoneum, thymus, inguinal lymph node, and
spleen were collected from naive WT and Bhlhe40GFP mice for analysis of GFP expression in
immune cells. Lungs were perfused with 10 ml PBS via injection into the right ventricle. Lungs
were minced and digested with 4 mg/ml collagenase D (Roche) at 37°C for 40–60 min with
stirring, followed by addition of EDTA (5 mM final concentration) with incubation on ice for 5
min. Brains and spinal cords from naive mice, immunized mice, or mice that received adoptive
transfers of 2D2 cells were collected after perfusion of the left ventricle with 30 ml PBS, and
were digested with 500 µg/ml type I collagenase (Sigma-Aldrich) and 10 µg/ml DNase I (SigmaAldrich) in the presence of 0.1 µg/ml TLCK trypsin inhibitor (Sigma-Aldrich) and 10 mM Hepes
(pH 7.4) in HBSS at room temperature for one hour with shaking. Centrifuged cells were
resuspended in a 70%/37%/30% Percoll gradient (Sigma-Aldrich) in HBSS and centrifuged for
30 min at 1,200g. The 30% Percoll layer containing debris was discarded and the cells from the
interface of the 30% and 37% layers were collected for subsequent use. From naive, PTXtreated, and immunized mice, DLNs were digested with 250 µg/ml collagenase B (Roche) and
30 U/ml DNase I (EMD) for 50–60 min at 37°C with stirring in Iscove’s modified Dulbecco’s
media (IMDM) containing 10% FCS, l-glutamine, sodium pyruvate, nonessential amino acids,
penicillin/streptomycin, and 2-mercaptoethanol (cIMDM). EDTA (5 mM final concentration)
was added, and cells were incubated on ice for 5 min. Spleens were mashed and filtered through
70-µm strainers to make single-cell suspensions. From all cell suspensions, erythrocytes were
lysed with ACK lysis buffer if necessary, followed by filtration through a 70-µm strainer.
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In vitro TH1 and TH17 polarization and adoptive transfer EAE models. Naive CD62L+
CD4+ T cells were magnetically purified from spleens and inguinal lymph nodes using EasySep
mouse naive CD4+ T cell isolation kits (StemCell Technologies). TH1 and TH17 cells were
polarized by the method of Jäger et al. with minor modifications210. In brief, naive CD4+ T cells
were cultured in cIMDM with WT, Bhlhe40-/- or Il1r1-/- irradiated splenocytes (3,400 rads), 2.5
µg/ml soluble anti-CD3 (clone 145-2C11; Bio X Cell or Leinco Technologies, Inc.), and anti–IL4 (20 µg/ml; clone 11B11; Bio X Cell or Leinco Technologies, Inc.). TH1 cell cultures also
included IL-12 (10 ng/ml; BioLegend). TH17 cells were polarized with the addition of anti–IFNγ (20 µg/ml; clone XMG1.2 [Bio X Cell] or clone H22 [Leinco Technologies, Inc.]),
recombinant human TGF-β1 (3 ng/ml; BioLegend), and recombinant mouse IL-6 (30 ng/ml;
BioLegend). In some experiments, recombinant mouse IL-1β (10 ng/ml; BioLegend) or anti–IL1R (20 µg/ml; clone JAMA-147; Bio X Cell or Leinco Technologies, Inc.) plus anti–IL-1β (20
µg/ ml; clone B122; Bio X Cell or Leinco Technologies, Inc.; IL-1 blockade) was added to the
culture. Cells were split on day 2 with or without the addition of recombinant mouse IL-2 (10
ng/ml; BioLegend) for TH1 cells or IL-23 (10 ng/ml; BioLegend or R&D Systems) for TH17
cultures. For analysis by flow cytometry or immunoblotting, TH17 cells were harvested on day
4–7. For generation of effector 2D2 T cells, naive WT 2D2 (CD45.1) and Bhlhe40-/- 2D2
(CD45.2) cells were magnetically purified and polarized in TH1 or TH17 conditions. Cells were
split on day 2 and cultured with IL-2 (TH1) or IL-23 (TH17) for 4 more days. Polarized cells were
harvested, counted, and restimulated with plate bound anti-CD3 (2 µg/ml) and anti-CD28 (2
µg/ml; clone 37.51; Bio X Cell or BioLegend) at a concentration of 2 × 106/ml for 48 hours.
After restimulation, cells were harvested, counted, and washed. 2 × 106 TH1 or TH17 cells were
injected i.p. into WT recipients. Mice were monitored for signs of EAE for at least 28 days.
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Lymph node γδ T cell stimulation. Inguinal lymph nodes were collected from naive
Bhlhe40GFP mice and cell suspensions were cultured at 5 × 105 cells/well in 200 µl cIMDM in
the presence or absence of 2.5 µg/ml soluble anti-CD3 and/or 10 ng/ml IL-1β. At day 3, flow
cytometry was performed to analyze GFP expression by γδ T cells.

Flow cytometry. The following anti–mouse antibodies were obtained from BioLegend: FITC
(17A2), APC, or APC-Cy7 (145-2C11) anti-CD3e, BV510 or PE-Cy7 anti-CD4 (RM45), APCCy7 or PerCP-Cy5.5 anti-CD8α (53-6.7), APC or PE-Cy7 anti-CD11b (M1/70), APC-Cy7 antiCD11c (N418), APC anti-CD25 (PC61), PB anti-CD44 (IM7), APC anti-CD45.2 (104), PE antiCD62L (MEL-14), APC anti–IL7Rα (CD127; SB/199), Alexa Fluor 488 anti-B220 (RA3-6B2),
FITC, PB, or PerCP-Cy5.5 anti-Ly6C (HK1.4), PE anti-Ly6G (1A8), BV510 or PB anti–I-A/I-E
(M5/114.15.2), A647 anti-ICAM2 (3C4), APC anti-NK1.1 (PK136), PerCP-Cy5.5 anti-NKp46
(29A1.4), PerCP-Cy5.5 anti–Siglec H (551), PB anti-TCRβ (H57-597), APC anti-TCR γδ (GL3),
PE-Cy7 anti–IFN-γ (XMG1.2), PerCP-Cy5.5 anti–L-17A (TC1118H10.1), and PE anti–GMCSF (MP1-22E9). The following anti–mouse antibodies were purchased from BD: V450 antiCD4 (RM4-5), APC-Cy7, V500, or BV510 anti-CD45 (30F11), V500 anti-B220 (RA3-6B2), PE
anti–Ki-67 (B56), PE anti-NK1.1 (PK136), and PE anti–Siglec F (E50-2440). The following
anti–mouse antibodies were obtained from eBioscience: PE-Cy7 anti-CD93 (AA4.1), PB antiCD49b (DX5), APC anti-Slamf6 (eBio13G3-19D), APC-e780 anti-CD45 (30-F11), PE antiFoxp3 (FJK-16s), and PerCP-eFluor710 anti-pro–IL-1β (NJT EN3). V450 or PerCP-Cy5.5 antiCD45.1 (A20), APC-Cy7 anti-CD45.2, and PE-Cy7 anti-Ly6G (1A8) were purchased from
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Tonbo Biosciences. PO-PRO-1 and 7-AAD obtained from Life Technologies were used for flow
cytometry performed on lungs to discriminate live and dead cells. Fc receptor blocking was
performed (clone 93; BioLegend or clone 2.4G2; Bio X Cell) in FACS buffer (0.5% BSA, 2 mM
EDTA, and 0.02% sodium azide in PBS) for 5–10 min at 4°C before surface staining (4°C for 20
min). ICS was performed after a 3–4 hour stimulation of T cells with PMA (50 ng/ml; Enzo Life
Sciences) and ionomycin (1 µM; Enzo Life Sciences) with brefeldin A (1 µg/ml; Enzo Life
Sciences). Cells were fixed in 4% paraformaldehyde (Electron Microscopy Sciences) at room
temperature for 20 min, followed by permeabilization with the Cytofix/Cytoperm Fixation and
Permeabilization kit (BD). ICS was performed in permeabilization buffer at 4°C for 20 min.
APC MOG38–49–I-Ab tetramers were obtained from the National Institutes of Health Tetramer
Core Facility. Splenic or CNS cells were incubated with 4.7 µg/ml (1:300) tetramers for 30 min
at 37°C. Cells were then used for surface staining. For Ki-67 staining, cells were initially fixed
with 2% paraformaldehyde (4°C for 20 min), and then fixed and permeabilized with the
eBioscience Foxp3/Transcription Factor Staining Buffer Set. Ki-67 staining was performed for
one hour at 4°C. For Foxp3 staining, sorted CD44−GFPneg, CD44+GFPneg, and CD44+GFPpos
CD4+ T cells from the CNS of EAE-induced mice were fixed and permeabilized with the
eBioscience Foxp3/Transcription Factor Staining Buffer Set. Foxp3 staining was performed for
30–60 minutes at room temperature. Flow cytometry was performed on a FAC SCanto II (BD) or
a FACS Aria II (BD). Flow cytometry data were analyzed with FlowJo software (Tree Star).

Fluorescent microscopy. Spinal cords from EAE-induced Bhlhe40GFP mice were dissected,
fixed in formalin followed by sucrose, frozen in OCT media, and cryosectioned as 10-µm
sections. Tissues were blocked with 0.4% Triton-X 100 in 10% FBS, and then in 10% FBS.
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Sections were then stained with primary antibody (biotin anti–mouse CD4; clone RM4-5; Bio X
Cell) or biotin anti–mouse CD11b (clone M1/70; Bio X Cell; both biotinylated in house) diluted
in 10% FBS, washed, and then stained with goat anti–rat IgG (H+L) Alexa Flour 555
(Invitrogen). Sections were mounted with Abcam Fluoroshield Mounting Medium with DAPI
and viewed on a Nikon Eclipse E800 epifluorescence scope equipped with a QImaging EXi Blue
camera and QCapture software (QImaging).

Enzyme-linked ImmunoSpot assay (ELISPOT). DLN cells from immunized mice were
cultured in Mutiscreen Filter Plates (EMD Millipore) at 0.5–1×106 cells/well in cIMDM and
stimulated with media, 10 µM MOG35-55 peptide, or 1 µg/ml concanavalin A (ConA; SigmaAldrich) at 37°C overnight. IFN-γ and IL-10 ELISPOT pairs were obtained from BD. IL-17A
and GM-CSF ELISPOT pairs and streptavidin-alkaline phosphatase were purchased from
BioLegend. An Immunospot counter (Cellular Technology Ltd.) was used for spot counting after
plate development with NBT/ BCIP substrate (Roche).

ELISA. DLN cells from naive, PTX-treated, or immunized mice were cultured at 106 cells/well
in 200 µl cIMDM and left unstimulated or stimulated with 50 µg/ml heat-killed Mtb at 37°C for
48 hours. Cell-free supernatants were analyzed for mature IL-1β by ELISA (BioLegend). Assays
were performed on Nunc Maxisorp plates and developed with streptavidin-HRP (BioLegend)
plus TMB substrate (BioLegend). Standard curves were generated with purified IL-1β
(BioLegend).
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Immgen data analysis and expression microarrays. Data from the Immgen Consortium (GEO
accession nos. GSE15907 [phase 1] and GSE37448 [phase 2]) were downloaded and used to
determine Bhlhe40 expression in a variety of immune cell types. Arraystar 5 software (DNAstar)
was used to normalize data using the robust multiarray analysis method with quantile
normalization. Naive CD4+ T cells from Bhlhe40GFP mice were cultured in TH17 conditions
(TGF-β1+IL-6+IL-23+IL-1β) for 4 days and stimulated for 3 hours with PMA and ionomycin.
GFPneg and GFPpos TH17 cells (CD45.2+CD4+CD8−) were purified (95% purity) by cell sorting
before total RNA was isolated (E.Z.N.A. MicroElute Total RNA kit; Omega Bio-Tek). RNA was
amplified using the Ovation PicoSL WTA System V2 (Nugen), biotin labeled with the Encore
Biotin Module (Nugen), fragmented, and hybridized to Affymetrix Mouse Gene 1.0 ST arrays.
Arraystar 5 software was used as described above. Data have been deposited in GEO under
accession no. GSE75407. GENE-E software (Broad Institute) was used to determine differential
gene expression and generate a heat map for the most expressed 14,000 probesets. The 700 genes
(5%) that were most highly expressed in GFPpos TH17 cells compared with GFPneg TH17 cells
were identified, and GENE-E software was used to determine the relative expression of these
700 genes in GEO accession no. GSE23505 (arrays performed on Affymetrix Mouse Genome
430 2.0 arrays)188 in which TH cells had been cultured in 6 different cytokine conditions.

Quantitative RT-PCR. GFPneg and GFPpos CD4+ T cells (gated on CD3+B220−CD4+ cells)
were sorted from DLNs on day 7 after immunization with MOG/CFA + PTX. RNA was isolated
(E.Z.N.A. MicroElute Total RNA kit; Omega Bio-Tek), and then cDNA was synthesized (High
Capacity RNA-tocDNA kit; Invitrogen). Quantitative real-time PCR was performed with Power
SYBR Green PCR Master Mix (Applied Biosystems) using a StepOnePlus Real-Time PCR
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machine (Applied Biosystems). Gene expression was determined relative to Hprt by the ΔCT
method. The following primers were used: Hprt, forward 5’TCAGTCAACGGGGGACATAAA-3’, reverse 5’-GGGGCTGTACTGCTTAACCAG-3’; Egfp ,
forward 5’-CCTACGGCGTGCAGTGCTTCAGC3’, reverse 5’CGGCGAGCTGCACGCTGCGTCCTC-3’; Bhlhe40 , forward 5’ACGGAGACCTGTCAGGGATG-3’, reverse 5’-GGCAGTTTGTAAGTTTCCTTGC-3’; Csf2 ,
forward 5’-GCCATCAAAGAAGCCCTGAA-3’, reverse 5’-GCGGGTCTGCACACATGTTA3’.

Immunoblotting. TH1 or TH17 cells were counted and lysed at 106/40 µl in Laemmli sample
buffer (Bio-Rad Laboratories) containing 2.5% β-mercaptoethanol. Cell lysates were loaded and
separated by 12% SDS-PAGE (Bio-Rad Laboratories) and transferred to BioBlot-PVDF
membranes (Costar). Blots were incubated with anti-Bhlhe40 (Novus Biologicals; used at
1:1,000) or anti-HDAC1 (Abcam; used at 1:2,000) primary antibodies at 4°C overnight with
shaking. Blots were washed at least four times before incubation with anti–rabbit IgG-HRP
(clone 5A6-1D10 [light chain specific]; Jackson ImmunoResearch Laboratories) at room
temperature for 60 min with shaking. After five washes, Clarity Western ECL substrate (Bio-Rad
Laboratories) or SuperSignal West Femto Maximum Sensitivity Substrate (Thermo Fisher
Scientific) was applied, and blots were placed on Blue basic autoradiography film (GeneMate).
Film was developed with a Medical Film Processor (model SRX-101A; Konica Minolta), and
scanned films were analyzed with ImageJ software (NIH).
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Statistical analysis. Data were analyzed by paired or unpaired two-tailed Student’s t tests
(Prism; GraphPad Software, Inc.) as indicated in the figure legends, with P ≤ 0.05 considered
significant.
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Figure 3-1. Bhlhe40GFP mice show Bhlhe40 expression in immune cells.
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Figure 3-1. Bhlhe40GFP mice show Bhlhe40 expression in immune cells.
(A–D) GFP (Bhlhe40) expression in multiple immune cell types in thymus (A), spleen (B and
D), and bone marrow, peritoneum, lung, and brain (C) from naive nontransgenic (Tg−) or
Bhlhe40GFP (Tg+) reporter mice. DN, double-negative cells; DP, double-positive cells; CD4SP,
CD4 single-positive cells; CD8SP, CD8 single-positive cells; mac, macrophages; mono,
monocytes; pDC, plasmacytoid DCs. All cell types were analyzed at least two times in at least
two independent experiments. (B) GFP (Bhlhe40) expression by splenic CD4+ and CD8+ T cells
from naive Bhlhe40GFP mice. CD44 and CD62L expression by GFPneg and GFPpos T cells were
analyzed. (E and F) Bhlhe40 expression in immune cells based on microarray datasets from the
Immgen Consortium, datasets GSE15907 (E; phase 1) and GSE37448 (F; phase 2). BM, bone
marrow; PMN, polymorphonuclear cells; MO, monocytes; DC, dendritic cells; FO B, follicular
B cells; GC B, germinal center B cells; MZ B, marginal zone B cells; Eos, eosinophils. Data are
mean ± SEM with dots representing individual microarrays performed by Immgen.
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Figure 3-2. Bhlhe40-expressing TH cells are enriched in the CNS and are robust cytokine
producers during EAE.
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Figure 3-2. Bhlhe40-expressing TH cells are enriched in the CNS and are robust cytokine
producers during EAE.
(A) GFP (Bhlhe40) expression by CD4+ T cells in the spleen and CNS of Bhlhe40GFP mice on
day 14 after EAE induction. Clinical scores of individual mice on the day of sacrifice are
indicated. One experiment out of four is shown (n = 10 mice total). (B) Quantitation of the
percentage of GFPpos cells (of CD4+ T cells) in spleen and CNS from A. Each line represents an
individual mouse (n = 10). Data are combined from four independent experiments performed at
day 13 or 14 after EAE induction. Clinical scores on the day of sacrifice are indicated by color.
(C) Immunofluorescent staining of a spinal cord section at day 15 after EAE induction in a
Bhlhe40GFP mouse (clinical score of 2). Dashed line represents the edge of the tissue. Bottom
right quadrant is the overlapping image of DAPI (blue), CD4 (red), and GFP (green). High
magnification images of selected CD4+ T cells expressing GFP are shown. Data are
representative of two independent experiments (n = 2 mice total). (D) ICS plots for IFN-γ, IL17A, and GM-CSF for GFPneg and GFPpos CD4+ T cells in the spleen and CNS at day 14 after
EAE induction in Bhlhe40GFP mice. One experiment out of two is shown (n = 5 mice). (E)
Quantitation of the frequency of GFPneg or GFPpos CD4+ T cells secreting IFN-γ, IL-17A, or
GMCSF from D. Each line represents an individual mouse (n = 5). Data are combined from two
experiments. Paired two-tailed Student's t test was performed to determine significance. ***, P ≤
0.001.
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Figure 3-3. PTX serves as an essential co-adjuvant by inducing Bhlhe40 expression in TH
cells.
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Figure 3-3. PTX serves as an essential co-adjuvant by inducing Bhlhe40 expression in TH
cells.
(A) GFP (Bhlhe40) and CD44 expression by CD4+ T cells from the DLN of Bhlhe40GFP mice on
day 7. Groups of mice were either unimmunized or immunized with MOG/CFA. PTX or mPTX
was administered i.p. on days 0 and 2. One experiment out of five is shown (n = 4–10/group).
(B) Quantitation of the percentage (left) of GFPpos cells (of CD4+ T cells) and the absolute
number (right) of GFPpos CD4+ T cells in the DLNs from (A). Dots represent individual mice.
Data are combined from five experiments (n = 4–10/group). (C) Mean EAE scores of WT mice
immunized with MOG/CFA. PTX or mPTX, where indicated, were administered i.p. on days 0
and 2. Data are combined from two experiments (n = 8–9). Incidence of clinical disease is
indicated. (D) ICS plots for IFN-γ, IL-17A, and GM-CSF for GFPneg and GFPpos CD4+ T cells in
the DLN in naive mice or at day 7 after immunization as indicated in Bhlhe40GFP mice. One
experiment out of three is shown (n = 9 mice). (E) Quantitation of the frequency of GFPneg and
GFPpos CD4+ T cells from MOG/CFA + PTX-immunized mice producing each of the eight
combinations of IFN-γ, IL-17A, and GM-CSF. Data are combined from three experiments (n =
9). (F) Mean fluorescence intensity (MFI) of Ki-67 by GFPneg or GFPpos CD4+ T cells from the
DLN of Bhlhe40GFP mice on day 7 after immunization with MOG/CFA + PTX. Data are
combined from two experiments (n = 7). (G) Quantitative RT-PCR analysis of Egfp, Bhlhe40,
and Csf2 expression by sorted GFPneg and GFPpos CD4+ T cells from the DLN of Bhlhe40GFP
mice on day 7 after MOG/CFA + PTX immunization (n = 3 mice from a single experiment).
Data are mean ± SEM. Unpaired (B) or paired (E–G) two-tailed Student's t tests were performed
to determine significance. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001.
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Figure 3-4. PTX co-adjuvanticity is Bhlhe40 dependent.
ELISPOT assays for the quantitation of cells secreting IFN-γ, IL-17A, GM-CSF, or IL-10
performed on DLN cells 7 d after MOG/CFA immunization of WT or Bhlhe40−/− mice treated
with or without PTX. Data are combined from four experiments (n = 7–13 mice/ group). Dots
represent individual mice. For clarity, only mean values (lines) are shown. Unpaired two-tailed
Student's t test was performed to determine significance. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤
0.001.
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Figure 3-5. Bhlhe40 expression identifies the cytokine-producing fraction of autoreactive
TH cells.
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Figure 3-5. Bhlhe40 expression identifies the cytokine-producing fraction of autoreactive
TH cells.
(A) Plots of MOG38-49–I-Ab tetramer staining and GFP (Bhlhe40) expression by CD4+ T cells
from the spleen and CNS of naive non-Tg and EAE-induced Bhlhe40GFP mice (day 15). One
experiment out of two is shown (n = 10 mice). (B) Quantitation of the percentage of CNS CD4+
T cells positive or negative for GFP (Bhlhe40) and/or MOG38-49–I-Ab tetramer staining in the
CNS at day 15 after EAE induction. Data are combined from two experiments (n = 10). (C)
Quantitation of the frequency of IFN-γ+ cells within the indicated CD4+ T cell subsets (as shown
in B). One experiment out of two is shown (n = 6). (D) Plots for (left) CD4 and CD45.1 and
(right) CD4 and GFP (Bhlhe40) on DLN cells after the transfer of T cells from 2D2 Bhlhe40GFP
CD45.1/CD45.2 mice into WT (CD45.2) recipients. 1 d after cell transfer, mice were left
unimmunized or immunized with the indicated peptide (MOG35-55 or OVA323-339) in CFA. Some
mice were treated with PTX on days 0 and 2. DLNs were harvested on day 7 after immunization.
One experiment out of three is shown (n = 3–10/group). (E) Quantitation of the percentage of
(top) CD45.1+ 2D2 cells (of CD4+ T cells) and (bottom) CD45.1+ 2D2 GFPpos cells (of CD45.1+
2D2 cells) in the DLNs from (D). Dots represent individual mice. Data are combined from three
experiments (n = 3–10 mice/group). (F) ICS plots for IFN-γ, IL-17A, and GM-CSF for host
CD4+ T cells, GFPneg, or GFPpos 2D2 cells in the DLN from MOG/CFA + PTX-immunized mice
from (D). One experiment out of three is shown (n = 10 mice). (G) Quantitation of the
frequency of host CD4+ T cells or GFPneg or GFPpos 2D2 cells secreting IFN-γ, IL-17A, or GMCSF from F. Lines connect data from individual mice (n = 10). Data are combined from three
experiments. (H) ICS plots for IFN-γ, IL-17A, and GM-CSF for host GFPneg or GFPpos CD4+ T
cells, or GFPneg or GFPpos 2D2 cells in the CNS at day 14 after EAE induction. T cells from 2D2
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Bhlhe40GFP CD45.1/CD45.2 mice were transferred into Bhlhe40GFP (CD45.2) recipients 1 d
before immunization with MOG/CFA + PTX. One experiment out of two is shown (n = 6 mice).
(I) Quantitation of the frequency of host GFPneg or GFPpos CD4+ T cells, GFPneg, or GFPpos 2D2
cells secreting IFN-γ, IL-17A, or GM-CSF from H. Lines connect data from individual mice (n
= 3). One experiment out of two is shown. Data are mean ± SEM. Unpaired (E) or paired (C and
G) two-tailed Student's t tests were performed to determine significance. *, P ≤ 0.05; **, P ≤
0.01; ***, P ≤ 0.001.
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Figure 3-6. Bhlhe40 is essential for the encephalitogenicity of TH cells in adoptive transfer
models of EAE.
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Figure 3-6. Bhlhe40 is essential for the encephalitogenicity of TH cells in adoptive transfer
models of EAE.
(A) ICS plots for the indicated cytokines from polarized WT and Bhlhe40−/− 2D2 TH1 or TH17
cells at day 4 of culture. One experiment out of three is shown (n = 10–14 mice/group). (B and
C) Mean EAE scores of WT mice after receiving transfers of WT or Bhlhe40−/− 2D2 TH1 (B) or
TH17 (C) cells. Data are combined from four (TH1, n = 10–14) or two (TH17, n = 10–11)
experiments. Incidence of clinical disease is indicated. (D–G) ICS plots for the indicated
cytokines (D and F) and quantitation of the frequency (E and G) of cytokine-producing WT and
Bhlhe40−/− 2D2 TH1 (D and E) or TH17 (F and G) cells in the spleen and CNS on days 28–34
after immunization. (D and E) Data are combined from two independent experiments (n =
7/group). (F and G) One experiment of two is shown (n = 3–4/group). Data are mean ± SEM.
Unpaired two-tailed Student's t test was performed to determine significance. **, P ≤ 0.01; ***,
P ≤ 0.001.
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Figure 3-7. Bhlhe40 expression negatively correlates with Foxp3 and IL-10 expression.
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Figure 3-7. Bhlhe40 expression negatively correlates with Foxp3 and IL-10 expression.
(A) Strategy for sorting CD44−GFPneg (R1), CD44+ GFPneg (R2), and CD44+ GFPpos (R3) CD4+
T cells in the CNS at day 16 after EAE induction. Foxp3 and CD25 expression on sorted cells
from each population is shown. One experiment out of two is shown (n = 5–7 mice). (B)
Quantitation of the frequency of Foxp3pos cells within each of the three populations as shown in
A. Data are combined from two experiments (n = 5–7). Data are mean ± SEM. (C) ICS plots
for IFN-γ and IL-10 for host GFPneg or GFPpos CD4+ T cells, or GFPneg or GFPpos 2D2 cells in the
CNS at day 14 after EAE induction. T cells from 2D2 Bhlhe40GFP CD45.1/ CD45.2 mice were
transferred into Bhlhe40GFP (CD45.2) recipients 1 d before immunization with MOG/CFA +
PTX. One experiment out of two is shown (n = 6 mice). (D) Quantitation of the frequency of
host GFPneg or GFPpos CD4+ T cells, GFPneg, or GFPpos 2D2 cells secreting IFN-γ or IL-10 from
(C). Lines connect data from individual mice (n = 3). One experiment out of two is shown. (E)
ICS plots for IFN-γ and IL-10 for GFPneg and GFPpos CD4+ T cells in the CNS at day 29 after
EAE induction in Bhlhe40GFP mice. One experiment out of two is shown (n = 5 mice). (F)
Quantitation of the frequency of GFPneg or GFPpos CD4+ T cells secreting IFN-γ (left) or IL-10
(right) from E. Lines connect data from individual mice (n = 5). Data are combined from two
experiments. Unpaired (B) or paired (F) two-tailed Student's t tests were performed to determine
significance. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001.
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Figure 3-8. Bhlhe40-expressing TH17 cells exhibit a pathogenic molecular signature.
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Figure 3-8. Bhlhe40-expressing TH17 cells exhibit a pathogenic molecular signature.
(A) CD4 and GFP (Bhlhe40) expression by polarized Bhlhe40GFP TH1 or TH17 cells at day 4 of
culture. Data are representative of at least five experiments with at least eight mice per
condition. (B) Strategy for sorting GFPneg and GFPpos TH17 cells at day 4 of culture. Sorted
cells were subjected to immunoblots for Bhlhe40 and HDAC1 (loading control). One
experiment out of two is shown (n = 5 mice). (C) Quantitation of the band intensity of Bhlhe40
relative to HDAC1 in sorted GFPneg and GFPpos TH17 cells from (B). Data are expressed as a
fold change in intensity comparing sorted cells from the same culture. Data are combined from
two experiments (n = 5). Mean ± SEM. (D) Heat map comparing gene expression between
sorted GFPneg and GFPpos TH17 cells from three mice. Listed genes have been associated with
EAE or represent surface markers amenable to flow cytometry (Cd93, Il7r, Slamf6, and Sell).
Shown are the 14,000 probesets with the highest mean expression across all six arrays. The
yellow box identifies the 700 genes (5%) that were most highly expressed in GFPpos TH17 cells
compared with GFPneg TH17 cells. The relative expression of these 700 genes was analyzed in
GEO DataSet GSE23505188 in which TH cells had been cultured in different cytokine conditions
as indicated (right). The red line indicates the mean expression of these genes. The green line
represents the expression of Bhlhe40. (E) CD4 and CD93, IL-7R, Slamf6, or CD62L (encoded
by Sell) expression by GFPneg and GFPpos TH17 cells cultured as in A. One experiment out of
two is shown (n = 4 mice).
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Figure 3-9. IL-1β increases Bhlhe40 expression in TH17 and γδ T cells.
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Figure 3-9. IL-1β increases Bhlhe40 expression in TH17 and γδ T cells.
(A) CD4 and GFP (Bhlhe40) expression by Bhlhe40GFP TH17 cells at day 4 of culture in the
indicated conditions. One experiment out of three is shown (n = 4 mice). (B) Kinetics of GFP
(Bhlhe40) expression by Bhlhe40GFP TH17 cells cultured in the presence of IL-1 blockade (anti–
IL-1β and anti–IL-1R) or IL-1β. Data are combined from two experiments (n = 3–5
mice/condition). (C) CD4 and GFP (Bhlhe40) expression by Bhlhe40GFP TH17 (TGF-β1 + IL-6
+ IL-23) cells at day 4 of culture in the presence of IL-1 blockade or IL-1β and with WT or
Il1r1−/− irradiated splenocytes. One experiment out of two is shown (n = 3 mice). (D)
Immunoblots of Bhlhe40 and HDAC1 in TH17 cells cultured with the indicated cytokines for 4 d
(bottom). Quantitation of the band intensity of Bhlhe40 relative to HDAC1. Data are
representative of four experiments (n = 2 mice/condition). (E) Quantitation of the frequency of
GFPneg or GFPpos TH17 (TGF-β1 + IL-6 + IL-23) cells secreting IL-17A, GM-CSF, or IL-10
cultured in the absence or presence of IL-1β or IL-1 blockade. Data are combined from four
experiments (n = 4–5 mice/condition). (F) CD4 and GFP (Bhlhe40) expression by Bhlhe40GFP
TH1 cells at day 4 of culture with IL-1β or IL-1 blockade. One experiment out of three is shown
(n = 5 mice). (G) Quantitation of the percentage of GFP (Bhlhe40)-expressing TH1 cells cultured
in the presence (IL-1β) or absence of IL-1β (no IL-1β or IL-1 blockade). Data are combined
from four experiments (n = 5). (H) Immunoblots of Bhlhe40 and HDAC1 in TH1 cells cultured
with or without IL-1β for 4 d. The fold change of band intensity of Bhlhe40 relative to HDAC1
is indicated. Data are representative of two experiments (n = 3 mice). (I) Quantitation of the
frequency of GFPneg or GFPpos TH1 cells secreting IFN-γ, GM-CSF, or IL-10 cultured in the
absence or presence of IL-1β or IL-1 blockade. Data are combined from four experiments (n =
3–5/condition). (J) CD44 and GFP (Bhlhe40) expression by lymph node γδ T cells from
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Bhlhe40GFP mice cultured for 3 d in the indicated conditions. One experiment out of three is
shown (n = 5 mice). (K) Quantitation of the percentage of GFP (Bhlhe40)-expressing γδ T cells
from (J). Data are combined from three experiments (n = 5 mice/condition). Data are mean ±
SEM. Unpaired (B, D, and K) or paired (G) two-tailed Student's t tests were performed to
determine significance. For E and I, p-values represent paired, two-tailed Student's t test when
comparing GFPneg to GFPpos cells from the same culture, and represent unpaired two-tailed
Student's t test when comparing cultures with no IL-1β or IL-1 blockade vs. IL-1β. *, P ≤ 0.05;
**, P ≤ 0.01; ***, P ≤ 0.001.
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Figure 3-10. IL-1R signaling is required in vivo for full Bhlhe40 expression by TH cells, and
systemic PTX induces IL-1β production by lymph node cells.
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Figure 3-10. IL-1R signaling is required in vivo for full Bhlhe40 expression by TH cells, and
systemic PTX induces IL-1β production by lymph node cells.
(A) GFP (Bhlhe40) expression by CD4+ T cells from the DLNs of Bhlhe40GFP or Il1r1−/−
Bhlhe40GFP mice on day 7 after immunization with MOG/CFA + PTX. One representative
experiment out of three is shown (n = 9–10 mice/group). (B) Quantitation of the percentage
(left) of GFPpos cells (of CD4+ T cells) and the (right) number of GFPpos CD4+ T cells in the
DLNs from (A). Data are combined from three experiments (n = 9–10/group). (C) GFP
(Bhlhe40) expression by CD4+ T cells from the DLNs of Bhlhe40GFP mice treated with control
Ab or IL-1 blockade in vivo on days −1, 1, and 4. Mice were left unimmunized or were
immunized with MOG/CFA ± PTX treatment (days 0 and 2). One experiment out of two is
shown (n = 1–3 mice/group). (D) Quantitation of the percentage (left) of GFPpos cells (of CD4+
T cells) and the (right) number of GFPpos CD4+ T cells in the DLNs from (C). One experiment
out of two is shown (n = 1–3 mice/ group). (E) Mean EAE scores of WT, Bhlhe40−/−, and
Il1r1−/− mice immunized with MOG/CFA + PTX. Data are combined from two experiments (n =
6–12). Incidence of clinical disease is indicated. (F) CD4+ T cells from the DLN of MOG/CFA
+ PTX-immunized Bhlhe40GFP (CD45.1/CD45.2) mice and Il1r1−/− Bhlhe40GFP (CD45.2) mice
were purified on day 7 and co-transferred to WT (CD45.1) recipients 1 d before immunization
with MOG/CFA + PTX. 7 d after this immunization, transferred Bhlhe40GFP or Il1r1−/−
Bhlhe40GFP GFPpos cells were identified. One experiment out of two is shown (n = 6). (G)
Quantitation of the percentage of transferred Bhlhe40GFP or Il1r1−/− Bhlhe40GFP GFPpos cells (of
GFPpos cells) in the DLNs from (F). One experiment out of two is shown (n = 6). (H) Groups of
WT mice were either unimmunized or immunized with MOG/CFA. PTX or mPTX was
administered i.p. on days 0 and 2. DLN cells, collected on day 7, were cultured with or without
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50 µg/ml heat-killed Mtb for 2 d and supernatants were analyzed for IL-1β. Data are combined
from three experiments (n = 3–7 mice/ group). (I) Quantitation of the percentage of pro–IL-1β+
cells (of B220− DLN cells) from WT mice treated as in (H). Data are combined from four
experiments (n = 3–12/group). (J) ICS for pro–IL-1β expression by B220− DLN cells from
representative mice shown in I. (K; left) Ly6G and Ly6C expression on B220− DLN cells from
the mice shown in (J). Numbers show the percentage of Ly6G+Ly6C+ neutrophils (right). MHC
class II and Ly6C expression by Ly6G−B220− cells. Numbers show the percentage of
monocytes/moDCs. One experiment out of four is shown (n = 3–12/group). (L) Quantitation of
the number of pro–IL-1β+ neutrophils, MHC II+Ly6C+ monocytes/moDCs, migratory DCs, and
resident DCs in the DLNs from (I-K). Data are combined from two experiments (n = 2–7/
group). Data are mean ± SEM. Dots represent individual mice except in (E). Unpaired (B, D,
H, I, and L) or paired (G) two-tailed Student's t tests were performed to determine significance.
*, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001.
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Chapter 4: Bhlhe40 regulates IL-10
production by innate immune cells and is
critical for control of Mycobacterium
tuberculosis

Note: A manuscript related to the content of this chapter is currently in preparation.
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4.1 Abstract
Mononuclear phagocytes and T cells control bacterial growth and limit pathology during
pulmonary Mycobacterium tuberculosis (Mtb) infection. IL-10 is an immunosuppressive
cytokine generated by several cell types during Mtb infection and is known to impair protective
responses to this pathogen. IL-10 can inhibit intracellular bacterial killing, antigen presentation,
IL-12 production, and TH1 cell priming. How IL-10 production is regulated by both innate and
adaptive immune cells during Mtb infection is unclear. In Chapter 2, we showed that the
transcription factor Bhlhe40 repressed IL-10 production by CD4+ T cells during EAE. In this
chapter, I describe our experiments in which we further uncovered that Bhlhe40 also negatively
regulates IL-10 expression by myeloid cells during Mtb infection in mice. In vivo, Bhlhe40-/mice rapidly succumbed to pulmonary Mtb infection with uncontrolled bacterial growth and
large neutrophil-rich lesions. This increased susceptibility was also seen in Rag1-/-Bhlhe40-/mice when compared to Rag1-/- mice, indicating that the innate compartment required Bhlhe40
for Mtb resistance. Using IL-10 reporter mice crossed to Bhlhe40-/- mice, we identified Bhlhe40/-

lung CD11b+ DCs and monocyte-derived cells as sources of abundant IL-10 during Mtb

infection. Genetic deletion of Il10 in Bhlhe40-deficient mice (Il10-/-Bhlhe40-/-) reversed the
susceptibility of Bhlhe40-/- mice to Mtb infection, confirming that negative regulation of IL-10
was an essential function for Bhlhe40. ChIP-qPCR and ChIP-Seq performed in myeloid cells
identified a putative regulatory element within the Il10 locus. Our results established a critical
role for Bhlhe40 in innate immune cells and provided novel insights into Il10 gene regulation
within these populations during mycobacterial infection.
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4.2 Introduction
Tuberculosis (TB) is caused by Mycobacterium tuberculosis (Mtb). This single pathogen is
responsible for more deaths than HIV and malaria. In 2015, an estimated 10.4 million new TB
cases were reported and about 1.8 million people died of this disease (WHO Fact Sheet 2017
http://www.who.int/mediacentre/factsheets/fs104/en/), making TB one of the top ten causes of
human mortality in the world. However, the only vaccine for TB, Bacille Calmette-Guerin
(BCG), is not effective for adults267. In addition, control of the global TB epidemic is challenged
by the emergence of multidrug-resistant TB (MDR TB)268. To develop new vaccines and
treatments for this disease, it is important to understand the immune response to Mtb infection.
Studies from experimental mouse models showed that TB is controlled by both innate and
adaptive immune responses. Upon Mtb infection, lung macrophages and DCs phagocytose the
pathogen and secrete antimicrobial molecules, including TNF, IL-1, IL-6, IL-12, and several
chemokines141, 268. Mice deficient in TNF, TNF receptor p55, IL-1 receptor (IL-1R), IL-α, IL-1β,
or the adaptor for IL-1R signaling Myd88 are highly susceptible to Mtb157, 269, 270 109, 271, 272, 273, 274,
275

. A recent study showed that the hydrolases within the alveolar lining fluid (ALF) released

Mtb cell wall components, which enhanced the anti-microbial properties of human
macrophages276. Nevertheless, even in WT mice, infected phagocytes fail to efficiently
eliminate the bacteria277, 278. Eight to 12 days after Mtb infection, pulmonary CCR7+ DCs
transport antigens to lung-draining mediastinal lymph nodes guided by the chemokines CCL19
and CCL21279, 280, 281, 282, 283. In DLNs, mature DCs provide TCR stimulation and secrete IL-12
to direct TH1 cell differentiation. About 14-17 days after infection, Mtb antigen-specific TH1
cells migrate to the lung and secrete IFN-γ to activate phagocytes as well as lung epithelial and
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endothelial cells284. Activated macrophages then produce reactive oxygen species (ROS) and
nitric oxide (NO) to kill Mtb or restrict its replication in the lungs110, 285, 286. Not surprisingly,
mice lacking T cells (eg. Rag1-/-, TCRαβ-/-, MHC-II-/-) or with impaired TH1 cell-mediated
responses (eg. Tbx21-/-, Stat1-/-, Ifng-/-, Ifngr-/-, Nos2-/- mice) all fail to generate protective
immunity to Mtb112, 113, 114 110, 111.
The anti-inflammatory cytokine IL-10 has been shown to limit the immune responses in mouse
models of mycobacterial infections287. Several studies observed that IL-10-deficient CBA/J,
BALB/c, and C57BL/6 mice showed stronger TH1 responses and enhanced protection from
aerosol Mtb infection152, 154, 155, 287. Others reported that transgenic overexpression of IL-10 by
immune cells in FVB, BALB/c, and C57BL/6 mice rendered the animals more susceptible to
chronic mycobacterial infection288, 289, 290, 291, 292. Turner et al. overexpressed IL-10 under the Il2
promoter in C57BL/6 mice and found that these mice had higher bacterial loads after four
months of Mtb infection292. Schreiber et al. generated transgenic FVB mice with macrophagespecific overexpression of IL-10, which failed to control Mtb replication and died significantly
earlier than their non-transgenic counterparts290. These studies indicated that the hyperproduction of IL-10 from T cells and phagocytes could increase Mtb susceptibility.
In the previous two chapters, we showed that Bhlhe40-/- T cells produce enhanced amounts of IL10, especially from IL-12-polarized TH1 cells11, 12. Although WT TH1 cells can restrict Mtb
replication, IL-10-hyperproducing TH1 cells might fail to do so and thus be detrimental. We
originally hypothesized that mice lacking Bhlhe40 would be susceptible to Mtb infection due to
impaired immune responses caused by higher levels of IL-10 production from CD4+ T cells. In
this chapter, we found that Bhlhe40-/- mice indeed succumbed to aerosol Mtb infection, and that
genetic deletion of Il10 in Bhlhe40-deficient mice (Il10-/-Bhlhe40-/-) significantly prolonged their
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survival. Nevertheless, our Rag1-/-Bhlhe40-/- mice data suggested that Bhlhe40 is actually
essential for the innate immune compartment to control Mtb infection in the early stage. Using
IL-10 reporter mice, we pinpointed several myeloid cell subsets that expressed higher levels of
IL-10 in infected Bhlhe40-/- lungs. Furthermore, ChIP-Seq and ChIP-qPCR performed in GMCSF-cultured bone marrow cells identified a putative regulatory element within the Il10 locus.
These results suggested a critical role for Bhlhe40 in Mtb resistance through regulating IL-10
expression by innate immune cells.
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4.3 Results
4.3.1 Bhlhe40-deficient mice succumb to Mtb infection
To examine the role of Bhlhe40 in immune responses to bacterial infections, we infected
Bhlhe40-/- mice via the aerosol route with the virulent Erdman strain of Mtb. While WT and
Bhlhe40+/- mice survived longer than 100 days after infection, Bhlhe40-/- mice were highly
susceptible to Mtb. Knockout mice started losing weight at day 21 and all died by seven weeks
post infection (p.i.) (Figure 4-1A and data not shown). Gross pathology showed several white
abscesses on the lung surfaces of Bhlhe40-/- mice at day 33 after infection (Figure 4-1B).
Compared to WT mice, Bhlhe40-/- mice had higher mycobacterial burdens in both lungs and
spleens at week three after infection (Figure 4-1, C and D). Our results showed that Bhlhe40 is
required for effective control of Mtb replication.

4.3.2 Anti-Ly6G treatment fails to rescue Bhlhe40-/- mice from Mtb-induced
lethality
Histology of lung sections showed that the lesions in infected Bhlhe40-/- mice were dominated by
granulocytes (Figure 4-2A). Using flow cytometry, we confirmed that the majority of CD45+
hematopoietic cells in the Bhlhe40-/- lungs were Ly6C+Ly6G+ neutrophils after three weeks of
infection (Figure 4-2, B and C). Exacerbated neutrophil recruitment is commonly associated
with poor outcomes after TB infection293. Massive neutrophilia was observed in several Mtbsusceptible mutant mice such as Card9-/- mice, Ifngr-/- mice, and Lyz2-Cre x Atg5fl/fl conditional
knockout mice, and all of these strains quickly succumb to Mtb infection112, 294, 295. Notably, the
survival of these mutant mice could be prolonged by treating them with anti-Ly6G antibody
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(clone 1A8), which specifically deletes neutrophils112, 294, 295. We utilized the antibody treatment
protocol reported by Kimmey et al. to test if neutrophil depletion affected the survival of
Bhlhe40-/- mice after exposure to Mtb. Anti-Ly6G treatments largely reduced Gr-1hiLy6C+
neutrophils in both naïve WT and Bhlhe40-/- mice, indicating that the antibody-mediated
phagocytosis machinery was functioning in the absence of Bhlhe40 (Figure 4-2D).
Nevertheless, the injections of anti-Ly6G antibody did not impact the susceptibility of Bhlhe40-/mice to Mtb. Bhlhe40-/- mice treated with control or 1A8 antibody lost weight at the same
kinetics and died at nearly the same time (Figure 4-2E and data not shown). Despite the
absence of Gr-1hiLy6C+ cells after anti-Ly6G injections, we observed a less frequent Gr1loLy6C+ population that resembled granulocytes in the lungs of Bhlhe40-/- mice (Figure 4-2F).
We concluded that anti-Ly6G treatment at least partially depleted the neutrophil subset in
Bhlhe40-/- mice but was unable to improve their resistance to Mtb.

4.3.3 Innate immune cells require Bhlhe40 to control Mtb infection
To test if Bhlhe40 is required by the hematopoietic compartment to restrict Mtb replication, we
generated bone marrow chimeras by reconstituting irradiated WT or Bhlhe40-/- mice with
Bhlhe40-/- or WT bone marrow cells. We found that Bhlhe40 was essential in the hematopoietic
compartment for the control of Mtb infection, since Bhlhe40-/- bone marrow-reconstituted WT or
Bhlhe40-/- recipient mice phenocopied global Bhlhe40-deficient mice upon Mtb infection
(Figure. 4-3A).
Next, we examined the requirements for Bhlhe40 in the innate and adaptive immune
compartments. Bhlhe40-/- mice were crossed to Rag1-/- mice and infected with Mtb.
Interestingly, we found that Rag1 deficiency did not affect the susceptibility of Bhlhe40-/- mice.
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Bhlhe40-/- mice and Rag1-/- Bhlhe40-/- mice died at the same time, about one week earlier than
Bhlhe40-sufficient Rag1-/- mice (Figure. 4-3B). Also, Rag1-/-Bhlhe40-/- mice showed increased
lung bacterial loads compared to Rag1-/- mice (Figure. 4-3C). These results led us to conclude
that Bhlhe40 was critical for Rag1-independent innate immune cells to restrain Mtb infection.

4.3.4 Bhlhe40-/- myeloid cells express higher levels of IL-10 in vivo
We next analyzed myeloid cell responses in Mtb-infected mixed bone marrow chimeras.
Irradiated mice reconstituted with only WT cells (but from two different donors) showed
minimal signs of lung inflammation at 3 wk p.i. In contrast, recipients reconstituted with mixed
WT and Bhlhe40-/- bone marrow cells exhibited an increased total proportion of neutrophils
(Figure. 4-4A) which originated equally from WT and Bhlhe40-/- progenitors (Figure. 4-4B).
Furthermore, both neutrophil populations, regardless of genotype, were highly infected by GFPlabeled Mtb (Figure. 4-4C). These results suggested that cell-extrinsic factors secreted from
Bhlhe40-/- bone marrow-derived cells remodeled the lung environment and diminished the ability
of WT cells to control Mtb infection.
Detection of cytokine and chemokine expression by WT and Bhlhe40-/- total lung cells after
infection revealed that Il10 transcripts and protein was upregulated in Bhlhe40-/- mice (Figure. 45, A and B). Stimulation of total lung cells from infected Bhlhe40-/- mice with heat-killed Mtb
also showed higher IL-10 production but a comparable amount of TNFα (Figure. 4-5C). IL-10
is an immunosuppressive cytokine secreted by multiple cell types during Mtb infection268. It has
been proposed that IL-10 impairs immune responses by inhibiting macrophage maturation, DC
antigen presentation and trafficking, and TH1 cell polarization, migration, and function139, 144, 268.
Monocytes from TB patients and the human mononuclear phagocytes infected with Mtb in vitro
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have been reported to secrete IL-10140, 141, 142. Since we have previously shown that Bhlhe40
negatively regulates IL-10 production by immune cells11, we hypothesized that Bhlhe40 might
repress IL-10 expression by myeloid cells to assure their ability to control infection.
To identify the cellular sources of IL-10 in the steady state and during Mtb infection, we crossed
Bhlhe40-/- mice to IL-10-Thy1.1 BAC transgenic (“10BiT”) reporter mouse296. No or very low
IL-10 expression was observed in naïve WT and Bhlhe40-/- animals, but its expression increased
after Mtb infection (Figure. 4-5D). Particularly, several immune cell subsets from infected
Bhlhe40-/- lungs, including CD11b+ DCs, monocyte-derived cells, and CD4+ T cells, showed
higher levels of IL-10 production in comparison to their WT counterparts (Figure. 4-5D). In
human patients, phagocytes rather than lymphocytes seem to be the major IL-10 producers
during TB infection297. At least at early time points after infection, we felt that the myeloid cells
rather than the T cells were the primary sources of the excess amounts of IL-10 observed in Mtbinfected Bhlhe40-/- mice, since Rag1-/-Bhlhe40-/- total lung cells also secreted more IL-10 when
compared to Rag1-/- cells after ex vivo heat-killed Mtb stimulation (Figure. 4-5E).

4.3.5 Bhlhe40 directly binds to the Il10 locus in bone marrow-derived
myeloid cells
In Chapter 2, we analyzed publicly-available ChIP-Seq data for Bhlhe40 performed in CH12
cells (a B cell lymphoma line) by the Mouse ENCODE consortium (Figure. 2-11)11. Our
analysis showed that Bhlhe40 might bind to the Il10 gene locus at cis regulator elements
(Figure. 2-11B). To test if Bhlhe40 was a direct transcriptional repressor of Il10 in myeloid
cells, we performed ChIP followed by quantitative PCR in WT and Bhlhe40-/- (served as
negative control) GM-CSF-cultured bone marrow cells. We chose these cells because they
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express Bhlhe40 and were easy to obtain in abundance. In addition, these cells can potentially
sense Mtb via TLR2 and respond to the stimulation by secreting IL-10123, 126. IL-10
concentrations were significantly higher in Bhlhe40-/- cultures than in WT cultures after heatkilled Mtb stimulation of these cells, suggesting that the system was relevant for studying how
Bhlhe40 regulates IL-10 secretion in myeloid cells (Figure. 4-6A).
WT and Bhlhe40-/- GM-CSF-cultured bone marrow cells were stimulated with heat-killed Mtb
and subjected to ChIP-qPCR. As expected, Bhlhe40 bound to its own promoter as previously
described (Figure. 4-6B)298. We then designed nine pairs of primers that generated amplicons
that span sites of Bhlhe40 binding found by ChIP-Seq in CH12 cells (Figure. 2-11B), and tested
if any of these sites were bound directly by Bhlhe40 in myeloid cells (Figure. 4-6C). Among all
the potential binding sites we examined, Bhlhe40 specifically bound to a novel regulatory region
encompassing the E-box motif CACGTG at +6.1 kilobase (kb) downstream of the Il10
transcription start site (Figure. 4-6C). To identify Bhlhe40 binding sites across the genome by
an unbiased method, we performed ChIP-Sequencing (ChIP-Seq) with heat-killed Mtbstimulated WT and Bhlhe40-/- GM-CSF-cultured bone marrow cells (Figure. 4-6, D-G). The
Model-based Analysis of ChIP-Seq (MACS) peak-calling method identified ~900 potential
Bhlhe40-binding sites, with greater than 1/3 of the peaks located in promoter regions (Figure. 46D). Comprehensive motif analysis performed by MEME-ChIP found that the E-box motif
CACGTG was the most common sequence within these sites (Figure. 4-6E), consistent with StPierre et al.'s report that CACGTG is the preferred binding motif for Bhlhe4021. Our ChIP-Seq
analysis identified two candidate Bhlhe40-binding sites within the Bhlhe40 promoter (Figure. 46F) and revealed the same +6.1kb site as the only Bhlhe40-binding site within the Il10 locus
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(Figure. 4-6G). We concluded that Bhlhe40 directly binds to the Il10 locus and represses the
cytokine's transcription in myeloid cells.

4.3.6 IL-10 deficiency rescues Bhlhe40-/- mice from early Mtb-induced death
To ask whether excessive IL-10 production renders Bhlhe40-/- mice highly susceptible to Mtb
infection, we generated Il10-/-Bhlhe40-/- mice and tested their susceptibility. We found that
genetically depleting Il10 was sufficient to protect Bhlhe40-/- mice from early fatal tuberculosis
(Figure. 4-6A). In contrast to Bhlhe40-/- mice, Il10-/-Bhlhe40-/- mice had lower mycobacterial
burdens (Figure. 4-6B), and milder neutrophil infiltration (Figure. 4-6C) in the lungs at day 21
p.i., indicating that Bhlhe40 must repress Il10 production to allow protective immunity to Mtb.
Nevertheless, when compared to WT or Il10-/- mice, Il10-/-Bhlhe40-/- mice still showed impaired
survival (Figure. 4-6A) and slightly higher lung CFUs as well as neutrophil proportions (Figure.
4-6, B and C). These results suggested that while it is critical for Bhlhe40 to suppress the
expression of IL-10 in innate immune cells to generate early protection, this transcription factor
regulates other as yet unidentified targets to promote fully effective immune responses to Mtb.
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4.4 Discussion
In this chapter, we established that Bhlhe40 has an essential role in murine host resistance
against Mtb. The absence of Bhlhe40 resulted in a lethal lung inflammation dominated by
neutrophils, and all Bhlhe40-/- mice died by seven weeks after aerosol Mtb infection. We found
that Bhlhe40 repressed IL-10 expression by innate immune cells, particularly CD11b+ DCs and
monocyte-derived cells. ChIP-qPCR and ChIP-Seq data revealed a putative Bhlhe40-binding
site within the Il10 locus in myeloid cells. Importantly, genetic deletion of Il10 significantly
decreased the bacterial loads and prolonged the survival of Bhlhe40-/- mice after Mtb infection,
confirming that negative regulation of IL-10 is a critical function for Bhlhe40. These findings on
Bhlhe40-dependent immune regulations might provide new insights for the development of
vaccines and treatments for human TB.
In active TB patients, neutrophils are usually associated with disease pathogenesis and poor
prognosis293. The neutrophil is the most abundant immune cell type and the predominant cell
subset infected with Mtb in patients’ sputum and bronchoalveolar lavage (BAL) fluid299. In the
blood of active TB patients, a neutrophil-driven interferon-inducible TB signature gene profile
has been identified300, 301. Moreover, high percentages of blood neutrophils correlate with
unfavorable outcomes in established TB patients302. Consistent with these observations in
humans, several mouse studies also connect lung neutrophilia with high Mtb susceptibility112, 294,
295, 303

. Massive and rapid neutrophil recruitment to the lung is a hallmark of severe pathology in

many Mtb-susceptible mouse strains including Card9-/- mice, Ifngr-/- mice, and Lyz2-specific
Atg5 conditional knockout mice. Lung-recruited neutrophils during infection are detrimental
because specific depletion of these cells by administrating anti-Ly6G antibody (clone 1A8) is
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able to prolong host survival112, 294, 295. Here, we found that Bhlhe40-/- mice were extremely
susceptible to virulent Mtb infection with remarkable granulocytic accumulation in the lungs by
three weeks of infection (Figure. 4-2, A-C). However, it was somewhat to our surprise that antiLy6G treatment neither prevented weight loss nor prolonged the survival of Mtb-infected
Bhlhe40-/- mice (Figure. 4-2E and data not shown). We felt that the antibody treatment was
effective because the same protocol successfully reduced the lung and splenic neutrophil
populations in uninfected Bhlhe40-/- mice, and our precise regimen of injections was able to
rescue Atg5 conditional knockout mice by Kimmey et al.295. The unresponsiveness to anti-Ly6G
antibody of infected Bhlhe40-/- mice indicated that the observed neutrophil accumulation was a
side effect downstream of Bhlhe40-dependent immune defects in response to Mtb but not the
main cause of the early lethality of these animals. To further confirm that Bhlhe40 is not
required by neutrophils to control Mtb infection, we are currently breeding Bhlhe40-/- mice to
Csf3r-/- mice, which lack G-CSF signaling and have decreased numbers of neutrophils304. Our
preliminary results show that G-CSF receptor deficiency minimally affects the survival of Mtbinfected Bhlhe40-/- mice (data not shown), supporting the notion that Bhlhe40 is required by
non-neutrophils for effective protection.
Although endogenous IL-10 has been shown to impair the immune response in mice infected
with M. bovis BCG and M. avium305, 306, 307 152, 308, the role of IL-10 in immune resistance against
M. tuberculosis is inconclusive. This controversy might be explained by differences in the
genetic backgrounds of the mice used and the stages of disease examined in various experimental
studies. In Mtb-infected CBA/J mice, anti-IL-10R treatment decreased lung bacterial loads at
day 150 p.i. and modestly improved their survival309. Consistent with this, Il10-/- CBA/J mice
were more capable of controlling infections as evidenced by significantly lower Mtb CFUs in the
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lungs and spleens154. In BALB/c background mice, IL-10 deficiency enhanced protection to
aerosol Mtb infection153. However, one early study showed that the absence of IL-10 in
C57BL/6.129 mice did not affect susceptibility to Mtb within the first 100 days post infection150.
C57BL/6 mice are more resistant to mycobacterial infection than other strains commonly used
for TB studies108, 308, 309. Jung et al. found no differences in bacterial burden in the lungs of WT
and Il10-/- C57BL/6 mice in the first 100 days after aerosol Mtb infection151. A more recent
study, however, argued that although Il10-/- C57BL/6J mice showed normal resistance in the first
five months, they failed to control Mtb growth at day 185 p.i. and died by day 200 p.i.155. In
addition, Roach et al. observed a transiently increased resistance to Mtb infection in Il10-/C57BL/6 mice examined at 4 wk p.i.152, and Redford et al. reported mild but significant Mtb
CFU reductions in the lungs and spleens of Il10-/- mice of the same background at days 56 and
128 p.i.153. An interesting study from Anne O'Garra's group showed that blocking IL-10
signaling during BCG vaccination enhanced subsequent immune responses to Mtb infection in
both CBA/J and C57BL/6 mice. Their results indicated that one of the mechanisms by which IL10 impaired immune responses to Mtb was to interrupt T cell priming310. Collectively, work
performed in C57BL/6 mice suggested a negative but moderate role of endogenous IL-10 during
Mtb infection.
To explore the effects of IL-10 overexpression on immune responses to mycobacterial infections,
several groups have generated transgenic mice that overexpress IL-10 in T cells or antigenpresenting cells in FVB, BALB/c, or C57BL/6 mice. IL-10 overexpression by T cells and
CD68+ macrophages in FVB mice resulted in higher M. bovis BCG burdens in the lungs288, 289.
BALB/c mice with increased IL-10 expression from MHC-II+ cells failed to control M. avium
growth and died by week 20 p.i.291. Turner et al. overexpressed IL-10 by T cells in C57BL/6
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mice and found that these mice had higher bacterial loads four months post Mtb infection292. In
the study from Schreiber et al., FVB transgenic mice with macrophage-specific overexpression
of IL-10 had increased lung Mtb burdens and died by day 126 p.i.290. In summary, these studies
showed that extra IL-10 production from immune cells diminished immune responses to
mycobacteria.
Here, we discovered that suppression of IL-10 by Bhlhe40 is absolutely required for protective
immune resistance against Mtb. In the absence of Bhlhe40, several immune cell subsets
including T cells and myeloid cells overexpressed IL-10 during infection. In TB patients,
macrophages rather than T cells have been shown to be the major source of IL-10297. Although
Bhlhe40 negatively regulated this cytokine in CD4+ T cells11, we concluded that Bhlhe40 must
also repress Il10 expression by innate immune cells to allow effective protection, because Rag1-/Bhlhe40-/- mice and Bhlhe40-/- mice were equally susceptible to Mtb, and both strains were more
vulnerable to this pathogen than Bhlhe40-sufficient Rag1-/- mice were (Figure. 4-3, B and C).
In the lungs of Mtb-infected Bhlhe40-/- mice, we found that CD11b+ DCs and monocyte-derived
cells expressed increased levels of IL-10 (Figure. 4-5D, bottom). Notably, Bhlhe40-/- lungresident myeloid cells and T cells did not hyper-produce IL-10 in the steady state (Figure. 4-5D,
top). The excess amounts of IL-10 only appeared after Mtb infection and greatly increased with
heat-killed Mtb stimulation ex vivo (Figure. 4-5, C and E). We speculate that Bhlhe40 tightly
controls IL-10 expression in multiple myeloid cell subsets at certain times and anatomical
locations in order to initiate and/or sustain protective immune responses to Mtb. This broad
expression and function of Bhlhe40 in the innate immune compartment might explain why
Bhlhe40-/- mice were more susceptible to mycobacterial infections than the aforementioned IL-10
transgenic mice.
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While IL-10 deficiency significantly improved the survival of and largely decreased Mtb loads in
Bhlhe40-/- mice, we observed that Il10-/-Bhlhe40-/- mice were still more susceptible to Mtb
infection when compared to WT or Il10-/- mice (Figure. 4-7). These results indicated that
Bhlhe40 likely regulates other targets which are particularly responsible for late-stage protection
to Mtb. To fully understand the complete role of Bhlhe40 in immune responses to
mycobacteria, future experiments should utilize the ChIP-Seq data generated in myeloid cells
and compare Il10-/-Bhlhe40-/- mice with Il10-/- mice to identify other genes controlled by this
transcription factor.
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4.5 Methods
Mice. C57BL/6 (Taconic), B6.SJL (CD45.1; Taconic), IL-10-Thy1.1 BAC transgenic "10BiT"
(on a C57BL/6 background; provided by Dr. Casey Weaver, University of Alabama at
Birmingham), Il10-/- (on a C57BL/6 background; The Jackson Laboratory), Rag1-/- (on a
C57BL/6 background; provided by Dr. Megan Cooper, Washington University in St. Louis),
Bhlhe40+/-, and Bhlhe40-/- (Sun et al., 2001; backcrossed 10 generations to the C57BL/6
background) mice were maintained in the Edelson Lab's SPF (BS2) facility or the Stallings' Lab
BS3 animal facility. IL-10-Thy1.1 BAC transgenic mice, Il10-/- mice, and Rag1-/- mice were
crossed to Bhlhe40-/- mice for some experiments. Adult mice (7–20 weeks of age) of both sexes
were used in the experiments.
To generate bone marrow chimeras, bone marrow cells were collected from femurs and tibias of
donor mice, and 10–20 million cells were injected intravenously into irradiated recipient mice
(1,000 rads). Mixed chimeras were generated by mixing donor bone marrow cells at a 1:1 ratio
before injection. Mice were used in experiments 13–20 weeks following transplantation.
All animal experiments were approved by the Animal Studies Committee of Washington
University in St. Louis.

M. tuberculosis infection of mice. The maintenance and infection of Mycobacterium
tuberculosis (Erdman strain) was described previously295. The mycobacteria was cultured at
37 °C in 7H9 (broth) or 7H10 (agar) (Difco) medium in the presence of 10% oleic
acid/albumin/dextrose/catalase (OADC), 0.5% glycerol, and 0.05% Tween 80 (for broth only).
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In brief, mice were placed in an Inhalation Exposure System (Glas-Col) and ~100 bacteria were
delivered to each animal. The exact bacterial titers in the lungs were determined in at least one
mouse at 24 h after infection. Lung and spleen bacterial burdens were determined by plating
serial dilutions of homogenates onto 7H10 agar plates and were incubated at 37 °C in 5% CO2
for 3-4 weeks before counting colonies. Beginning one week after infection, infected mice were
monitored for weight loss and survival.

Lung harvest. Lungs were perfused with 10 ml PBS via injection into the right ventricle and
were collected for multiple analyses. For histology experiments, left lungs were dissected, ﬁxed
in formalin, embedded in parafﬁn, sectioned and stained with hematoxylin and eosin (H&E).
To generate homogenates, the right lobe of lungs were homogenized in 1 ml (uninfected mice) or
5 ml (Mtb-infected mice) PBS + 0.05% Tween 80. Supernatants from homogenized tissue were
filtered (0.22 μm) and analyzed by ELISA. In some experiments, total RNA was isolated
(RNeasy Kit, Qiagen). cDNA was synthesized with SuperScript III reverse transcriptase using
oligo-dT primers (Life Technologies) and quantitative real-time PCR was performed according
to the manufacturer’s instructions with iTAQ SYBR Green (BioRad). Expression of genes was
determined relative to β-actin. The following primers were used: Il10 forward, 5′AGCCTTATCGGAAATGATCCAGT -3′; reverse, 5′- GGCCTTGTAGACACCTTGGT -3′;
Actb forward, 5′- ACCTTCTACAATGAGCTGCG -3′; reverse, 5′CTGGATGGCTACGTACATGG -3′.
To generate single-cell suspension, lungs were minced and digested with 625 μg/ml collagenase
D (Roche) and 75 U/ml DNase I (Sigma) at 37°C for 40–60 min. Total lung cells were counted
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and some cells were used for flow cytometry analysis. In some experiments, 2x105 lung cells
were placed in wells of 96-well plates and treated with or without 100 µg/ml heat-killed Mtb
(H37Ra strain, Difco) overnight. Supernatants were collected for TNFα or IL-10 ELISA assays.

In vivo neutrophil depletion. Anti–Ly6G antibody (200 µg/dose; clone 1A8; Bio X Cell or
Leinco Technologies, Inc.) or control rat IgG (Sigma) were diluted in 200 µl of PBS and injected
i.p. into mice on every other day from days 10 and 30 p.i. Mice were monitor for weight loss
and survival. Efficacy of neutrophil depletion in lungs and spleens was determined by flow
cytometry at day 21 p.i.

Bone marrow cell cultures and stimulation. Bone-marrow cells were isolated from femurs
and tibias of mice and treated with ACK lysis buffer (0.15 M NH4Cl, 10 mM KHCO3, 0.1 mM
EDTA) to lyse red blood cells. To generate GM-CSF-cultured bone marrow-derived dendritic
cells and macrophages, 6x105 bone marrow cells were cultured in complete RPMI (10% heatinactivated FBS+ L-glutamine+ Penicillin/Streptomycin+ β-mercaptoethanol) in 6-well plates
with the addition of 20 ng/ml GM-CSF (PeproTech). To generate M-CSF bone marrow-derived
macrophages, 4x106 bone marrow cells were cultured in complete IMDM (10% heat-inactivated
FBS + L-glutamine + Penicillin/Streptomycin + β-mercaptoethanol+ nonessential amino acid +
sodium pyruvate) in petri dishes with the addition of 20 ng/ml M-CSF (PeproTech). Cells were
incubated at 37 °C in 8% CO2 for 8-9 days. At the end of the cultures, cells were harvested,
counted, and adjusted to the desired cell concentrations. For flow cytometry analysis and ELISA
assays, suspension cells were seeded at the concentration of 5x105 cells/well in 96-well plates
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and were stimulated with or without 50 µg/ml heat-killed Mtb (H37Ra strain, Difco) for 18 h
(FACS) or 24 (ELISA) hours. In some experiments, suspension cells were stimulated in the
presence of 10 µg/ml heat-killed Mtb (H37Ra strain, Difco) for 4 hours for ChIP assays.

Flow cytometry. Lung single-cell suspension and bone marrow-derived cells were stained with
Fc receptor antibody (clone 2.4G2; Bio X Cell) for 5 min at 4°C and surface staining for 20 min
at 4°C in FACS buffer (0.5% BSA, 2 mM EDTA, and 0.02% sodium azide in PBS). For
samples from Mtb-infected mice, stained cells were fixed before analysis on FACSCanto II (BD)
or FACSAria II (BD) flow cytometers. Flow cytometry data were analyzed with FlowJo
software (Tree Star). The following anti–mouse antibodies were obtained from BioLegend:
APC-Cy7 (17A2) anti-CD3e, PE-Cy7 or APC-Cy7 anti-CD4 (RM4-5), APC-Cy7 or PerCPCy5.5 anti-CD8α (53-6.7), APC or PE-Cy7 anti-CD11b (M1/70), APC-Cy7 or BV605 antiCD11c (N418), APC-Cy7 or BV605 anti CD19 (6D5), PB anti-CD44 (IM7), APC anti-CD45.2
(104), PE anti-CD62L (MEL-14), FITC anti-CD90.1 (Thy-1.1) (OX-7), PerCP-Cy5.5 antiCD103 (2E7), Alexa Fluor 488 anti-B220 (RA3-6B2), PB, PerCP-Cy5.5, or APC-Cy7 anti-Ly6C
(HK1.4), PE anti-Ly6G (1A8), PB anti–I-A/I-E (M5/114.15.2), PB anti-TCRβ (H57-597), APC
anti-TCR γδ (GL3). The following anti–mouse antibodies were purchased from BD Biosciences:
V450 or BV510 anti-CD4 (RM4-5), BV510 anti-CD45 (30F11), and PE anti–Siglec F (E502440). The following anti–mouse antibodies were obtained from Tonbo Biosciences: PerCPCy5.5 anti-CD8α (53-6.7), redFluor710 anti-CD44 (IM7), V450 or PerCP-Cy5.5 anti-CD45.1
(A20), PE-Cy7 anti-Ly6G (1A8), and redFluor710 anti-I-A/I-E (M5/114.15.2). FITC anti-mouse
Ly6B (7/4) was purchased from Bio-Rad. Fixable Viability Dye eFluor780 was obtained from
eBioscience.
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Chromatin immunoprecipitation (ChIP). Anti-Bhlhe40 ChIP was modified from the protocol
published by Chou et al.311. Bone marrow cells from WT and Bhlhe40-/- mice were collected and
cultured with GM-CSF at 20 ng/ml. Suspension cells were harvested after culturing with GMCSF for 8-9 days and stimulated with10 ug/ml heat-killed Mtb (H37Ra strain, Difco) for 4 hours.
The stimulated cells were fixed for 10 minutes at room temperature with 1% PFA with shaking.
Cross-linked chromatin was fragmented by sonication and then immunoprecipitated with a
commercially available polyclonal rabbit anti-Bhlhe40 antibody (Novus NB100-1800). After
immunoprecipitation, DNA was purified by the GenElute PCR clean-up kit (Sigma). For ChIPqPCR, we used the SYBR green method to determine the abundance of different candidate
regions of the Il10 locus in the IP. The following primers were used for real-time PCR analysis:
Il10 -25.7k, CCAGGCTATGAGTCAGATGACG and CTTTGGCCCAGAGGCTGT; Il10 20.1k, CCCTCCAGGTCTCGTCTCAAG and CTTTTGATTCCCATGCCTTACC312; Il10 -9k,
CTTGAGGAAAAGCCAGCATCA and TTTGCGTGTTCACCTGTGTTT (modified from Lee
et al)204; Il10 promoter (pro), GCCCATTTATCCACGTCATTATG and
TGTTCTATGTACAGAGGCCCTCATC312; Il10 +1.8k, GGTCTCTTGCTCATCTGTCTCTGA
and AGGCTATGCGCAAATCTTCAC312; Il10 +6.1k, GGATAAGGGGAAATAATGAGCTG
and CCTTCCGATGGTTACTTTAACTGA (modified from Chang et al.)313; Il10 +6.3k,
GCAGAGAGTGGGATGGCTCA and TCTCACTGGTGCCCGCA312; Il10 +18.4k,
AGGAGTTCAGGAGGCATGGA and TCACCATGTCTTGTGGTAACAGC312; Il10 +18.8k,
ACTTGTAGTTTTACCTTCCCGAGA and CTTTGCAAGGCCAGCTGAG; Bhlhe40 promoter
(pro) CAGCTGGGCAGGACTCTG and GGGTGGGTAGAAGCTACGTG.
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For ChIP-Seq, purified DNA was used for library construction, followed by 50–base pair singleread sequencing on a HiSeq3000 system (Illumina) at the Genome Technology Access Center
(GTAC) at Washington University in St. Louis. Sequences were mapped to the NCBI37/mm10
mouse genome assembly by GTAC and peak calling was performed using MACS software
within Galaxy (http://usegalaxy.org/)222, 223, 224. Tracks were viewed in the UCSC Genome
Browser. Discriminative DNA Motif Discovery (DREME) software218 was used as part of the
online version of MEME-ChIP (http://meme.nbcr. net/meme/cgi-bin/meme-chip.cgi)219 to
validate that Bhlhe40 ChIP-Seq data identiﬁed the expected consensus motif for Bhlhe40
(CACGTG)21.

ELISA. TNFα or IL-10 ELISA assays were performed on Nunc Maxisorp plates using TNFα
capture and detection antibodies (BioLegend) and IL-10 ELISPOT antibody pairs (BD
Bioscience). The enzyme reaction was developed with streptavidin-HRP (BioLegend) and TMB
substrate (BioLegend). Puriﬁed TNFα or IL-10 proteins were used to generate standard curves
for these ELISAs.

Immunoblotting. Bone marrow-derived cells were counted and lysed at 106/40 µl in Laemmli
sample buffer (Bio-Rad Laboratories) containing 2.5% β-mercaptoethanol. Cell lysates were
loaded and separated by 12% SDS-PAGE (Bio-Rad Laboratories) and transferred to BioBlotPVDF membranes (Costar). Blots were incubated with anti-Bhlhe40 (Novus Biologicals; used at
1:1,000) or anti-HDAC1 (Abcam; used at 1:2,000) primary antibodies at 4°C overnight with
shaking. Blots were washed 4-5 times before incubation with anti–rabbit IgG-HRP (clone 5A6142

1D10 [light chain specific]; Jackson ImmunoResearch Laboratories) at room temperature for 60
min with shaking. After five washes, Clarity Western ECL substrate (Bio-Rad Laboratories) or
SuperSignal West Femto Maximum Sensitivity Substrate (Thermo Fisher Scientific) was
applied, and blots were placed on Blue basic autoradiography film (GeneMate). Film was
developed with a Medical Film Processor (model SRX-101A; Konica Minolta), and scanned
films were analyzed with ImageJ software (NIH).

Data and statistical analysis.
All experiments were performed at least twice independent. Each sample represents biological
replicates of mice randomly sorted into each experimental group. In some experiments, mice
were excluded only when morbidity and mortality unrelated to Mtb infection was observed.
Determination of statistical differences was performed with Prism 5 or 7 (Graphpad Software,
Inc.) using unpaired two-tailed Student’s t-tests, one-way ANOVA with Tukey’s multiple
comparisons tests. In some figures, central values and error bars represent the mean ± SEM.
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Figure 4-1. Bhlhe40-deficient mice succumb to Mtb infection.
(A) The survival of Bhlhe40+/+, Bhlhe40+/-, and Bhlhe40-/- mice infected with 100-200 CFU
aerosolized Mtb. The number of biological replicates is indicated in parentheses. (B) Gross
pathology of the left lungs of Bhlhe40+/+, Bhlhe40+/-, and Bhlhe40-/- mice at day 33 p.i. (C) Lung
and (D) splenic Mtb CFU of Bhlhe40+/+ and Bhlhe40-/- mice at week 2, 3, and 4 after aerosol Mtb
infection. Data are mean ± SEM. Statistical differences were by two-tailed unpaired Student’s ttest. *p<0.05, **p<0.01.
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Figure 4-2. Anti-Ly6G treatment fails to rescue Bhlhe40-/- mice from Mtb-induced lethality.
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Figure 4-2. Anti-Ly6G treatment fails to rescue Bhlhe40-/- mice from Mtb-induced lethality.
Bhlhe40+/+ and Bhlhe40-/- mice were infected with 100-200 CFU of aerosolized Mtb. (A) Lungs
from naïve and infected mice (day 21 p.i.) were sectioned and stained by hematoxylin and eosin
(H&E). (B) Representative FACS plots of lung cells gated on CD45+ cells. The frequency of
Ly6C+Ly6G+ neutrophils is shown prior to infection or at days 14, 22, and 29 p.i. (C) Total
numbers of neutrophils in the left lungs of naïve or Mtb-infected Bhlhe40+/+ and Bhlhe40-/- mice.
Statistical differences were determined by two-tailed unpaired Student’s t-test. *p<0.05,
***p<0.001. (D) Representative FACS plots of lung cells (gated on non-B, non-T CD11b+ cells)
from naïve Bhlhe40+/+ or Bhlhe40-/- mice treated with control rat IgG or monoclonal anti-Ly6G
(clone 1A8) antibody every other day for 5 injections. Lung cells were stained for neutrophil
markers to assess depletion efficacy. (E) Bhlhe40+/+ (black symbols) and Bhlhe40-/- (red
symbols) mice were infected with 100-200 CFU aerosolized Mtb and treated every other day
from day 10 to 30 p.i. with rat IgG (filled symbols) or anti-Ly6G (open symbols) antibody from
days 10-30 p.i. Mice were monitored for changes in body weight. (F) Representative FACS
plots of lung cells (gated on non-B, non-T CD11b+ cells) from Mtb-infected (day 21 p.i.)
Bhlhe40+/+ or Bhlhe40-/- mice treated with control rat IgG or anti-Ly6G antibody every other day
starting at day 10 p.i.
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Figure 4-3. Innate immune cells require Bhlhe40 to control Mtb infection.
(A, B) The survival of (A) the indicated bone marrow chimeric mice, or (B) Bhlhe40+/+, Bhlhe40, Rag1-/-, or Rag1-/-Bhlhe40-/- mice infected with 100-200 CFU of aerosolized Mtb. (C) Right

/-

lung Mtb CFU of the mice in (B) at day 21 p.i. Statistical differences were determined by
unpaired Kruskal-Wallis test with Dunn’s multiple comparison test. **p<0.01, ***p<0.001.
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Figure 4-4. The presence of Bhlhe40-/- cell diminishes the ability of WT neutrophils to
control Mtb infection.
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Figure 4-4. The presence of Bhlhe40-/- cell diminishes the ability of WT neutrophils to
control Mtb infection.
Congenically-marked WT irradiated recipient mice were reconstituted with CD45.1+ Bhlhe40+/+
and CD45.2+ Bhlhe40+/+ or with CD45.1+ Bhlhe40+/+ and CD45.2+ Bhlhe40-/- bone marrow cells
at a 1:1 ratio. After bone marrow transplantation, these mixed bone marrow chimeric mice and
non-chimeric Bhlhe40+/+ and Bhlhe40-/- mice were infected with GFP-labeled Mtb. (A)
Representative FACS plots gated on lung CD45+ cells. The frequency of Ly6C+Ly6G+
neutrophils mixed bone marrow chimeric mice at day 21 p.i. is shown. (B) The ratios of grafted
CD45.1+ Bhlhe40+/+/CD45.2+ Bhlhe40+/+ (black) and CD45.1+ Bhlhe40+/+/CD45.2+ Bhlhe40-/(red) neutrophils from (A). Data are mean ± SEM. These two groups are not statistically
different (n.s.) determined by two-tailed unpaired Student’s t-test. (C) Representative FACS
plots gating on neutrophils from non-chimeric and mixed bone marrow chimeric mice at day 21
post Mtb infection. The frequencies of Mtb-infected (GFP-positive) neutrophils in lungs are
shown.

151

Figure 4-5. Bhlhe40-/- myeloid cells express higher levels of IL-10 in vivo.
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Figure 4-5. Bhlhe40-/- myeloid cells express higher levels of IL-10 in vivo.
(A-C) Bhlhe40+/+ and Bhlhe40-/- mice were infected with Mtb and lungs were harvested at day 21
p.i. to analyze IL-10 expression. Total lung homogenates were used to detect (A) Il10 RNA by
qRT-PCR and (B) IL-10 protein by ELISA. (C) 2 x105 lung cells were stimulated without (No
stimulation) or with (Mtb) 100 µg/ml heat-killed Mtb overnight. Supernatants were collected for
IL-10 (left) and TNFα (right) ELISA. (D) Representative FACS plots of lung immune cell
populations from naïve (top) or Mtb-infected (day 21 p.i., bottom) Bhlhe40+/+ or Bhlhe40-/Thy1.1-IL-10 reporter (10BiT Tg+) mice. Thy1.1 (IL-10) expression from five indicated
immune cell types are shown. (E) Bhlhe40+/+, Bhlhe40-/-, Rag1-/-, or Rag1-/-Bhlhe40-/- mice were
infected with Mtb for 21 days. 2 x105 lung cells were stimulated without (No stimulation) or
with (Mtb) 100 µg/ml heat-killed Mtb overnight. Supernatants were collected for IL-10 ELISA.
Data are mean ± SEM. Statistical differences were determined two-tailed unpaired Student’s ttest. *p<0.05, **p<0.01, ***p<0.001.
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Figure 4-6. Bhlhe40 directly binds to the Il10 locus in bone marrow-derived myeloid cells.
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Figure 4-6. Bhlhe40 directly binds to the Il10 locus in bone marrow-derived myeloid cells.
(A) Bhlhe40+/+ and Bhlhe40-/- GM-CSF-cultured bone marrow cells were stimulated with heatkilled Mtb for 24 hours. Supernatants were analyzed for IL-10 (left) and TNFα (right) by
ELISA. Data are mean ± SEM. Statistical differences were determined two-tailed unpaired
Student’s t-test. *p<0.05, ***p<0.001. (B-G) Bhlhe40+/+ and Bhlhe40-/- GM-CSF-cultured bone
marrow cells were stimulated with heat-killed Mtb for 4 hours and subjected to ChIP analysis.
ChIP-qPCR analysis of Bhlhe40 binding to (B) the Bhlhe40 promoter or to (C) multiple sites
indicated within the Il10 locus. (D-F) ChIP-seq analysis for Bhlhe40. (D) Pie chart showing
genomic locations of Bhlhe40 binding sites. (E) Consensus Bhlhe40 binding motif identified by
Discriminative DNA Motif Discovery (DREME)218, used as part of the online version of
MEME-ChIP. (F-G) ChIP-Seq analysis identifies the Bhlhe40 binding sites within (F) the
promoter region of Bhlhe40, and (G) at the +6.1kb site within the Il10 locus. The degree of
vertebrate conservation is shown in the blue tracks.
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Figure 4-7. IL-10 deficiency rescues Bhlhe40-/- mice from early Mtb-induced death.
(A) The survival of Bhlhe40+/+, Bhlhe40-/-, Il10-/-, and Il10-/-Bhlhe40-/- mice after infection with
100-200 CFU aerosolized Mtb. (B) Right lung Mtb CFU and (C) the frequency of lunginfiltrating neutrophils among total CD45+ cells of the mice in (A) were analyzed at day 21 p.i.
Statistical differences were determined by one-way unpaired ANOVA with Tukey’s post-test.
**p<0.01, ****p<0.0001.
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Chapter 5: Conclusions and Discussion
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In this study, we have used an autoimmune (Chapter 2 and 3) and an infectious disease model
(Chapter 4) to demonstrate that Bhlhe40 is a critical pro-inflammatory transcription factor. The
presence of Bhlhe40 renders mice susceptible to T cell-mediated autoimmune
neuroinflammation, but protects mice from Mtb infection. Bhlhe40 is required for normal
cytokine production in a T cell-intrinsic manner, where it positively regulates the production of
GM-CSF and negatively regulates the production of IL-10. PTX, serving as a co-adjuvant for
EAE induction, induces IL-1β secretion by myeloid cells which enhance Bhlhe40 expression by
CD4+ T cells. We define a PTX - IL-1β - Bhlhe40 axis that is essential for T cell pathogenicity
in EAE. In contrast, Bhlhe40 assures protective innate and adaptive immune responses against
Mtb by direct repression of Il10 in several immune cell types during infection. Bhlhe40-/- mice
fail to control Mtb replication and die by seven weeks after exposure to Mtb, whereas IL-10
deficiency largely rescues these mice from mycobacteria-induced early death. Overall, by
analyzing the immune response in the absence of Bhlhe40 in two different disease models, we
showed that Bhlhe40 is harmful in terms of autoimmunity, but is indispensable for a protective
immune response to mycobacterial infection.

158

5.1 The requirements for TH cell transcription factors
during EAE induction
It has been debated which autoreactive TH cell subset, TH1 or TH17 cells, mediates
neuroinflammation in mice and humans. Several studies have demonstrated that neither IFN-γ
nor IL-17 is absolutely required for EAE development in C57BL/6 mice167, 168, 169. Recent
reports have generally agreed that self-reactive cells with features of both TH1 and TH17 cells
may represent the most pathogenic subset (termed TH1/TH17 cells)266, 314, 315. These cells likely
mediate their pathogenicity through the production of GM-CSF174, 175. Notably, utilizing an IL17 fate mapping reporter system, Hirota et al. identified an “ex-TH17” population in the DLN and
CNS during EAE that was positive for IFN-γ, but that had previously produced IL-17316. These
ex-TH17 cells produce GM-CSF, and seem to represent the pathogenic subset of TH cells.
A large body of research has been devoted to identifying the transcription factors that drive T
cell pathogenicity during EAE. Early reports showed that T-bet was essential for EAE induction
317, 318

. Using myelin-specific B10.PL transgenic mice, the group of Amy Lovett-Racke claimed

that T-bet regulates the pathogenicity of both TH1 and TH17 cells319, 320. When in vitro-polarized
WT or Tbx21-/- TH17 2D2 cells were adoptively transferred to C57BL/6 recipients, Wang et al.
found that T-bet-deficient cells failed to induce disease by two weeks321. However, the
importance of T-bet for T-cell encephalitogenicity has been challenged by more-recent papers.
Duhen et al. showed that selective deletion of T-bet in T cells did not prevent the generation and
infiltration of IL-17+IFN-γ+ or GM-CSF+ T cells into the CNS and did not protect mice from
EAE induction262. Two other studies simultaneously reported that Tbx21-/- mice are nearly as
susceptible as WT mice to active EAE induction322, 323. O'Connor et al. found that IL-12159

polarized (TH1 condition) myelin-reactive T cells from previously-immunized Tbx21-/- mice
cannot initiate disease in recipient mice, while IL-23-treated (TH17 condition) cells are still
pathogenic even when T-bet is absent322. In agreement with this finding, Grifka-Walk et al.
showed that DLN cells from EAE-induced Tbx21-/- mice cultured under TH17 polarization
conditions (IL-23, IL-1β, anti-IFN-γ and anti-IL-4) are sufficient to cause neuroinflammation
upon transfer to WT or Rag1-/- mice, despite a delayed onset and milder symptoms323.
Collectively, these results indicate that T-bet may not be universally-required for all TH subsets
to induce EAE.
The orphan nuclear receptors RORγt and RORα are two primary transcription factors regulating
TH17 differentiation324, 325. T cells deficient in either of these two proteins exhibit a significant
reduction of IL-17 production both in vitro and in vivo. One paper proposed that RORγt might
regulate TH cell pathogenicity by directly binding to the Csf2 locus and promoting GM-CSF
expression174, whereas another report did not find changes in GM-CSF production by RORγtdeficient TH cells175. Rorc-/- mice were initially thought to be resistant to EAE, but later Yang et
al. discovered that only mice lacking both Rorc and Rorα are truly protected from this disease 324,
325, 326

. An important observation regarding the requirements for T-bet and RORγt for T-cell

pathogenicity was published by Brucklacher-Waldert et al, who genetically deleted Tbx21 and
Rorc in IL-17-producing cells327. They bred Il17-Cre mice to Tbx21fl/fl or Rorc fl/fl mice and
found that the deficiencies of T-bet or RORγt specifically in IL-17-producing cells did not
prevent EAE development. These authors concluded that T-bet and RORγt are largely
dispensable for TH17-associated autoimmunity.
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5.2 The role of T cell-expressed Bhlhe40 in EAE induction
The transcription factor Bhlhe40 is not expressed by naïve T cells but is upregulated upon TCR
ligation and CD28 costimulation32, 33, and we found that myeloid cell-derived IL-1β can enhance
its expression by CD4+ T cells12. Bhlhe40 can be found in both TH1 and TH17 cell subsets
polarized in vitro, and loss of Bhlhe40 only has a limited impact on their hallmark cytokine
production (i.e. IFN-γ and IL-17A, respectively), showing that Bhlhe40 is dispensable for TH cell
differentiation11. However, Bhlhe40 is absolutely required for TH cell pathogenicity in the EAE
model. Rag1-/- mice reconstituted with Bhlhe40-/- but not WT CD4+ T cells are completely
resistant to active EAE induction (Figure. 2-1F)11, 33. Moreover, we have shown that myelinreactive, IFN-γ or IL-17A-producing TH1 or TH17 2D2 cells polarized in vitro required Bhlhe40
to mediate passive EAE in WT recipients (Figure. 3-6, A-C)12. 2D2 Bhlhe40-/- TH cells could be
recovered in the recipient mice more than a month after transfer. These cells persisted in the
spleen and even in the CNS, maintaining expression of IFN-γ or IL-17A, but were unable to
initiate EAE (Figure. 3-6, D-G)12.
To further examine if Bhlhe40 is essential specifically for the pathogenicity of IL-17-producing
cells, we have generated Il17-Cre x Bhlhe40fl/fl mice and actively induced EAE in these animals
(Figure. 5-1A). These conditional knockout mice displayed a delayed onset and less severe
clinical EAE symptoms compared to Bhlhe40fl/fl mice. Interestingly, Il17-Cre x Bhlhe40fl/fl mice
appeared to almost completely recover from clinical disease by 25 days post-EAE induction. I
interpret this result to mean that Bhlhe40 is required by TH17, TH1/TH17, or ex-TH17 cells to
sustain neuroinflammation. Intrigued by the finding that Bhlhe40 is critical for TH17-mediated
immunopathology, we generated IL-17-tdTomato fate mapping Bhlhe40GFP double reporter mice
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(Figure. 5-1, B-D). Our preliminary data showed that tdTomato+Bhlhe40-expressing T cells
were not present in the DLN from naïve mice but appeared after immunization (Figure. 5-1B).
ICS analysis further revealed that Bhlhe40 was expressed at the highest levels in tdTomato+IFNγ+IL-17A- “ex-TH17” cells and tdTomato+IFN-γ+IL-17A+ TH1/TH17 cells (Figure. 5-1, C and
D). Overall, our results imply that Bhlhe40 expression occurs within the pathogenic TH cells,
and serves a more important role in the context of EAE than the traditional TH1 and TH17 master
transcription factors.
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5.3 Cell type-specific requirements for Bhlhe40 in EAE
We and others have provided strong evidence that Bhlhe40 is absolutely required for TH cell
pathogenicity in both active and passive EAE models11, 12, 33. Nevertheless, Bhlhe40 is also
expressed by several other immune cell types including DCs, macrophages, Ly6Clow monocytes,
and perhaps neutrophils. Does the expression of Bhlhe40 in these immune cell subsets also
contribute to neuroinflammation? To examine the cell-intrinsic requirements for Bhlhe40 in
EAE development, we generated Bhlhe40 conditional knockout mice by crossing several cell
type-specific Cre mice to Bhlhe40fl/fl mice and induced EAE in the offspring. Deletion of
Bhlhe40 in T cells (Cd4-Cre x Bhlhe40fl/fl) largely decreased the incidence and severity of EAE
(Figure. 5-2A), confirming the finding that Bhlhe40 is required for TH cell pathogenicity11, 12, 33.
We also tested the effect of depleting Blhe40 in neutrophils (MRP8-Cre x Bhlhe40fl/fl) during
EAE and found equal susceptibility between control mice and Bhlhe40 conditional knockout
mice (Figure. 5-2B). Currently, we are breeding Bhlhe40fl/fl mice to Itgax-Cre (CD11c-Cre) and
Lyz2-Cre (LysM-Cre) mice. In the near future, we will be able to test the roles of Bhlhe40 in
DCs and monocytes/macrophages during EAE.
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5.4 Cell type-specific requirements for Bhlhe40 in the
mouse model of TB
Although we have shown that Bhlhe40-/- mice and Rag1-/-Bhlhe40-/- mice fail to control Mtb
replication and rapidly succumb in an IL-10-dependent manner, we have not yet fully determined
which cell type(s) requires Bhlhe40 to control Mtb infection. Using our Bhlhe40GFP mice, we
found that several immune cell types in the lung express Bhlhe40 at different levels (Figure. 5-3,
A and B). Alveolar macrophages and CD11b+ and CD103+ DCs showed high-to-medium levels
of Bhlhe40 expression, while moDCs/Mac and neutrophils appeared to express Bhlhe40 at lower
levels (Figure. 5-3A). The expression of Bhlhe40 by these myeloid cells seemed to be only
mildly affected by Mtb infection (data not shown). In contrast, all three lung T cell subsets
examined, in particular CD4+ T cells, increased their Bhlhe40 expression three weeks after Mtb
infection (Figure. 5-3B). We speculated that at least some of these activated, Bhlhe40expressing TH cells were Mtb-specific. We used 10BiT reporter mice to explore IL-10
expression by lung immune cells before and after Mtb infection (Figure. 5-3 and Figure. 4-5D).
We found that after Mtb infection, some Bhlhe40-expressing cell types including CD11b+ DCs,
moDCs, and T cells expressed higher IL-10 levels when Bhlhe40 was absent (Figure 4-5D,
bottom), implying that Bhlhe40 might repress Il10 in these cell types. However, even though
alveolar macrophages express the highest level of Bhlhe40 in WT mice, we did not detect any
IL-10 reporter signals from this phagocyte population during Mtb infection (Figure. 4-5D and
Figure. 5-3A). In contrast, we did observe an increased amount of IL-10 from Bhlhe40-/- Ly6Chi
monocytes, a population which does not express Bhlhe40 in naïve or Mtb-infected WT animals
(Figure. 5-3A and data not shown). These results suggest that the function of Bhlhe40 might
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be cell-type dependent, and the increased expression of IL-10 in Bhlhe40-/- cell subsets during
Mtb infection might not be entirely cell-intrinsic.
To identify the cell type(s) that requires Bhlhe40 to control Mtb infection, we infected the
aforementioned Bhlhe40 conditional knockout mice (See Chapter 5.2) with Mtb. Our
preliminary results have shown that Bhlhe40 deficiency in only neutrophils (MRP8-Cre x
Bhlhe40fl/fl mice) or monocytes/macrophages (Lyz2-Cre x Bhlhe40fl/fl mice) does not impair the
protective immune response to this pathogen. Both strains of mice survived significantly longer
than global Bhlhe40-deficient mice (Figure. 5-3C and data not shown). Interestingly, deletion
of Bhlhe40 in CD11c+ cells (Itgax-Cre x Bhlhe40fl/fl) rendered mice Mtb-susceptible (in a single
pilot experiment at the time of this dissertation) (Figure. 5-3C). These Bhlhe40 conditional
knockout mice started losing weight at ~25 days post Mtb infection and died at about day 60 p.i.,
indicating that Bhlhe40 was required by classical DCs, CD11c+ moDCs/Macs, or other CD11c+
subsets to control infection. Moreover, deletion of Bhlhe40 in T cells (Cd4-Cre x Bhlhe40fl/fl)
also impaired host defense and immunity to Mtb. Mice lacking Bhlhe40 in T cells failed to resist
Mtb infection and died in the same time frame as Itgax-Cre x Bhlhe40fl/fl mice (Figure. 5-3C).
These data suggest that Bhlhe40 is essential for both CD11c+ cells and T cells to control Mtb
infection. Notably, in our previous data showing a role for Bhlhe40 in Mtb resistance in the
absence of T and B cells (i.e. in Rag1-deficient mice, Figure. 4-3B), Rag1-/-Bhlhe40-/succumbed to Mtb infection at approximately day 30-40 p.i. (the same time as Bhlhe40-/- mice).
In the context of our experiments in cell type-specific conditional knockout mice, overall our
data would suggest that Bhlhe40-deficiency in CD11c+ cells has a more profound impact on
susceptibility when this cell type-specific deficiency is placed in the setting of absent adaptive
immunity.
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5.5 The relevance of the murine findings to human disease
One important question is whether the function of Bhlhe40 is relevant to human disease.
Bhlhe40 is an evolutionarily-conserved gene which can be found in fish, amphibians, reptiles,
birds, and mammals. The human and mouse Bhlhe40 gene and protein show 87.9% and 90.5%
identity, respectively (NCBI HomoloGene: https://www.ncbi.nlm.nih.gov/homologene). The
Human Protein Atlas demonstrates that BHLHE40 protein is expressed by many human tissues
at various levels (http://www.proteinatlas.org/ENSG00000134107-BHLHE40/tissue), and
BHLHE40 transcript can be detected in blood TH cell subsets from healthy donors (Figure. 54A)328. Our preliminary immunoblotting data showed that cultured TH17 cells from a health
donor expressed BHLHE40 protein, and its level was enhanced with the addition of IL-1β and
IL-12 to cultures (Figure. 5-4B). It will be worth examining if BHLHE40 expression by human
T cells is critical for MS pathogenesis as observed in the mouse model. In chapter 3, we showed
that IL-1R signaling strongly impacts on Bhlhe40 expression levels in murine TH17 cells
(Figure. 3-8, 3-9, and 3-10)12. IL-1 has been shown to induce Bhlhe40 in primary human
gingival epithelial cells through a PI-3K–Akt pathway256, and in primary human amnion
mesenchymal cells257. It will be interesting to study if IL-1β promotes T cell encephalitogenicity
during MS.
In recent years, several studies have compared the whole blood transcriptomes of active TB
patients to those from healthy individuals or latent TB patients. Examination of the blood
transcriptional signature could provide information on the immune response occurring during
active TB disease. Interestingly, our own analysis of publicly-available datasets generated from
studies performed with human samples from the Gambia329, South Africa300, or the UK300, 301
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revealed that BHLHE40 expression was significantly lower in active TB patients as compared to
healthy controls or latent TB patients (Figure. 5-4C, left; GSE1949132 and data not shown),
while the expression of STAT1, a signature gene of the TH1response, was significantly higher in
the blood of active TB patients (Figure 5-4C, right). Lower BHLHE40 expression during active
TB disease correlates with our findings that Bhlhe40-deficient mice are more susceptible to Mtb
infection (Chapter 4). Future experiments would be required to examine the role of BHLHE40
in human anti-TB immunity.
A transcription factor could be targeted by direct inhibition of its expression, by disruption of its
binding to DNA or other partner proteins, or by manipulation of chromosome accessibility330. A
recent success story came from the group of Ari Melnick, who designed small-molecule
inhibitors targeting the oncogene BCL6 and found that these inhibitors could suppress mouse and
human B cell lymphomas331. In addition, the expression and action of a transcription factor
could be affected by its upstream and downstream signaling pathways. For instance, blocking
IL-1β production might reduce BHLHE40 expression by human T cells, and blockade of IL-10
might overcome the adverse effects (if any) resulting from low BHLHE40 expression. Our study
provides impetus and new insights for exploring the role of BHLHE40, or pathways that regulate
its expression and function, as candidate therapeutic targets in human autoimmunity and
infectious diseases.
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Figure 5-1. Bhlhe40 is critical for IL-17-associated pathogenicity in EAE.
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Figure 5-1. Bhlhe40 is critical for TH-17-associated pathogenicity in EAE.
(A) Mean clinical scores of EAE in immunized Bhlhe40fl/fl (n=10) or Il17-Cre x Bhlhe40fl/fl mice
(n=7). Data are combined from three independent experiments. (B-D) IL-17-tdTomato fate
mapping Bhlhe40GFP double reporter mice were left untreated (naïve) or immunized with
MOG35-55/CFA subcutaneously in the footpads with systemic PTX treatments on days 0 and 2.
DLNs were harvested for flow cytometry analysis on day 7. (B) Representative FACS plots
visualizing tdTomato (IL-17 fate mapping reporter) and GFP (Bhlhe40 reporter) in the indicated
T cell subsets. (C) DLN cells were simulated with PMA/ionomycin in the presence of brefeldin
A for 4 hours. Representative ICS plots for IFN-γ and IL-17A expression by tdTomato+CD4+ T
cells were shown. (D) GFP (Bhlhe40) expression in each of the four cytokine-producing
tdTomato+CD4+ subsets shown in (C).
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Figure 5-2. Bhlhe40 is required by T cells but not neutrophils to induce EAE.
Mean clinical scores of EAE in immunized Bhlhe40fl/fl, (A) Cd4-Cre x Bhlhe40fl/fl mice, or (B)
MRP8-Cre x Bhlhe40fl/fl mice. For (A), data are combined from three independent experiments.
For (B), the data is from one experiment.
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Figure 5-3. Bhlhe40 is required by CD11c+ cells and T cells to control Mtb infection.
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Figure 5-3. Bhlhe40 is required by CD11c+ cells and T cells to control Mtb infection.
(A) GFP (Bhlhe40) expression in lung myeloid immune cell types from Mtb-infected
nontransgenic (Tg-negative) or Bhlhe40GFP (Tg-positive) reporter mice at day 21 p.i. (B) GFP
(Bhlhe40) expression in lung T cell subsets from naïve or Mtb-infected Bhlhe40GFP (Tg+)
reporter mice at day 21 p.i. (C) The survival of WT (Bhlhe40+/+), Bhlhe40-/-, Bhlhe40fl/fl mice,
and three strains of Bhlhe40 conditional knockout mice infected with 100-200 CFU aerosolized
Mtb. The number of biological replicates is indicated in parentheses. Data is from one
experiment.
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Figure 5-4. BHLHE40 expression in human T cells and PBMCs.
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Figure 5-4. BHLHE40 expression in human T cells and PBMCs.
(A) The relative expression of five transcription factors was analyzed in GEO DataSet
GSE43005328 in human primary CD4+ T-cell subsets. GATA3, RORC, and FOXP3 have been
shown in Figure 1 of the original report published by Zhang et al. in 2013. (B) Immunoblots of
BHLHE40 and HDAC1 in FACS-sorted human blood TH17 cells (CD161+CCR6+CXCR3-)
cultured with the indicated cytokines for 4 days (top). Quantitation of the band intensity of
Bhlhe40 relative to HDAC1 is shown (bottom). (C) The relative expression of BHLHE40 and
STAT1 was analyzed in GEO DataSet GSE43005300 in the blood of healthy control, latent or
active TB patients recruited in the UK. Error bars show mean ± SEM. Statistical differences
were determined two-tailed unpaired Student’s t-test. **p<0.01, ***p<0.001.
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